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Abstract 
Alterations of Endometrial Basement Membrane Integrity and Stem/Progenitor 
Cell Markers in Endometriosis 
Palial, K; Drury, J, Heathcote, L, Valentijin, A.J, Gazvani, R, Rudland, P.S. and Hapangama, 
D.K.  
1
Department of Women's and Children's Health, University of Liverpool, Liverpool, United 
Kingdom, L8 7SS. 
2
School of Biological Sciences, University of Liverpool, Liverpool, 
United Kingdom, L69 7ZB 
Degradation of basement membrane (BM) is reported to be involved in the metastatic process 
of cancers, and has been shown to be aberrantly expressed in the benign metastatic disease of 
endometriosis. Emerging evidence show endometrial stem/progenitor cells are involved in 
endometrial physiology and in certain endometrial pathological conditions, however markers 
for these cells are lacking. We tested a panel of stem cell markers including cytokeratin 5/6 
(CK5/6) and podocalyxin-like protein (PODXL) and stage specific embryonic antigen 1 
(SSEA1) in endometrial tissue. Using immunohistochemistry, we aim to investigate if an 
alteration of BM integrity is associated with differential expression of these stem cell markers 
in eutopic endometrium collected from fertile controls, post-menopausal (PM) women and 
patients with endometriosis and endometrial cancer.   
1. In the fertile control group, expression of BM components, Collagen IV and laminin, 
changed across the menstrual cycle and some of these changes agree with previously 
reported findings. Expression of stem cell markers SSEA1 and PODXL also showed 
similar changes across the menstrual cycle with both having maximal expression 
during the ProlP. Expression of BM components appeared to be correlated with stem 
cell markers. No cyclical changes in CK5/6 were reported in fertile controls. 
2. In the PM group a few differences were seen in BM integrity compared with the 
fertile control group, especially in BM supporting endometrial vessels. Nonetheless, 
PODXL and SSEA1 expression was similar to the fertile control group. 
3. Complete disruption of BM in the endometrial cancer group provided confirmatory 
results that BM is disruption in this invasive metastatic disease.  
4. In the endometriosis group, differences were seen in the expression of the key BM 
components in eutopic endometrium sampled from women with endometriosis when 
compared with fertile controls, and this was similar to previous reported findings. 
Whereas SSEA1 showed a phase dependent expression in the fertile control group, 
this was lost in the endometriosis group.  
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Chapter One: 
INTRODUCTION 
 
The endometrium is a highly dynamic tissue lining the uterine cavity. Under the influence of 
ovarian hormones, significant morphological changes occur in the endometrial epithelium 
and in the underlying stroma and vasculature. These structural changes are precisely timed in 
the menstrual cycle in order to prepare the uterus for implantation. Correlated with these 
events, an array of biochemical changes occurs in the organisation of the extracellular matrix 
(ECM) of this specialised tissue. Basement membrane (BM) is an important part of this 
matrix that underlies all epithelial sheets, and separates them from the surrounding 
connective tissue. Degradation of BM has been reported to be involved in the metastatic 
process of endometrial cancer and has been proposed to play a part in the pathogenesis of 
endometriosis(1, 2).  
The endometrium is a site of repetitive physiological injury and repair. For this reason it has 
also been hypothesised that the endometrium contains stem cells that may account for its 
distinct ability to regenerate. Alongside with the disruption of BM reported in the disease 
process of endometriosis and endometrial cancer, these stem cells are thought to be involved 
in the pathogenesis of both diseases(3, 4). Additionally, there is some evidence that 
disruption of BM may cause activation of stem cells(5). Therefore we explored the integrity 
of BM and associated expression of stem cell markers in the endometrium sampled from 
normal fertile controls, and from patients with endometriosis and endometrial cancer. In order 
to make accurate comparisons across these different subject groups, a thorough literature 
review on the structure and function of the endometrium, endometrial BM and stem cell 
activity will be discussed.  
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1.1 – Structure & Function of the Endometrium 
The uterus is a pear shaped organ consisting of a fundus superiorly, body, isthmus and the 
inferior cervix. It comprises of an outer serosal lining, a thick fibromuscular wall known as 
the myometrium and a modified mucosal lining known as the endometrium(6). Human 
endometrium is structurally and functionally divided into two major regions: the functionalis 
and the basalis regions, see figure 1.1. The functionalis, comprising the upper two thirds of 
the endometrium, contains a superficial layer with a few glands and abundant stroma and a 
deeper layer with many glands and less stroma(7). Epithelial cells constitute the luminal and 
glandular epithelium. The lower basalis layer containing the basal region of the glands, dense 
stroma and large vessels, is thought to serve as the germinal compartment for generating the 
new functionalis each month(8). The endometrium responds to ovarian hormones and 
undergoes a remarkable series and variety of morphological changes during the reproductive 
years and after menopause. The ovarian and uterine cycle will be discussed in detail outlining 
these changes.           
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Micrograph illustrating the structure of the endometrium.  
Luminal epithelium 
Functionalis Layer 
Basalis Layer 
Glandular 
Epithelium 
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Blood  
vessel 
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1.1.1 The Ovarian Cycle 
A normal menstrual cycle is mostly a reflection of the ovarian cycle. At birth the human 
ovaries contain approximately 1,000,000 primordial follicles arrested at prophase of the first 
meiotic division. Over time, the follicle pool continually depletes, with regular escape of 
follicles from the “resting state” re-entering meiosis. Of these ‘escaped’ follicles, only 400 
will sequentially mature and ovulate during an average women’s reproductive lifetime(9).   
Initiation of follicular recruitment and maturation from the primordial pool is a process that 
continuously occurs over several months and is independent of gonadotrophin control(10). 
Subsequently the gonadotrophins, follicular stimulating hormone (FSH) and luteinising 
hormone (LH), play distinct roles in follicle maturation in a cylical manner. Both are released 
by the anterior pituitary in response to pulsatile stimulation of hypothalamic gonadotropin 
releasing hormone (GnRH)(11). During the luteal-follicular transition, FSH serum 
concentrations rises as oestrogen decreases due to the demise of the corpus luteum (10). This 
intercycle rise in FSH, recruits a cohort of mature FSH responsive pre-antral follicles which 
synchronously develop into large antral pre-ovulatory follicles(10). From the mid- to late-
follicular stages, a critical concentration of FSH opens the ‘FSH window’ allowing entrance 
of the most sensitive antral follicle. This ‘lead’ follicle will acquire significant aromatase 
enzyme activity within its granulosa cells, leading to increased synthesis and secretion of 
oestradiol from androgenic precursor. The “two-cell, two gonadotropin” hypothesis specifies 
the need for both LH, to stimulate production of precursor androgens by theca cells, which 
are then transferred into granulosa cells to be aromatised into oestrogens under the influence 
of FSH(11, 12). Such actions of both FSH and LH are influenced by paracrine and autocrine 
actions of substances produced locally in the ovaries(12). Raised serum oestradiol ensures 
rapid suppression of FSH production, via a negative feedback system(12). The mid follicular 
fall of FSH causes atresia of the less mature follicles that are unable to grow without adequate 
FSH concentrations, ensuring mono-ovulation(10).  
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A rapid rise in oestradiol, during the latter days of the follicular phase, promotes 
hypothalamic GnRH pulses to increase in both magnitude and frequency, via  positive 
feedback system(11). This produces the so called ‘LH surge’ during mid-cycle, with a rapid 
outpouring of LH and to a lesser extent FSH(11). The LH surge initiates a gene cascade in 
granulosa cells that signal the cell to commence meiotic maturation(13). Furthermore, it 
induces an inflammatory type reaction at the apex of the Graafian follicle adjacent to the 
outer surface of the ovarian cortex. Angiogenesis associated with a release of prostaglandins 
(PG) and cytokines leads to rupture of the follicular wall and ovulation approximately 36 
hours after initiation of the LH surge. The empty follicle fills with blood, producing a corpus 
haemorrhagicum, and the theca and granulosa cell layers of the follicle wall luteinise forming 
the corpus luteum. In response to LH and human chorionic gonadotrophin (hCG), the corpus 
luteum produces and secretes progesterone, oestrogen and inhibin. If conception follows, the 
placenta will subsequently be the main source of progesterone production once it has 
developed sufficiently(14). Otherwise, progesterone and inhibin levels will fall with 
regression of the corpus luteum and FSH levels will rise again. 
1.1.2 The Uterine Cycle 
The endometrium is a dynamic remodelling tissue with the main function of embryo-
implantation. In order to prepare for implantation, the upper functionalis layer undergoes well 
defined cycles of proliferation, differentiation and shedding in response to a prevailing 
steroid hormonal environment of sequential ovarian steroid exposure(15).  
Oestrogens, progesterones and androgens all play vital, but as yet not fully defined roles in 
the complex mechanisms underlying endometrial development necessary for successful 
embryo implantation(16). The expression of steroid receptors varies temporally and spatially 
across the menstrual cycle, contributing to the changes in the impact of steroid hormones on 
target cells(17). Oestrogen receptors (ER) exist in two isoforms, ERα and ERβ, which are 
both found in glandular and stromal compartments. Like oestrogen, two isoforms of 
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progesterone receptors (PR) also exist, PR-A and PR-B. It is of upmost importance to identify 
the mechanisms regulating endometrial events involved in the normal endometrial functions 
of implantation and menstruation if we are to elucidate the abnormal endometrial pathologies 
such as endometriosis or endometrial cancer.  
Three distinct phases are described during the uterine cycle: the menstrual phase; the 
proliferative phase (ProlP), corresponding to the follicular phase of the ovary; and the 
secretory phase, corresponding to the luteal phase of the ovary.  
1.1.2.1 Menstruation Phase: 
In the absence of pregnancy, the demise of the corpus luteum causes progesterone and 
oestrogen levels to fall towards the end of the secretory phase in the menstrual cycle. 
Withdrawal of progesterone results in shedding of the upper two thirds of the functional layer 
of the endometrium exposing open blood vessels and glands. This rapid but incomplete 
degeneration of the functional layer is called menstruation and the first day of menstrual 
bleed is considered as day 1. During this period the endometrium quickly starts to regenerate 
with epithelium re-growing most likely at the stumps of the glands. Thereafter two thirds of 
the luminal surface is covered by epithelium as it grows out of the edges of the cone shaped 
glands, and epithelial growth is complete within 48 h after shedding(18). The molecular 
mechanism by which sex steroids induces these events involves complex interactions 
between the endocrine and immune system.  
1.1.2.2 Proliferative phase (ProlP): 
The average duration of a cycle is 28 days, with alterations in the length of cycle mainly due 
to the duration of the proliferation phase (varying from 8-21 days)(7). The ProlP coincides 
with the follicular phase of the ovarian cycle and takes place between the menstrual phase 
and ovulation, day 4-14. Increasing circulating oestrogen levels induces remarkable 
endometrial regeneration, with endometrial proliferation and vascularisation. As a 
6 
 
consequence the endometrium regenerates from an initial 0.5-1mm thick post menstruated 
endometrium to 5-7mm(18). Increasing circulating levels of oestrogen increases the 
expression of endometrial ERα, which is essential for the upregulation of PR, therefore 
endometrium to respond to progesterone during the secretory phase(16). Therefore, pre-
ovulatory endometrium contains proliferating cells in glands, stroma and endothelium, 
leading to relative hypertrophy of the uterine mucosa. Narrow straight glands, a thin surface 
epithelium and compact stroma are features of the ProlP. Stromal cells are often elongated 
and spindle shaped(19). Multiple mitoses are present in the “naked nucleus” type of stroma. 
As growth of the glands and stroma continues, angiogenesis also occurs as ovulation 
approaches(15). Spiral artery elongation is an important part of endometrial angiogenesis and 
is crucial for endometrial re-growth(15). Unlike other ovarian hormone receptors, ERβ is 
found in endometrial endothelial cells. Therefore it is reasonable to deduce that any direct 
effects of oestrogen on angiogenesis is likely to be mediated by ERβ(16). Oestrogen may also 
influence endometrial angiogenesis indirectly via actions on their mediators such as 
angiopoietin 1 and vascular endothelial growth factor.   
1.1.2.3. Secretory Phase:  
Following ovulation, progesterone dominates the rest of the menstrual cycle as it controls 
cellular differentiation(20). Differentiation is defined as a gene controlled change in cellular 
phenotype and function(21). Cellular differentiation transforms the oestrogen primed 
endometrium into secretory tissue. These morphological changes also reflect the pattern of 
sex steroid receptor expression across the secretory phase.  
This phase of the menstrual cycle is constituted by an early, mid and late secretory phase.  
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Early secretory phase (ESP) 
ESP, day 15-18, is regulated by both oestrogen and progesterone, as shown by microarray 
studies. Sub-nuclear vacuolation of the glandular epithelium is maximal during the ESP. 
Eventually vacuoles enlarge and pushes the nuclei into an orderly row. By the end of the 
ESP, glands are tortuous and stromal vascularity peaks making the endometrium both 
morphologically and functionally well prepared for implantation during the MSP(14).  
Mid secretory phase (MSP) 
MSP, day 19-23, is a short period of uterine receptivity towards embryonic implantation, 
designated as the “window of implantation” (WOI).  Endometrial receptivity to implantation 
is between 6 and 10 days after the LH surge and ovulation(14). This period coincides with 
peak circulating progesterone levels and is regulated by progesterone alone. The key 
endometrial events associated with MSP include vacuoles moving into a supra-nuclear 
position and empty their contents into the lumen via exocytosis. Nuclei then approach the 
base of the cell. During the MSP there is increased expression of chemokines and cytokines, 
the presence of increased numbers of leukocytes including uterine natural killer cells, and the 
onset of pre-decidualisation(15).  
Unlike oestrogen, progesterone down-regulates both ERα, PRα and PRβ (inhibiting further 
action of oestrogen) in the glandular and luminal epithelium and in stromal cells around 
vessels, thus cellular mitoses are completely blocked and cells commence differentiation(16). 
It is notable that PR persists in the stroma in the functionalis and is highly expressed by 
stromal cells in close proximity to the uterine vasculature(16). Thus, the role of progesterone 
on vascular function is thought to be mediated by the PR-positive stromal cells around blood 
vessels(16). Stromal proliferation reduces to some extent and commences pre-decidualisation 
8 
 
during the mid-late secretory phase. Pre-decidualisation is an event where stromal cells 
differentiate beneath the surface epithelium and around blood vessels, a requirement for 
implantation. In particular, enlargement of nuclei and increase in cytoplasm within peri-
arteriolar stromal cells constitutes as the earliest visible pre-decidual change(20). Other 
histological features of the MSP include maximal glandular secretions and stromal 
oedema(20).  
Late secretory phase (LSP) - Decidualisation 
Whilst progesterone is the dominant hormone in the secretory phase, during the LSP ERβ 
expression is maintained in the stroma, mirroring the decline in endometrial ERα, PR and 
androgen receptor. Since the functions of ERβ and the actions of progesterone counteract 
most of the classical ERα mediated actions of oestrogen in the endometrium, the rising ERβ 
may potentiate progesterone action in the endometrium despite the decline in PR expression.  
Pre-decidualisation continues into the LSP, irrespective of whether or not a blastocyst is 
present. The stromal compartment shows the most profound changes with the cells becoming 
plumper, developing a myofibroblast-like phenotype and increasing production of proteins 
such as prolactin, insulin-like growth factor binding protein-1 and tissue factor. Additionally, 
polymorphonuclear leukocyte invasion becomes characteristic in the LSP. Upon 
implantation, endometrial stromal cells complete decidualisation and terminally differentiate. 
An impairment of receptivity is often seen in women with endometriosis.  
In the absence of pregnancy, a drop in both progesterone and oestrogen levels terminates the 
secretory phase and the endometrium undergoes dynamic remodelling, resulting in menses 
and the beginning of the next menstrual cycle. 
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1.1.2.4 Basalis layer of the endometrium 
The lower basalis layer contains dense stroma, glands and large thick walled arteries and 
serves as a germinal compartment for generating the new functionalis layer each month(8). 
The stroma is more cellular than in the functionalis layer with a higher nucleo-cytoplasmic 
ratio(7). Hormonal regulation is different in the basalis and the glands express PR and ER 
throughout the menstrual cycle, unlike the functionalis(16). This reflects the diverse 
morphological events that occur in the functionalis in comparison with the basalis layer.  
1.1.3 Post menopausal (PM) endometrium 
The depletion of the oogonial stem cell population before birth establishes a limited supply of 
primordial follicles in the ovary(22). With the loss of a cohort of follicles each month during 
reproductive years, the total number of primordial follicles decreases with increasing age. In 
the last 12 years or so of reproductive life, there is a much steeper decline in the remaining 
number of follicles and anovulatory cycles increasingly occur(23). Eventually, only a few 
follicles remain in the involuting ovaries, causing a permanent cessation of menstruation and 
this defines the transition into menopause. The loss of oestrogen and progesterone supply 
causes many physiological effects on a woman’s body. Particularly in the endometrium, this 
loss subsequently ends the cyclical cellular proliferation, differentiation and endometrial 
shedding. The lack of hormonal stimulation causes the endometrial epithelium to flatten, the 
necks of tubular glands to close, and the stroma also changes and resembles the basalis 
stroma of cycling women(20). Additionally, proteinaceous material accumulates in the glands 
producing a classic histologic picture known as “cystic atrophy”(24). Eventually, these 
changes contribute to endometrial atrophy and consequently the post-menopausal 
endometrium is very thin(20). As a consequence, the functionalis layer is very difficult to 
separate from the basalis.   
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1.2 – Basement Membrane 
BM are specialised sheet like structures which separate cell monolayers (epithelium and 
endothelium) and connects them to the interstitial matrix, together creating the ECM(25). 
They possess binding sites for cell adhesion molecules that frequently serve as ligands for 
cell surface receptors(25). Binding of these receptors to BM proteins initiates intracellular 
signalling pathways influencing cellular activities(25). Therefore, as well as providing 
structural support they also mediate many essential functions such as development, 
proliferation, differentiation and cellular growth(5). They also regulate cell polarity, cell 
adhesion, spreading and migration via their effects on the cytoskeleton(5, 26).  
1.2.1 BM Composition 
As seen under the electron microscope after conventional fixation and staining, most BM 
consist of three layers(27). The innermost layer lying adjacent to the basal plasma membrane 
of the resting cells, is the lamina lucida. The lamina densa is the middle layer and is electron 
dense. The outermost third layer, the lamina reticularis, connects the basal lamina to the 
underlying connective tissue(27).  
Depending on the tissue in which they are localised in, BM have heterogeneous molecular 
compositions and biochemical complexity, which is nearly as diverse as their unique 
biological functions(25). Their heterogeneity results from variation in the amounts of BM 
components and the kinds of subtypes used(25). The four major proteins that make up the 
BM include type four collagen (COLIV), laminin, nidogen/entactin and perlecan. Laminin 
and COLIV self assemble into suprastructures, and both networks are crucial for BM stability 
and assembly. Nidogen/entactin and perlecan bridge the laminin and COLIV networks, 
increase their stability and influence the structural integrity of BM(25). Since COLIV and 
laminin are the two main proteins needed for BM structure they will both be evaluated in 
endometrial tissue in this study.  
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1.2.1.1. Collagen Type IV 
Collagens are the major structural component of the ECM, but are also important for tissue 
architecture organisation and cellular processes(28). COLIV is one of 28 different types of 
collagen and is the principal component by weight in BM(28). Even though COLIV is a 
major component of BM, it is not required for BM synthesis and is rather needed for BM 
maintenance(28). In additional, COLIV mediates cell adhesion to BM through binding with 
integrin and non-integrin receptors (refer to section 1.2.2-Integrins).   
The basic monomers found in COLIV protein are α-chain of which there are six types (α1 to 
α6 chains). Each α-chain is 400nm long and is composed of three domains: an amino-
terminal 7S domain (26 kDa), a middle triple helical collagenous domain (120 kDa) and a 
non-collagenous (NC1) terminal domain(28), see figure 1.2.  
 
Figure 1.2: α-chain monomer of COLIV.  
COLIV is a type of non-fibrillar collagen due to the presence of a NC1 terminal domain and 
its composition makes each of the six α-chains unique. The collagenous domain consists of 
repetitive Gly-X-Y amino acid sequence in which X and Y are often proline and 
hydroxyproline, or lysine and hydroxylysine, providing structural integrity. Numerous short 
interruptions ensure good flexibility which is characteristic of collagens(29). The 7S domain 
also consists of interrupted Gly-X-Y repeats.  
A protomer is a single unit of COLIV suprastructure and is composed of three α-chains which 
are linked in their NC1 domains, to create a heterotrimer helix(30). Protomers are synthesised 
in the golgi apparatus and assemble in the endoplasmic reticulum. Only three different 
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protomers, α1α1α2, α3α4α5 and α5α5α6, exist despite the 56 possible combinations(5). 
Following bonding in the NC1 domain, the three α-chains then fully bind in a zipper like 
fashion and protomer secretion occurs, see figure 1.3(28). During development, α1α1α2 is the 
most widely expressed protomer and is distributed throughout the BM. During maturation 
this network gets partially replaced by other protomers that defines the BM particular 
function(5). 
 
 
 
 
 
 
 
 
Figure 1.3: NC1 interactions to initiate COLIV protomer formation.  
Once secreted, the NC1 and 7S domains of protomers play a critical role for producing the 
lattice network of collagen which forms the nucleus for a COLIV scaffold to ensure stability. 
The scaffold evolves into a COLIV suprastructure, with the help of end to end associations 
and also lateral associations between COLIV protomers(30). 
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1.2.1.2. Laminin 
Laminin is needed for initial BM formation and early development and is the most abundant 
non-collagenous component in BM(28). It links the BM to the cell surface through 
interactions with cell surface receptors modulating cell behaviour and also provides a 
structural role.  
Laminins are hetero-trimeric glycoproteins consisting of an α, β and γ chains(5). When these 
chains assemble together they form a cruciform shape with one long and two or three short 
arms (figure 1.4). Five α, four β and thee γ chains exist which can assemble into 16 different 
isoforms of laminin. These isoforms are named in the new nomenclature according to their 
composition, such that lam-111 consists of α1, β1 and γ1 chains(31).  These isoforms are 
differentially distributed during development and in adult tissues, fulfilling specific functions 
as key regulators of tissue structure and cell behaviour. Laminin 1 is the first laminin 
expressed during the development at embryonic stage day 4.5 in mice and is the most 
abundant type of laminin found in BM(25).  
 
Figure 1.4: Structure of laminin unit 
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Each chain contains a laminin N-Terminal (LN) domain on the short arm emerging from the 
long arm which makes each chain unique. The α-chain contains the L4a and L4b globular 
domains, and the β and γ chains contain LF and L4 gobular domain respectively. Rod like 
spacers formed by laminin epidermal-growth-factor-repeats separate the globular domains. 
Laminin initially self assembles by non-covalent bonding between LN domains, and is 
required for calcium dependent interaction between the three chains(32). The long arm is 
formed by parts of all three chains, forming the alpha helical coiled coil (LCC) domain(32). 
The LCC is subsequently flanked by a C-terminal containing five homologous globular 
motifs collectively known as the LG domain(25). LG domains mediate cell adhesion through 
binding receptors including integrins, dystroglycan, syndecan and heparan.  
1.2.2. Integrins 
Many components of the ECM crosstalk with cells through specific transmembrane receptors 
named integrins, triggering a cascade of intracellular events. Apart from cell adhesion, and 
linkage of the cytoskeleton to the ECM, integrins act by signalling receptors, mediating 
growth, differentiation and survival signals from the ECM. Integrins are heterodimers formed 
by α and β chains linked by disulphide bonds, distributed at the cellular surface in a polarised 
manner(33). The pairings determine the ligand specificity, which may also be determined by 
cell type and BM composition. A rearrangement of integrins has been widely reported in the 
endometrium along the menstrual cycle(34). The following combinations are known to be 
involved in receptors for COLIV: α1β1, α1β1, α2β1, α3β1, α6β1, α10β1, α11β1, αvβ3 and 
αvβ5(5). Additionally for COLIV, non-integrin receptors also show COLIV chain specific 
binding including CD44 and discoidin domain receptor-1. A number of integrins have also 
been identified as laminin receptors, of which α3β1, α6β1, α7β1 and α6β4 are the major 
types. These interactions are modulated by the physiological proteolytic degradation of the C-
terminal, usually through the loss of LG domains 3-5(32). 
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1.2.3. Altered Basal Lamina integrity  
COLIV and laminin heterogeneity is the major molecular basis for tissue specific BM 
compositions that create functional diversity across the BM. 15 possible combinations for 
laminin and 6 different types of collagen IV protomers are differentially expressed 
throughout the whole body(25). However, if there are aberrations in any of these subtypes 
after gene mutations, then it may potentially prohibit BM formation(28). In turn, this could 
result in pathological conditions as seen in the kidney, placenta and eye to name a few. On 
the other hand, damage of the BM from injury or pathophysiology is followed by BM 
remodelling. In this case, altered BM integrity triggers cellular activities that aid tissue repair 
such as recruitment of immune cells and activation of fibroblasts. This then initiates BM 
remodelling through protein self assembly, deposition and network formation(29).  
1.2.4. Basal Lamina in Normal Endometrium 
As described in the “Uterine Cycle” section, human endometrial tissues are remodelled every 
month regulated by cellular proliferation, differentiation, and cell death of epithelial cells. 
These cellular events not only depend on cell-cell interactions but also cell-matrix 
interactions. Thus, cyclic remodelling of the endometrium is also thought to be regulated by 
changes of the BM composition(35). Endometrial BM provides an interface between 
epithelial and mesenchymal environments, giving structural support and also playing a 
crucial role in the expression of epithelial phenotype(27). COLIV and laminin have been 
reported to localise in BM of human endometrial epithelium and shown to undergo a 
menstrual cycle dependent production in epithelial and stromal cells(36-38). Ovarian 
hormones are believed to regulate the production of BM, since defective and discontinued 
BM around glandular epithelium in cases of endometrial hyperplasia and endometrial 
carcinoma, is observed to be restored after exogenous progesterone treatment(39).  
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1.2.4.1. Menstrual Phase 
Matrix metalloproteinases (MMPs) are a large family of proteases. In the endometrium 
progesterone has shown to inhibit the action of MMPs, as seen in many microarray 
studies(40). When LSP ceases and in the absence of pregnancy, the accompanying drop in 
both oestrogen and progesterone removes this inhibitory influence on MMPs. Expression of 
MMPs then increases in the endometrium during menstruation and early ProlP, and plays a 
proteolytic role in tissue breakdown of the endometrium during menstruation, together with 
plasminogen activator/inhibitor system(41, 42). In particular, MMPs 2 and 9 preferentially 
degrade BM components, therefore together these proteolytic enzymes degrade the BM 
supporting the epithelium of the decidualised endometrium and the endometrial blood 
vessels, among other ECM components of the endometrium(43).   
1.2.4.2. Proliferative phase 
In the ProlP, important cellular activities take place to recover the thickness of the 
functionalis layer of the endometrium after menstruation(36). During the ProlP, there is a 
high cellular mitotic index and a large number of ECM components being produced in the 
endometrium(2, 42). It has been well established that the proliferative capacity of many cells 
types is strongly influenced by the ECMs(1). 
Surface luminal & glandular epithelium, and vascular endothelium 
Both COLIV and laminin have been shown to be localised in BM structures during early 
ProlP. Using immunohistochemistry (IHC), they are visualised as narrow, continuous bands 
supporting blood vessels and glandular epithelium only(36, 44). Tanaka et al demonstrated, 
however, that COLIV immuno-reactivity intensity was significantly decreased in the BM at 
the luminal and glandular epithelium and vascular endothelium during the late ProlP when 
compared to other phases of the cycle(35). This may demonstrate that the circulating ovarian 
oestrogen at this time may partially regulate COLIV production or specific COLIV 
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proteolytic activities. In contrast laminin expression was seen to be highest throughout the 
proliferative phase out of the whole menstrual cycle(35).   
Tanaka et al used a human endometrial epithelial cell line, that retains many of the 
intracellular signalling pathways found in normal endometrial epithelial cells, to identify the 
effects of COLIV and laminin on cellular proliferation and general morphological changes on 
endometrial cells(35). In particular, laminin was found to enhance endometrial epithelial cell 
growth and inhibit epithelial apoptosis, in contrast to COLIV(35). This suggests that laminin 
may play a pivotal role in endometrial epithelial regeneration after menstruation.  
Stroma 
Unlike epithelial cells, human endometrial stromal cells (ESCs) are found to be immuno-
positive for laminin and COLIV(38). This may reveal that in human endometrium COLIV 
and laminin are produced by stromal cells, but not epithelial cells, and are then transported to 
intercellular spaces and subsequently to the sub-epithelial BM structures. Towards the end of 
the PP, expression of both COLIV and laminin increased in the stroma, although the levels 
increase further in the LSP and deciduas(38). 
1.2.4.3. Secretory Phase 
In the secretory phase functional changes are characterised by intense ECM rearrangement, 
aimed at embryo implantation. Implantation consists of a complex series of interactions 
between embryonic and maternal tissue. Successful implantation in humans requires that the 
trophoblast penetrates several tissue components in its effort to reach maternal blood supply, 
including the epithelial lining, BM and underlying stroma(27).  
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Surface luminal & glandular epithelium, and vascular endothelium 
Positive laminin and COLIV immune-reactivity of BM structures around glands and vascular 
endothelium has shown to persist in the secretory phase(44). Specifically, strong COLIV 
mRNA signals are observed in BM supporting endothelial cells(45). However, laminin 
expression has been shown to be significantly reduced in BM supporting the luminal surface 
epithelium only(35). However, the authors did not conclude what laminin type was reduced, 
as the antibody to laminin used in this study was polyclonal. This is important as one study 
investigated the expression of COLVI, laminin-111 and laminin-332 in secretory normal 
endometrium. They found that COLIV and laminin-111 expression were regular along the 
BM, whereas laminin-332 appeared uneven and interrupted(42). Therefore this may suggest 
that the reduced expression of laminin-332 could be so great that it can affect the overall 
laminin protein integrity in the BM during the secretory phase. As laminin expression 
decreases along the luminal epithelium along the secretory phase, COLIV expression 
becomes dominant in the BM supporting the luminal epithelium. As COLIV is seen to inhibit 
cellular growth and stimulate apoptosis, its strong expression under the LE may contribute to 
the process of implantation, increasing the embryo-implantation receptivity(46).  
Stroma 
Many reports show that ovarian steroid hormones mainly regulate the production of COLIV 
and laminin in ESCs. During the MSP, studies have shown that laminin and COLIV are 
found in streaks and spots in the stroma(36). By the LSP, COLIV and laminin immuno-
reactivity significantly increases(35). Moreover, decidualised ESCs show the strongest 
expression for both components, which develop into a fully formed aura in a mature decidual 
cell(38). mRNA studies supports these findings as stronger laminin and COLIV mRNA 
signals are detected in secretory ESCs and decidual cells, compared to proliferative 
ESCs(45). In some cases, laminin mRNA signals appear stronger in cells adjacent to 
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glandular structures than in more peripherally located ESCs(45). This suggests that COLIV 
and laminin play important biological roles in human decidualised stromal cells. This was 
confirmed by cell viability assay studies having demonstrated that differentiation and 
viability of ESCs in the LSP endometrium maybe be auto-regulated by both BM 
components(35). In particular, laminin has shown to inhibit ESC differentiation(47). The 
development of an aura of BM is likely to restrict the motility of decidual cells. Thus this 
static framework may provides an essential environment within which the events of 
implantation, placentation, immune-modulation and fetal growth occur(36).  
1.2.5 Basement Membrane in PM Endometrium 
Furness and Lam studied the immuno-localisation of BM component laminin in endometrial 
samples taken across all phases of the menstrual cycle (n=56) and in PM endometrium 
(n=11)(48). Results showed that laminin was present in BM supporting glandular epithelium 
and remained to be intact in all phases of the cycle and was similar in PM endometrium. 
Iwahashi et al used immunofluorescence to investigate the effects of oestrogen on the ECM 
in the PM endometrium(24). They found in samples taken from the untreated group, there 
was immuno-localisation for laminin but none for COLIV(24). In contrast, both BM 
components were found in the endometrium of oestrogen treated women, and resembled 
endometrium of cycling women in the proliferative phase. This supporting evidence confirms 
that circulating levels of ovarian hormones are important for the production of BM 
components and this is lost after menopause. Additionally, laminin has also been reported to 
be immuno-localised in BM supporting vascular endothelium in PM endometrium as 
illustrated by Tanaka et al, but the expression was significantly lower than that seen in 
cycling endometrium(35).  
 
 
20 
 
1.3 Uterine Stem Cells 
Stems cells are the fundamental units of biological organisation, playing a critical role in the 
replenishment and regeneration of dying cells and damaged tissues(49). They are defined as 
undifferentiated cells capable of reproducing themselves and differentiating into many 
different cell types(50). During the course of stem cell development, they are first totipotent, 
being able to differentiate into any cell type in embryonic germ layers (ectoderm, mesoderm 
and endoderm) and extra-embryonic tissue (trophoblast, placenta and extra-embryonic 
membranes)(49). Thereafter, they can differentiate into pluripotent stem cells giving rise to 
cells that form all the three germ layers only. As embryonic development ensues, the 
differentiation potential becomes increasingly restricted, producing cells that give rise to 
multiple types of cells within the same germ layer, called multipotent somatic stem cells(51). 
These cells then usually differentiate along only one lineage producing component cells of 
the tissue in which they reside, and are known as unipotent somatic cells. Therefore, 
depending on the stage of development, stem cells can be either classified as either 
embryonic; derived from blastocysts, or adult stem cells (ASCs); derived from post-
embryonic cell lineages(49).  
1.3.1 Embryonic stem (ES) cells  
ES cells, first isolated from the mouse in 1981, are a type of pluripotent stem cell derived 
from the inner cell mass of the blastocyst(52). They have the ability to differentiate to form 
the trophoblast and derivative of all three germ layers(52). Due to their characteristics, ES 
cells show great promise in understanding organ physiology, for example in the heart and 
brain(53, 54). However, ES cell studies face hurdles of problems, including risks of teratoma 
formation and the ethical arguments over the creation, usage and the destruction of human 
embryos. Therefore the application of ASCs may provide an alternative, and research to 
determine their full potential is currently being undertaken. 
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1.3.2 ASCs 
ASCs are small populations of quiescent cells found in an undifferentiated state throughout 
the body after embryonic development(55). They maintain tissue homeostasis through 
replacement of cells in cellular turnover, thereby contributing to the structural and functional 
preservation of the tissues during the lifetime of the individual(55). ASCs are defined by their 
functional properties as seen in vitro: 
 High proliferative potential 
 Substantial self renewal capacity 
 Ability to differentiate into at least one or more lineages  
 Clonogenicity 
Proliferative potential is determined by analysing the total number of cell population 
doublings of one cell by serial passage until senescence(4). Maintenance of the stem cell 
population requires cellular self renewal through mitotic cell division to produce identical 
daughter stem cells(51). Stem cells are classically identified by their clonogenic activity, 
defined as the ability of a single cell to self renew and produce a colony when seeded at 
extremely low densities(49). This well characterised functional activity of ASCs in vitro has 
been used to demonstrate their existence in various tissues.  
There are two types of cell division that maintains this stem cell pool: (a) asymmetric and (b) 
symmetric cell division.  
a) Asymmetric cell division produces an identical daughter cell, which maintains its own 
population of undifferentiated cells (self renewal), and a more differentiated 
progenitor cell, see figure 1.5(56). These progenitor daughter cells undergo rapid 
proliferation, and their daughter cells proliferate producing a more mature progeny 
known as transit amplifying (TA) cells. TA cells which have properties intermediate 
between stem cells and end stage differentiated cells. Although they have limited 
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proliferative potential and inability to self renew, TA cells undergo rapid proliferation 
and increase in cell number(55). As they undergo rounds of cell division they acquire 
differentiation markers as part of the cellular amplification process producing 
numerous terminally differentiated functional cells(51, 55).  
 
 
 
 
 
 
 
Figure 1.5: Diagram to show asymmetric cell division 
b) In contrast to asymmetrical division, symmetrical cell division (see figure 1.6) 
produces two identical daughter stem cells or two TA progenitor cells.   
 
 
 
Figure 1.6: Diagram to show symmetrical cell division 
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Over the past several years there has been a substantial body of literature questioning the fate 
of ASCs. ASCs have previously been thought to have restricted differentiation potential in 
order to produce derivatives limited to the tissue which they reside in or within their 
embryonic germ layer boundaries(51). Nevertheless, this assumption has been greatly 
challenged as in some cases stem cells have shown to transdifferentiate from one tissue 
lineage to a different lineage, a process known as plasticity(57). This involves an acquisition 
of new cellular markers and function of the new cell type without an intervening cell 
division(51). This plasticity has been detected in mesenchymal stem cells in bone marrow, as 
these cells are known to traffic via the blood stream and incorporate into damaged tissue and 
change into many cell types(58). Thus it is now believed that in the setting of tissue damage 
and a change in the extracellular environment, some ASCs such as haematopoietic stem cells 
may not be lineage restricted and may be able to differentiate into other cell types in new 
locations, in addition to their usual progeny of organ of residence(59).  
1.3.3. Endometrial Stem/Progenitor Cells 
As previously explored, the endometrium is a highly dynamic tissue which undergoes 
repeated cycles of growth and regression with each menstrual cycle, and undergoes uterine 
decidualisation in pregnancy(60). Additionally, endometrial growth also follows parturition 
and in PM women taking oestrogen replacement therapy. This level of cellular turnover is 
similar to that seen in highly regenerative tissues such as haemopoetic tissue, intestinal 
epithelium and the epidermis, where ASCs are responsible for generating replacement 
cells(60). Based on these features, ASCs have also been hypothesised to be involved in the 
regeneration and development of glandular and stromal components in the endometrium(61). 
Recent experimental approaches have demonstrated the classical functional properties of 
ASCs in endometrial tissue.   
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Chan et al provided the first evidence for the existence of endometrial stem/progenitor cells 
using cell cloning studies(56). Thereafter, the same group demonstrated endometrial cell 
clonogenicity, as they found 0.22% of epithelial cells and 1.25% of stromal cells were able to 
form individual colonies when seeded at clonal density and they also demonstrated the 
differentiation potential of these cells(62).  They reported that the stromal clonogenic cells 
were able to differentiate into a number of cell types including chondrocytes, adipocytes, 
osteoblasts and smooth muscle cells which are characteristics of bone marrow and adipose 
tissue mesenchymal stem cells(63). They further demonstrated a high proliferative potential 
of  endometrial stem cells with epithelial and stromal cell fractions capable of 30-32 
population doublings before senescence or transformation, whereas non-stem-like 
endometrial cells were capable of only 12 population doublings(51).  
Colongenicity in endometrial tissue has been tested across all phases of the menstrual cycle, 
and also in inactive PM endometrium(62). It has been demonstrated that clonogenic potential 
in epithelial and stromal cells do not differ between the phases of the menstrual cycle and 
between endometrial samples from reproductive and PM women(61, 64). As PM 
endometrium only contains the basalis layer, these findings suggests that putative 
stem/progenitor cells reside in the basalis layer. The lack of difference in clonogenicity 
between the patient groups also suggests that ovarian hormones may not have a regulatory 
control over the stem cell activity, since they fall in PM women. In agreement with this, 
Gargett’s group identified mesenchymal stem cells in the endometrium that did not express 
either PRs or ERα but expressed ERβ(61, 64).  
Stem cells can also be identified as a ‘side population’ (SP) as shown in various adult tissues. 
This method involves incubation with a DNA-binding dye Hoechst 33342 and then analysing 
cells using a dual emission wavelength fluorescence activated cell sorting (FACS). Since 
stem cells are able to pump out the dye via the ATP-binding cassette transporter G2 
(ABCG2) in the plasma membrane, they should appear as a low Hoechst population and are 
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characterised as the side population(60). Given that ABCG2 is a characteristic marker of SP 
cells, it was used to study the spatial distribution of SP in the endometrium using 
immunofluorescence(55). Since endometrial functionalis is thought to regenerate from the 
remaining basalis after menstruation; this suggests that the putative endometrial 
stem/progenitor cells reside in the basalis. Interesting, ABCG2 cells were distributed evenly 
throughout the functional and basalis layers of the endometrium(55, 60).   
The main problem with the proposed stem/progenitor cells from the endometrium is that the 
potential stem cells have not been able to conclusively produce an endometrial like tissue in a 
3D culture or animal model. Furthermore, there are no markers of endometrial epithelial 
stem/progenitor cells. For those reasons, although many studies have tried to investigate the 
source and location of endometrial stem/progenitor cells, their precise origin remains elusive. 
It has been thought that fetal epithelial and mesenchymal cells remain in adult endometrium 
and contribute to the regenerative ability of the endometrium(65). Additionally, several lines 
of evidence suggest that bone marrow-derived cells congregate at sites of tissue damage and 
incorporate into various organs, including the endometrium(60). Recently, a particular study 
showed that female mice receiving bone marrow transplantation from male donors, 
demonstrate genotypically male-derived cells incorporated in their endometrium(66). 
Therefore, it has been postulated that once bone marrow-derived cells populate the 
endometrium, they are able to transdifferentiate into endometrial stem/progenitor cells and 
contribute to the pool of already resident ASCs.  
1.3.4 The Role of BM in the Stem Cell Niche  
In 1978 Schofield hypothesised that stem cells are embedded within fixed compartments 
called niches. Recently, mammalian stem cell niches have been described in germinal, 
haematopoetic, neural, epidermal and intestinal systems(67-70). These physiological 
microenvironments are highly tissue specific structures, comprising of ECM molecules with 
additional surrounding cells, which anchor the ASCs. Niches are thought to play a crucial 
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role in maintaining tissue homeostasis in various ways. Firstly, during periods of inactivity 
they maintain ASCs in a dormant state (G0) by signalling inhibitory pathways, protecting 
them from differentiation, proliferation and apoptotic cues(71). Secondly, they determine the 
fate of stem cell daughters by balancing stem cell replacement (self renewal) and provision of 
functional differentiated cells required for organ function(72). Additionally, they provide a 
protective environment to maintain the genetic fidelity over the stem cells’ life span(60).   
A well organised ECM is crucial for stem cell niche function and mainly comprises of 
cadherins to mediate the adhesive interactions between niche cells and stem cells, and 
integrins to control interactions between ECM and cells(60). It has been proven that breast 
epithelial stem cells live in a niche where ECM proteins provide an optimal 
microenvironment(73). As part of this matrix, BM is an important component to which stem 
cells attach on to(5). The BM is believed to have important function for the structural 
integrity of stem cells, facilitating the polarisation of cells, which is important for cell 
division(5). Such an environment may regulate the stem cells and their proliferating and 
differentiating progenies via the epithelial-mesenchymal cross talk. Therefore, a highly 
selective specialised ECM is needed to maintain stem cell properties, particularly during 
development.  
Growth factors, including epidermal growth factor (EGF), platelet derived growth factor BB 
and transforming growth factor alpha have been shown to support endometrial clonogenic 
activity, and have been suggested to have a role in stem cell niche(61). Interestingly, 
interactions between ECM and growth factors are integral in tissue repair processes(5). ECM 
components can directly bind to and release certain growth factors enhancing their activity or 
protecting them from degradation. This is seen when cleavage of laminin by MMPs releases a 
protein molecule that can bind to EGF receptor, subsequently enhancing cell motility and 
migration, hence enabling tissue repair(5).  
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1.3.5. Stem Cell Markers 
Although functional analyses help identify stem cell activity in the endometrium, definite 
markers for endometrial stem/progenitor cells are unknown and research into indentifying 
specific markers is ongoing(74). A panel of known stem cell markers, including cytokeratin 
5/6 (CK5/6), podocalyxin-like protein 1 (PODXL) and stage specific embryonic antigen 
(SSEA1) will be used in this study to potentially identify putative stem/progenitor cells in the 
endometrium sampled from all patient groups studied.  
1.3.5.1 CK 5/6  
Cytokeratins are the largest subgroup of intermediary filament (IF) proteins, which are 
preferentially expressed in epithelial tissues(75). IF is part of the cellular cytoskeleton which 
are very long, chemically stable, unbranched filaments of ~10nm in diameter(76). These 
filaments braid the nucleus, span the cytoplasm and attach onto cytoplasmic plaques of the 
typical epithelial cell-cell junctions, known as desmosomes(76). Additionally they attach onto 
hemidesmosomes that connect a cell to the ECM. Thus this provides a continuum of stability 
not only between epithelial cells itself, but also to BM and connective tissue compartment of 
the given epithelium.  
Two types of cytokeratins exist: the acidic type 1 cytokeratin (CK 9-20) and the basic type II 
cytokeratin (CK 1-8)(76). Based on their molecular weight and immuno-reactivity, specific 
cytokeratin fingerprinting allows the classification of all epithelia. The type of CK expression 
depends on the type of epithelium and how well differentiated and developed the epithelium 
is(77). Thus for this reason CKs are used to try morphologically classify stem cells, 
intermediate TA cells and their progenies, particularly in mammary and prostate tissue(78, 
79).  
CK5/6 is a marker of differentiated epithelial cells illustrated by its distinctive role in breast 
cancer histology. The mammary gland consists of a network of ducts that form before birth 
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which branch out into the mammary fat pad. These ducts are lined with a double-layered 
epithelium consisting of a basal layer of contractile myoepithelial cells and a luminal layer of 
specialised glandular cells(80). Further differentiation takes place during puberty when there 
is a rapid outgrowth of the ducts. Nonetheless, thereafter, breast epithelium remains relatively 
immature as it is constantly renewed during the menstrual cycle. The final stage of epithelial 
differentiation occurs during pregnancy and lactation. In order for repeated pregnancies to be 
sustained, a subgroup of breast cells needs to retain the potential for rapid proliferation and 
differentiation and this is the function of stem cells, which has also been hypothesised to be 
the driving force behind mammary carcinogenesis(80). This recognition of the regenerative 
capacity has led to the recent isolation of stem/progenitor cell-enriched populations from the 
mouse mammary epithelium(81).  
In breast tissue, it has been shown that the luminal epithelial cells express CK 8/18, CK 7 and 
CK 19, while basal/myoepithelial cells express CK 5/6, CK 14 and CK 17(82). It has been 
suggested that CK5 positive cells display the phenotypic and behavioural characteristics of 
stem/progenitor cells for both the glandular and myopepithelial cell lineages(83). Using 
immunohistochemistry, Bőcker et al stained paraffin sections of breast tissue with CK5/6 and 
suggested that a breast stem cell is CK5/6 positive in the basal positioned cells that 
differentiate into all other breast cell types(84) and these results were verified by other 
studies(85, 86). However, shortly after, Clarke et al studied the expression of CK5/6 in 
matched pairs of paraffin wax embedded and frozen breast specimens. The staining patterns 
reported previous CK5/6 positive staining in antigen-retrieved paraffin sections but no CK5/6 
only cells were found in frozen sections of the normal breast(87).  
Recently, cytokeratin expression was analysed in cultured mouse mammary epithelial cells 
(MEC) during early and post natal development phases(88). The study found CK6+ putative 
mammary progenitor cells arise during embryogenesis with distinct temporal and spatial 
distribution(88). Whereas CK5 expression was considerably lower than CK14, which are two 
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CKs that are often co-expressed, during the first postnatal weeks of mammary 
development(88).  
Since both breast and endometrial tissue undergo significant changes during the menstrual 
cycle and are both responsible to ovarian hormones, CK5/6 will be investigated as a marker 
of endometrial stem/progenitor cells in this study.  
1.3.5.2 PODXL 
Podocalyxin is a transmembrane glycoprotein, encoded by the PODXL gene, belonging to the 
sialomucin protein family(89). This protein was originally identified as an important 
component of glomerular podocytes. Podocytes are highly differentiated epithelial cells with 
inter-digiting foot processes covering the outer aspect of the glomerular BM. The foot 
processes of podocytes are covered on their apical surface with an anionic glycocalyx, which 
PODXL is a major component of(90). It contributes to podocyte characteristics as it is an 
intensely negatively charged molecule present in large amounts on podocyte foot processes 
and lines the surface of endothelial cells(91, 92). This negative charge is thought to maintain 
the distance between foot processes of neighbouring cells and between circulating cells and 
the endothelium(89). The basal surface of podocyte foot processes is connected to the 
glomerular BM at focal contacts(93). It has been suggested that glomerular BM components 
play morphogenetic roles in foot process formation, correlating with the expression of 
podocalyxin. Nonetheless, there is evidence that podocalyxin inhibits cell binding and 
spreading to BM components(93). This anti-adhesive effect is thought to contribute to the 
specialised conformation of podocytes(93). After its discovery, this protein was first cloned 
in 1995 from rabbit glomerulus, and was termed podocalyxin-like protein 1 (abbreviated as 
PODXL) sharing many of the characteristics of the original podocalyxin protein(89). 
 
 
30 
 
Subsequently, PODXL was found to be expressed in the haematopoietic system with close 
relation with hematopoietic stem cell marker CD34, and the recently discovered sialomucin, 
endoglycan(94, 95). Thereafter, PODXL was identified as a marker of malignant testicular 
tumour expressed on human embryonic carcinoma (EC) cell lines(96). Human EC cell lines 
are established malignant pluripotent stem cell lines derived from human germ cell tumours, 
therefore based on these results, PODXL is known as a marker of undifferentiated embryonic 
stem cells(97). In addition, it is abnormally expressed in subsets of breast, liver, pancreatic 
and kidney cancer as well as leukaemia(98). Strikingly, it is often associated with the most 
aggressive cases, and it is likely involved in metastasis(98).  
 
1.3.5.3. Stage specific embryonic antigens (SSEA) 
Extracellular glycolipids, cell surface carbohydrates, are the first cellular component 
encountered by approaching cells, antibodies and other molecules(99). It is well known that 
the expression patterns and levels of glycolipids drastically change during development, 
meaning that they can be useful stage-specific marker molecules of developing cells, 
including stem cells(100).  Carbohydrate antigens were first described by Solter and Knowles 
to show a stage-specific expression in undifferentiated mouse ES cells and undergo marked 
alterations in their localisation in defined regions of the embryo(101). Therefore, they are of 
practical value in analysing cell differentiation(101). Significant carriers of stage specific 
carbohydrates on ES cells are the lactoseries (SSEA-1) and globuloseries (SSEA-3 & SSEA-
4)(101).  
The epitope of SSEA-1 antibody has shown to correspond to that of Lewis X antigen (LeX), 
but strictly, is not equal to as LeX.(100). According to the cluster of differentiation (CD) 
nomenclature, SSEA-1 is also referred to as CD15(100). SSEA1, detected by a monoclonal 
antibody against mouse EC cells, is also shown to be an established marker of mouse ES 
cells. It appears first in the late eight-cell mouse embryos (in approximately 50% of ES cells), 
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later becoming restricted to specific cell types (appearing is less than 10% of ES)(102). 
Overall, this illustrates the importance of SSEA-1 as a marker for mouse undifferentiated 
cells(102). The functional role of SSEA-1 is not well understood, however, it is generally 
considered to be involved in cell adhesion and compaction of the mouse embryo at the 
morula stage and also in EC cells(102).  
In contrast with mouse, human ES and EC cells do not express SSEA-1 in the same manner. 
During the course of differentiation of human EC cells, there is a transition from SSEA-3
+
, 
SSEA-4
+
/SSEA
- 
to SSEA-1
+
 only phenotype(103). The diminished expression of SSEA-3 
and SSEA-4 in the plasma membrane upon differentiation makes them useful markers for 
pluripotency, and additionally, SSEA1 has been prospectively utilised to isolate multi-
potential embryonic stem cells(99). However, it has been postulated that they do not have a 
functional role in human ES cells as their depletion using inhibitors had no significant effect 
on the cell’s ability to remain undifferentiated(99). Primordial germ cells have shown 
resemblance to ES cells by their ability to induce teratocarcinomas. Human primordial germ 
cells with similar properties to ES cells are called embryonal germ (EG) cells, and have been 
shown to express SSEA-1, SSEA-3 and SSEA-4(102, 104).  
Neural stem cells are defined as undifferentiated neural cells, derived from adult brain or 
from embryos, which yield both neurons and glial cells and are expected to be valuable in 
therapy in neurodegenerative diseases. Flow cytometric analysis reveal both mouse and 
human neural stem cell express SSEA-1, at postnatal day 1 and at gestational week 17 
respectively(105). Thus, as SSEA1 are expressed in more mature progenitor cells of nervous 
tissue, this indicates its role as a marker for more differentiated TA cells(100).  
Although carbohydrates are complex structures, their cellular expression is highly regulated 
and appears to be dependent on the pattern of glycosyltransferases, found in the golgi 
apparatus, modulating post-translational glycosylation(106). The fucosyltransferases (FUT) 
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are a family of glycosyltranferases that play a crucial role in the developmental control of cell 
surface glycans(106). In mammals, fucosylated glycans linked to proteins are involved in a 
wide range of mechanisms such as cell adhesion during development, inflammatory response 
and leukocyte trafficking(106). Different FUT enzymes transfer different carbohydrates 
components on glycans on various linkages(106). Interestingly, FUT4, a key enzyme that 
transfers fucose at α1,3 linkage, is lost during in vitro differentiation of mouse EC cells in 
parallel to the disappearance of SSEA1(101).  
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1.4 - Endometriosis 
Endometriosis is one of the commonest gynaecological conditions characterised by the 
presence of endometrial tissue found outside the endometrial cavity. These ectopic lesions are 
morphologically and biologically similar to normal endometrium, containing functional 
endometrial glands and stroma. Endometriosis is predominantly found in women of 
reproductive age, from all ethnic and social groups with an estimated prevalence of 2-
22%(107). It should be suspected in women with subfertility, severe dysmenorrhoea, deep 
dyspareunia and chronic pelvic pain(108). However, the clinical presentation varies 
depending on the location and severity of the disease process. As well as physical well being, 
these associated symptoms can also impact on mental and social well being too, creating a  
huge burden on the economy.  
1.4.1. Pathophysiology 
There have been significant developments in recent years regarding our understanding of 
endometriosis, however the pathogenesis of endometriosis still remains unclear and the origin 
of endometriotic implants has long been an area of active investigation.  
Currently there are three theories that describe the aetiology of endometriosis: 
THEORY ONE: Menstrual regurgitation  
‘Menstrual regurgitation’ is the most widely accepted theory that was proposed by Sampson 
in 1927(109). This theory states that fragments of endometrium are transferred through the 
fallopian tubes in a retrograde manner at the time of menstruation. This is followed by 
implantation of viable endometrial cells into the peritoneum and pelvic organs to establish 
ectopic growth of endometrial tissue. Thus, endometriotic cells are thought to have an 
invasive phenotype similar to metastatic tumour cells. However, the fundermental 
mechanisms by which menstrual endometrium adhere, proliferates, and established a 
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functional vasculature in an ectopic site remain to be elucidated. Retrograde menstruation is a 
universal phenomenon, occurring in at least 76-90% of women undergoing peritoneal dialysis 
and laparoscopy(110, 111). Nevertheless, given that retrograde menstruation occurs in most 
women, it is still unclear why some women develop endometriosis whilst others do not. This 
suggests a primary role of abnormal eutopic endometrial cells (lining the uterine cavity) or an 
altered peritoneal environment contributing to the establishment of endometriosis. 
A Baboon Model for Endometriosis 
In order to understand the early and progressive events associated with the establishment of 
endometriosis, a Baboon model has been developed in which the disease can be 
induced(112). In this model, menstrual endometrium is harvested from baboons, specifically 
Papio Anubis, using a pipelle and during laparoscopy the pipelle contents are deposited at 
three sites: the pouch of Douglas, the broad ligament adjacent to the oviducts and on the 
uterus. At the subsequent menses, the animals undergo a second laparoscopy and endometrial 
re-seeding at the same ectopic sites(112). The advantage of the induced model is that the 
progressive changes in both eutopic and ectopic endometrium can be studied in a non-human 
primate model at specific times during the menstrual cycle and as the disease process 
continues(112). Hapangama et al used the baboon model to demonstrate the relationship 
between eutopic and ectopic endometrial cells(113). They found that during the disease 
process eutopic endometrial cells acquired a more pro-proliferative potential that contributes 
to the pathogenesis of endometriosis via repeated retrograde menstruation(113).  
THEORY 2: Coelomic Metaplasia 
The second theory, coelomic metaplasia, states that endometriosis develops from metaplasia 
of the cells lining the visceral and abdominal peritoneum induced by a stimulus(114). This 
hypothesis can account for cases where endometriosis is found in men, pre-pubertal and 
adolescent girls, distant ectopic sites and endometriosis found in women with congenital 
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absence of mullerian structures(4). Despite these intriguing findings, evidence to support this 
particular theory remains elusive.  
THEORY 3: Embryonic rest theory 
Lastly, the embryonic rest theory proposes that at puberty there is activation of cells of 
Mullerian duct origin at various sites in pelvic cavity producing endometrial tissue(115). This 
theory supports the findings of rare cases in which endometriosis lesions are found in males, 
as the male embryo initially develops female-specific embryological structures(116). 
However, again, this theory also remains to be unproven and entirely hypothetical. 
 
Link between endometriosis and cancer 
For many decades, endometriosis has been suspected to play a role in the aetiology of ovarian 
cancer. Epidemiological data suggests a link between endometriosis and ovarian cancer with 
a twofold increased risk of developing ovarian cancer in patients with endometriosis in 
general and a further fourfold increased risk for high risk endometriosis patients with 
infertility(117). In ovarian cancer, the metastatic spread of malignant cells first involves the 
disruption of the mesothelium exposing the underlying ECM which provides an environment 
of cell adhesion, invasion and growth(118). Similarly, in endometriosis endometrial cells 
adhere to the exposed mesothelium where the initiate ectopic growth of endometrium.  
Therefore, endometriosis is thought to exhibit some of the characteristics of tumours since the 
two diseases involve the metastatic spread of cells. 
1.4.2 Diagnosis and Staging 
A history and examination can yield a number of significant findings, however none is 
diagnostic. Similarly, ultrasound scan can only give a presumptive diagnosis of ovarian 
involvement of endometriosis(119). Surgical exploration of the peritoneal cavity through 
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laparoscopy followed by histological confirmation is the gold standard for the diagnosis of 
endometriosis(119). Three clinically distinct forms of endometriosis include endometriotic 
implants on the surface of the pelvic peritoneum and ovaries (peritoneal endometriosis), 
ovarian cysts lined by endometrial mucosa (endometriomas) and a complex solid mass 
comprised of endometriotic tissue blended with adipose and fibromuscular tissue, residing 
between the rectum and the vagina (rectovaginal endometriotic nodule)(120). During 
laparoscopy, the peritoneum, fallopian tubes, ovaries and the pouch of douglas are examined 
for the presence of endometriosis, adhesions, fibrosis and cyst formation. The extent of 
endometriosis is then staged I-IV according to the American Society for Reproductive 
Medicine (ASRM) system which correlates well with chances of infertility, see table(121).  
 
Table 1.1 – American Society for Reproduction Medicine Classification of Endometriosis 
 
However, this classification lacks a description of women with pain, and needs to be included 
since it can be a recurrent and long-standing feature of endometriosis. Additionally, the 
classification does not take into account of the functionality of different endometriotic 
implants, nor does it include any biological markers(119). It may be impossible to include all 
these factors and it is unlikely that an accurate staging system will be introduced until we 
have a better understand of the pathophysiology behind endometriosis. 
Histological features of ectopic lesions include the presence of stromal and endometrial 
epithelial cells, chronic bleeding and signs of inflammation. Since endometriosis is already 
established in many women when they first present with symptoms, the initiation of the 
Stage Description 
I Superficial lesion present with or without a few adhesions. 
II As above, in the presence of deep infiltrating lesions found in the cul de 
sac 
III As above, in the presence of endometriomas on the ovary in addition to 
more adhesions 
IV As above with large endometriomas and extensive adhesions.  
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disease is difficult to establish. Endometriotic glandular tissue is morphologically 
heterogenous and, in comparison with eutopic endometrium, the glands appear larger and 
more disorganised(122).  
1.4.3. Management 
Treatment of endometriosis needs to be tailored to the individual woman depending on her 
symptoms, priorities and stage of endometriosis. Treatment of endometriosis entails surgical 
and pharmacological intervention, either individually or combined. Medical treatment relies 
on manipulating ovarian hormones and inducing amenorrhoea, and includes combined oral 
contraceptive pill, analogues of GnRH, or progesterone analogues and aromatase 
inhibitors(114). These medications are suitable in reducing pain, but their side effect profile, 
e.g. increased cardiovascular risk, limits their long term use. Additionally recurrence is 
common on discontinuation and does not improve fertility(114). If fertility is priority, 
conservative surgery is effective in reducing pelvic pain as well as improving pregnancy. 
Surgical interventions include excising or ablating endometriotic lesions and the removing 
adhesions in the peritoneal cavity(114). Overall, currently, there is no universally accepted 
protocol for the treatment of endometriosis thus treatment is very much individualised.  
1.4.4 Basement Membrane in Endometriosis   
As previously explored, the endometrium is a highly dynamic tissue and therefore 
dysregulation of important structural macromolecules of BM may have a role in endometrial 
pathologies. It has already been established that expression of tenascin, an ECM glycoprotein 
found in endometrial stroma, is significantly higher in ectopic lesions than in eutopic 
endometrium, confirmed by western blotting analyses (123). ESCs from women with 
endometriosis have also shown to have a significantly increased adhesive capacity when 
placed in tenascin-C, suggesting this ECM protein may have a role in the pathogenesis of 
endometriosis. Whatever the mechanism by which endometriosis is established, its 
38 
 
development is likely to involve cell adhesion, proliferation, invasion into the underlying 
tissue, and differentiation of the ectopic endometrial cells. As these cellular events are 
modulated by ECM components, it is possible that endometriosis may be associated with 
aberrantly regulated cell-BM interactions.   
There are similarities and differences seen in the eutopic endometrium taken from women 
with no endometrial pathologies (controls) and women with endometriosis. Using IHC, 
Harrington et al showed that the basalis region of the eutopic endometrium collected from 
endometriosis patients showed strong staining for COLIV and laminin, irrespective of what 
phase of the menstrual cycle the sample was collected in(123). This immuno-expression was 
consistent to what was seen in the endometrium collected from controls. This suggests that 
basalis layer in the endometrium of patients with endometriosis remains in its preserved 
functional state across the menstrual cycle. Another study analysed BM components in the 
LSP endometrium of women with unexplained infertility, a condition closely associated with 
endometriosis, and also in endometrium from normal fertile controls(37). In contrast to the 
previous study, all endometrial biopsies were immuno-negative for COLIV and laminin in 
ESCs and BM supporting blood vessels and glands in the infertility group(37). The lack of 
endometrial ECM components may have a negative effect on cell recruitment and migration 
and could result in incomplete embryo-maternal recognition, a possible consequence of 
which may be implantation failure.  
Additionally, remarkable similarities have been observed between eutopic and ectopic 
endometrial samples in the expression and localisation of BM components. These include 
similar strong expression of laminin epithelial BM and COLIV in glandular epithelium BM 
in matched eutopic and ectopic endometrial samples(123, 124). In addition, when studying 
endometrial stroma, laminin expression appears to be similar between ectopic lesions and of 
control eutopic endometrium when all sampled during the LSP. Notably, laminin 5 has been 
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reported to be discontinuous and interrupted in normal secretory endometrium, and this same 
pattern has also been noted in endometriosis lesions(42).  
Proteolytic activity has seen to be increased in ectopic lesions since higher levels of MMP-9 
and a higher ratio of MMP-9 to tissue inhibitor of MMP (TIMP)-1 are found, when compared 
to eutopic endometrium from women with and without endometriosis(42). This could result 
in enhanced proteolytic potential of endometrial fragments undergoing retrograde 
menstruation, increasing invasiveness and facilitating the development of endometriotic 
foci(1). Using collagen invasion assays, Gaetje et al were able to show that cells from 
peritoneal endometriotic lesions express this invasive phenotype(125). Interestingly, a 
retrospective analysis showed that in 12 out of 15 samples of fine needle aspirations from 
endometriotic cysts showed oval structures very strongly stained for COLIV. The authors 
concluded that repeated bleeding and inflammation, involving proteolytic activity, in ectopic 
lesions can greatly fragment BM, therefore, assuming this oval shape(126). 
Petra et al investigated the role of BM components COLIV and laminin in endometrial cell 
adhesion and proliferation, both of which are known to take place in the pathogenesis of 
endometriosis. The authors claimed that as cultured ESCs retain integrin expression in vitro, 
ESCs can be accepted as a model for investigating the function of integrins and their ligands, 
and effectively analysing cellular adhesion(1). Using this model, ESCs derived from 
peritoneal surface and ovarian lesions and from endometrium of women with endometriosis 
exhibit an increased attachment to BM components. In particular ESCs from ovarian 
endometriotic lesions exhibited 2.5-3 fold increase in attachment to COLIV and laminin(1). 
Additionally, ESCs from peritoneal surface lesions exhibited a 1.5-2 fold increase in 
attachment to COLIV(1). Experiments have shown that endometrial cells do not adhere to 
intact epithelium but preferentially adheres to sub-epithelial structures(127). In the event of 
mesothelial injury or rupture of primary ovarian follicle, this may allow peritoneal and 
ovarian BM components to be exposed thus providing potential sites for attachment. This 
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interaction between endometrial cells and the sub-epithelial layer is likely to be 
communicated by integrins(128). Peritoneal fluid also contains released proteolytic fragments 
of COLIV and laminin during ovulation, increasing the interaction between endometrial cells 
and ECM components for attachment in the peritoneum.  
Endometrial cellular proliferation has shown to be increased in endometriosis(129). It has 
been thought that the development of ectopic endometrial implants involves proliferation of 
ESCs subsequent to their attachment to the peritoneal tissue(1). To measure the proliferative 
capacity of ESCs in different ECM components, DNA synthesis was analysed in both eutopic 
and ectopic stromal cells(1). These experiments revealed that ESCs derived from eutopic 
endometrium from women with endometriosis demonstrated a 1.5-3 fold increase in DNA 
synthesis when separately placed on COLIV, laminin and other ECM components. 
Additionally, ESCs derived from ovarian lesions exhibited a 2-4 fold increase in DNA 
synthesis when separately placed on laminin and other ECM components(1). Therefore, these 
molecules could modify the adhesive and proliferative behaviour of ESCs in menstrual 
effluent that are transported into the peritoneal cavity through retrograde menstruation. 
 
1.4.5. Stem/progenitor cell function in Endometriosis 
Recent characterisation of possible endometrial stem/progenitor cells has provided new 
insights into endometrial physiology and the pathophysiology of various gynaecological 
disorders including endometriosis and endometrial cancer. To date there is no direct evidence 
for the role of stem/progenitor cells in the pathogenesis of endometriosis. However, there are 
numerous studies that give plenty of indirect evidence for the function of endometrial 
stem/progenitor cells in the development of endometriotic implants. The array of evidence 
given can support all theories of the cellular origin of ectopic endometriotic deposits:  
 
41 
 
Retrograde Menstruation 
Recent evidence suggests women with endometriosis have a greater amount of basalis 
endometrium in their menstrual debris than normal fertile women, as described by 
Leyendecker et al(130). Fundamental differences have been seen between the cyclical pattern 
of ovarian hormone receptors of the basalis and functionalis layers in the endometrium. 
Leyendecker et al used this concept and also explored for any potential similarities or 
comparisons in PR and ER expression between eutopic and ectopic endometrium. They 
found that ectopic endometrium mimicked the cyclical pattern of ER and PR of the basalis 
and was ‘out of phase’ with the functional eutopic endometrium(130). This study also 
showed that significantly more basalis layer of the eutopic endometrium was shed in the 
menstrual flow of women with endometriosis compared with that of healthy controls(130). 
Thus, in combination with evidence suggesting endometrial stem/progenitor cells mainly 
reside in the basalis and that women with endometriosis have larger volumes of retrograde 
menstrual flow, this supports the theory that endometrial stem/progenitor cells are transported 
in a retrograde fashion and reach peritoneal cavity where they adhere and establish ectopic 
lesions. It is thought that long term ectopic lesions develop from endometrial stem/progenitor 
cells and ectopic lesions that easily resolve are established by more mature TA cells(51). 
Additionally, it is possible that the endometrial stem cell activity may also be abnormally 
high in endometriosis patients, increasing their capacity to implant and establish themselves 
as ectopic tissue(51).  
Coelomic Metaplasia 
Metaplasia of the peritoneal lining has been suggested as a possible cause of endometriosis. 
However, another source of metaplastic cells is the bone marrow-derived cells, with trans-
differentiation capacity, that gain access to the peritoneal cavity via the circulation. Bone 
marrow-derived cells as an extra-uterine source of stem cells may be responsible for the 
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observations that support the theory of coelomic metaplasia. Du and Taylor tested this theory 
by using an experimental model for endometriosis. In this study, samples of wild type 
endometrium were transplanted into the peritoneal cavity of hysterectomised mice. These 
mice were then recipients for bone marrow transplantation from LacZ transgenic mice. 
Ectopic endometrial lesions were later sampled and LacZ expressing stem cells were found to 
be incorporated into the implants, and were capable of differentiating along epithelial and 
stromal cell lineages at a frequency of 0.04% and 0.1% respectively(131). Altogether, this 
suggests that bone marrow-derived cells can not only transdifferentiate into functional 
endometrial cells after seeding the endometrium, but can also behave similarly outside the 
endometrial environment. In light of this evidence, bone marrow-derived cells may contribute 
to the normal endometrial physiology and the development of endometriosis.  
Embryonic rest theory 
Remnant Mullerian cells have some characteristic stem cell properties of high proliferative 
potential, multipotency and self renewal. Thus, it is possible that potential stem/progenitor 
cells can persist in the remnants of the mullerian system, which can form endometriotic 
implants(4).  
Even though there is a vast amount of indirect evidence indicating the role of putative 
endometrial stem/progenitor cells there is still a lot of unanswered questions. For example it 
is not known whether there is a difference in the endometrial stem-like cells between women 
with and without endometriosis. Additionally, even though “retrograde menstruation” is the 
most widely accepted theory behind the pathogenesis of endometriosis, there is evidence 
lacking behind the idea that endometrial stem/progenitor cells actually are shed in a  
retrograde fashion. Extensive research into the role of stem cells in endometriosis is still 
needed, nonetheless, it is an area difficult to investigate.  
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1.5.  Endometrial Carcinoma  
Endometrial carcinoma, a common gynaecological cancer affecting 142,000 women, with an 
estimated 42,000 deaths per year worldwide (132). In the UK, 7536 women were diagnosed 
with endometrial cancer in 2007, making it the fourth most common cancer to affect women 
after breast cancer(133).  Endometrial cancer can be divided into two major groups 
depending on histopathology, epidemiology, and clinical behaviour(133). Type 1 tumours are 
the most common tumours and constitute oestrogen dependent endometrioid  
adenocarcinoma and type 2 are more aggressive tumours that carry a poor prognosis. 
Endometrial cancers are also graded, from I to III, using the International Federation of 
Gynaecology and Obstetrics (FIGO) grading system and this classification is based on the 
architecture of the tumour, the appearance of the nucleus in cancer cells and the mitotic 
index(134).  
1.5.1. Basement Membrane in Endometrial Cancer 
With the carcinogenesis process, the organised epithelial stromal cellular architecture is lost 
in the endometrium(2). Altered BM composition and assembly may influence endometrial 
carcinoma cell growth and invasion and metastasis(135). When analysing BM integrity in 
accordance with the tissue grade, it has been shown that well differentiated endometrial 
carcinomas appear to have a preserved intact BM in most areas of the tumour, whereas a 
progressive lack of these structures seems to parallel an increasing degree of tumour 
dedifferentiation(135). This disruption or absence may reflect increased degradation or 
decreased production and deposition of BM material by the tumour cells(135). Since this 
alteration of the BM is a hallmark of carcinogenesis, for comparison with the BM of the 
normal and regulated endometrial regeneration and in the benign metastatic disease of 
endometriosis we examined the BM integrity in endometrial cancer.  
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1.5.2. Stem Cell Activity in Endometrial Cancer 
A small number of cells within the tumours have been shown to have stem cell properties that 
contribute to its growth and metastases and they are referred to as cancer stem cells 
(CSCs)(51). CSCs have been identified in acute myeloid leukaemia, breast cancer, 
glioblastoma and prostate cancer(136). CSCs differ from ASCs in that they are no longer 
controlled by their stem cell niche(51). Thus, there is no regulation on proliferative activity in 
turn producing cells comprising the bulk of the tumour. Recently, Hubbard et al demonstrated 
a role for CSCs in endometrial cancer(3). This comprehensive study showed that in all 34 
samples endometrial cancerous tissue, a small population of clonogenic tumour cells were 
identified and were able to be serially cloned. This indicates that endometrial tumour cells 
have a self renewal capacity and this property was shown to increase with increasing tumour 
grade. Additionally, a side population have also been identified in endometrial cancer, also 
indicating a small population of cells similar to ASCs(137).  
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1.6 – Summary and Project Hypotheses 
The pathophysiology of endometriosis is an area of ongoing debate. It has been suggested 
that eutopic endometrium from women with endometriosis have altered cellular activities, 
contributing to the pathogenesis. Many theories have been proposed to establish the cause of 
endometriosis, two of which include altered endometrial ECM proteins and altered 
endometrial stem cell activity in the eutopic endometrium.  
Therefore, this project will test the following hypotheses: 
1. Is endometrial basement membrane (BM) integrity altered in women with 
endometriosis?    
In normal fertile women, endometrial basement membrane (BM) has been shown to 
have a menstrual cycle dependent production in order to help prepare endometrial 
receptivity to implantation. BM has shown to be disrupted in the metastatic process of 
endometrial cancer and has been postulated to be altered in the benign metastatic 
disease of endometriosis. Thus, we aim to explore in detail whether BM is disrupted in 
eutopic endometrium collected from women with endometriosis, by assessing the 
expression of endometrial collagen IV and lamina across the menstrual cycle. In order 
to gain comparative results, we will also to assess the expression of both BM 
components endometrium collected from fertile control women.  
2. Is BM disrupted in the pathogenesis of endometrial cancer?  
Additionally we will explore the expression of BM components in endometrial cancer 
tissue samples to confirm that they are aberrantly expressed in this malignant disorder. 
In order to gain comparative results we will also test BM components in endometrium 
collected from PM women.  
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3. What are the expression levels and patterns of stem cell markers CK5/6, PODXL 
and SSEA-1 in the endometrium of normal fertile controls? 
It has been postulated that endometrial stem/progenitor cells contributes to the highly 
regenerative ability seen in the endometrium. However markers for endometrial 
stem/progenitor cells are lacking. By using known stem cell markers for extra-uterine 
tissues; PODXL, CK5/6 and SSEA1, we will assess whether these are expressed in the 
normal cycling endometrium and how expression changes along the course of the 
menstrual cycle. 
4. Do these stem cell markers (PODXL, CK5/6 and SSEA1) display a different 
pattern and level of expression in endometrium collected from women with 
endometriosis? 
Recent characterisation of possible endometrial stem/progenitor cells has provided 
new insights into endometrial pathologies. Altered endometrial stem/progenitor cells 
are thought to play a role in pathogenesis of endometriosis.  By using the above stem 
cell markers, we will also test whether they are aberrantly expressed across the 
menstrual cycle, in eutopic endometrium collected from women with endometriosis. 
5. Do endometrial cancer cells display stem cell markers PODXL, CK5/6 and 
SSEA1 and how? 
Endometrial cancerous cells have shown to possess stem cell properties. By again 
using the above panel of known stem cell markers, we will investigate if they are 
expressed by endometrial cancer cells.   
6. Is BM integrity correlated with the stem cell markers investigated? 
Basal lamina components are also important for the structure and function of stem cell 
niches. We will investigate for any potential relationships between basal lamina 
integrity with the expression of endometrial stem/progenitor cell markers in the fertile 
control, PM and endometriosis groups.   
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Chapter Two: 
METHODS & MATERIALS 
 
2. 1 - Ethical approval 
Ethical approval for the project, including collecting human endometrial samples was 
obtained from Liverpool (Adult) Research Ethics Committee. All samples included were 
collected from patients attending Liverpool Women’s Hospital and they all gave informed 
written consent. The benign endometrial samples of women in the reproductive age (both 
fertile control and endometriosis patients) were collected under the ethical approval 
09/H1005/55 and 04/Q1505/112. The post menopausal samples and endometrial cancer 
samples were collected under the ethical approval 11/H1005/4. (For letters of approval from 
LREC, see appendix 2). A comprehensive literature review (using pubmed, ovid, etc) was 
performed initially to confirm the originality of the work included in this study.  
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2.2 - Study Groups 
Endometrial biopsies were taken from four different groups of patients. All participants were 
only included in the study if they met the inclusion criteria. The exclusion criteria for the 
study were women taking any form of hormonal treatment in the preceding three months, if 
they were breast feeding or pregnant.  
2.2.1 Fertile Control Group 
30 endometrial biopsies were obtained from normal fertile women in 3 different time points 
in the menstrual cycle; the ProlP (n=10), MSP (n=10) and LSP (n=10).   
Inclusion criteria: 
 Normal ovulating women  
 Women undergoing surgical procedures for benign conditions e.g. laparoscopic 
sterilisation 
Exclusion Criteria: 
 Any history of abnormal vaginal bleeding 
 Women currently breast feeding or pregnant 
 History of infertility or recurrent pregnancy loss 
 History of endometriosis 
2.2.2 Endometriosis Group 
30 eutopic endometrial biopsies were obtained from patients with active, peritoneal 
endometriosis diagnosed concurrently at the time of sampling the endometrium, during the 
ProlP (n=11), MSP (n=11) and LSP (n=8).  
Inclusion criteria:  
 Women with regular menstrual cycles 
 Surgically diagnosed active peritoneal endometriosis at the time of biopsy taking 
 Dysmenorrhoea and/or chronic pelvic pain.  
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2.2.3 Endometrial Cancer Group 
Endometrial samples were also collected from patients with endometrial cancer. Biopsies 
were obtained from patients with FIGO grade I (n=5), grade II (n=5) and grade III (n=3) 
endometrioid adenocarcinoma.   
Inclusion criteria: 
 Patients undergoing surgical treatment with a histological diagnosis of endometrioid 
adenocarcinoma 
2.2.4 Post-Menopausal Group 
All patients with endometrial cancer who participated in this study were post-menopausal. In 
order to have a comparative group for these post menopausal women with endometrial 
cancer, endometrial biopsies were also taken from post-menopausal women (n=5) who were 
undergoing hysterectomy for non-endometrial pathology related conditions such as uterine 
prolapse. 
Inclusion criteria: 
 Patients undergoing a hysterectomy for benign non-endometrial pathology related 
causes, e.g. utero-vaginal prolapse 
Exclusion criteria: 
 History of endometrial pathology 
 History of post menopausal vaginal bleeding 
 On hormone replacement therapy 
2.3 - Participant Identification and Enrolment 
Suitable patients for the study were highlighted by checking through theatre lists and 
reviewing patients’ notes. Gynaecology outpatient clinic, pre-operative clinic, and 
gynaecology ward staff were given appropriate patient information leaflets to pass onto the 
selected patients as soon as they attended the hospital after being listed for their planned 
surgery. This allowed patients to read about the background of the study and what it entailed, 
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before verbal information was given from researchers. Only Good Clinical Practice (GCP) 
trained personnel who were fully aware of the ethical principals involved in informed 
consent, were allowed to consent and recruit patients for the study. After verbal consent was 
given, written consent was also obtained from all patients considered for the study. Patient 
demographical information including age, weight, height, body mass index (BMI), last 
menstrual period, cycle regularity, parity and past medical history was obtained from each 
participant. In the endometriosis group, the disease stage was notified at the time of 
diagnostic laparoscopy for each patient and was also recorded. See appendix 3 for sample of 
patient information leaflets, consent forms and patient demographic data form.  
2.4 - Collecting the biopsy 
Trained professionals obtained endometrial biopsies in a safe and sterile manner from all 
patients who were consented to take part in the study. Samples were collected after the 
planned surgical procedure; this ensured that no added discomfort or inconvenience was 
brought upon the patients.  Two types of endometrial samples were collected for the study; 
full thickness and pipelle samples.  
2.4.1. Full thickness samples 
For women who underwent a hysterectomy, a full thickness sample was taken immediately 
after the uterus was removed illustrated in figure 2.1. In order to obtain this biopsy, the 
removed uterus was first placed on its anterior side on a surgical trolley. Using a carbon steel 
surgical blade (size 22, Swann-Morton, Sheffield, UK), a median incision was made on the 
posterior side of the uterus(a), from the uterine fundus down into the cervical canal exposing 
the endometrial cavity. A 25mm lateral incision was then made within the endometrial cavity, 
dissecting 10mm into the wall of the uterus(b). The piece of uterine tissue made more 
accessible was held with a pair of bonney tissue forceps (Phoenix Surgical Instruments Ltd, 
UK), whilst another median incision was made into the myometrium to free the tissue(c).  
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This ensured that endometrium, endo-myometrial junction and additionally myometrial layers 
were all obtained in the biopsy. 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Procedure for taking a full thickness endometrial sample.  
2.4.3. Endometrial Pipelle Samples 
For women who did not undergo a hysterectomy and for all participants in the endometrial 
cancer subject group, endometrial samples were obtained using a pipelle endometrial sampler 
at the start of the operation. In theatre, the patient was first placed in the lithotomy position 
and the external genitalia, vagina and anus were washed thoroughly using sterile aqueous 
solution containing chlorhexidine gluconate 0.05% (Sterets Unisept, Medlock Medical Ltd, 
UK). Insertion of a Sims speculum into the vagina exposed the cervix, and a pair of Teales 
Vulsellum uterine forceps (Phoenix Surgical Instruments Ltd, UK) was used to grip onto the 
anterior lip of the cervix and bring it down into the vagina. A pipelle, figure 2.2, was then 
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passed through the cervical canal, into the uterine cavity until the fundus was reached. The 
length of the uterus and cervical canal was measured using the ruler on the pipelle. The 
plunger was then pulled back to create a suction effect and draw endometrial tissue into the 
pipelle. By slowly withdrawing the pipelle out of the uterine cavity, whilst being rotated from 
side to side, enabled as much of the endometrial tissue to be sampled.  
Figure 2.2: Endometrial Pipelle Sampler 
2.5 - Processing the Biopsy  
To prevent tissues from drying out and necrotic degradation, all endometrial biopsies 
collected were immediately immersed into a universal tube containing 10% neutral buffered 
formalin (NBF). This is a special fixative fluid that prevents autolysis, stabilises the 
microanatomy of the tissue and inhibits the growth of bacteria and moulds that give rise to 
putrefactive changes. Fixation is the first step of tissue processing, in order to preserve the 
tissue cells as they naturally occur. The size dimensions of the full thickness and pipelle 
samples obtained in theatre is adequate to allow enough penetration of NBF through the 
tissue. All endometrial samples were left in NBF between 24 hours and 5 days to give 
optimal fixation results. 
In order to make the cutting of the sections easier, tissue fixation medium was replaced with 
wax. This was done by placing samples in a processing machine (Shandon Citadel 1000, 
Cheshire, UK). This machine took tissue biopsies through a series of incubations in 
increasing alcohol concentrations to 100% and then xylene and hot paraffin wax, replacing 
the water content within the tissue. See appendix 4A “Tissue Processing” for more details.  
Samples were then embedded in paraffin wax blocks, see appendix 4B “Embedding Tissue 
Biopsies”. 
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2.6 - Preparation of the Slides 
Processed tissues were then embedded in paraffin blocks, with an orientation that was able to 
give the best representation of its morphology when sliced into sections. Paraffin blocks were 
cut with 3-5μm thickness using Microm rotary microtome (Microm Ltds, Thame, UK) and 
were carefully floated onto a pre-warmed water bath, see appendix 4C “Cutting Paraffin 
Sections”. The best sections were selected and were picked up onto aminopropyl triethoxy 
saline (APES) coated microscope slides, see appendix 4D “APES Coating Procedure”. Slides 
were left positioned in an upright position overnight to help drain off the water.  
2.7 - Dating the Endometrial Biopsy 
Dating endometrial biopsies was achieved by ensuring consistency across a set of parameters, 
including date of last menstrual period (LMP) in context with regular cycles, histological 
dating.  
To histologically date samples, haematoxylin and eosin (H&E) staining procedure was used 
for nuclear and cytoplasmic staining, respectively. For H&E staining of paraffin sections, 
slides were deparaffinised, rehydrated and then counterstained with haematoxylin. When 
reacted with tissue, haematoxylin is oxidised to haematein, staining cellular nuclei blue. 
Staining was differentiated by rapidly immersing slides in acid alcohol. This process of 
differentiation was arrested by returning slides to water, whereupon the haematein had taken 
on a blue hue. During tissue dehydration in alcohol, sections were stained with eosin 
yellowish (tetrabromofluorescein, disodium salt) to obtain full cellular detail, followed by 
washes in water to remove any excess eosin. See appendix 4E “H&E staining of biopsy tissue 
samples” for more details. 
All H&E stained sections were assessed for tissue integrity and endometrial dating was 
carried out by a trained consultant gynaecologist. A gynaecological pathologist was able to 
provide a second independent dating assessment for all samples obtained following a 
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hysterectomy. For all samples dated by both consultant gynaecologist and gynaecologic 
pathologist, there were no discrepancies between the two independent dating assessments.  
Endometrial samples were dated as per the classic paper by Noyes et al in the very first issue 
of Fertility and Sterility in 1950 (previously discussed in chapter one).  
2.8 - Immunohistochemistry (IHC) 
IHC involves the application of antibodies to tissue sections to bind to specific antigens on 
tissue proteins, thus making it possible to visualise the distribution and localisation of specific 
cellular components within the tissue. The IHC reagent kit used for this study was supplied 
by Vector ImmPRESS. See appendix 4F “Immunohistochemistry” for full method protocol 
used. Before the IHC method is discussed, it is important to have a good understanding of the 
pivotal reagent in IHC: the antibody. 
Antibodies belong to a group of proteins called immunoglobulins (Ig) comprising of five 
major classes: immunoglobulin G (IgG), IgA, IgM, IgD and IgE. These are present in the 
blood of immunised animals that remains in the serum, also known as the antiserum, after the 
removal of cells and fibrin. In this study, both polyclonal and monoclonal antibodies were 
utilised. Polyclonal antibodies are a heterogenous mixture of antibodies, with slightly 
different specificities and affinities, directed against various epitopes of the same region as 
shown in figure 2.3.  
 
 
 
 
Figure 2.3. Polyclonal antibody binding to various epitopes of the protein. 
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Polyclonal antibodies are mainly raised in rabbits due to the ease in maintenance of the 
animal and relative rarity of human antibodies to rabbit proteins. In contrast monoclonal 
antibodies are a homogenous population of Ig directed against a single epitope that are most 
commonly raised in mice as shown in figure 2.4. 
 
 
 
 
 Figure 2.4: Monoclonal antibody binding to a single type of epitope. 
When comparing both types of antibodies together, there are advantages and disadvantages to 
both types. As polyclonal antibodies can recognise multiple epitopes on a single molecule, 
they are not as subject to the damaging effects of sample processing as are monoclonal 
antibodies. However, the presence of antibodies to multiple epitopes can increase the chance 
of cross reactivity with other proteins.   
2.9 - Vector ImmPRESS IHC Methodology 
2.9.1 Dewaxing 
In order for aqueous antibody solution to properly adhere to and penetrate tissue, paraffin 
wax must be completely removed off the tissue. Slides were first heated for 1 hour at 60˚C or 
overnight at 37˚C to soften the wax and remove any moisture between the section and the 
slide which would contribute to the section lifting off the slide. Next, the wax was then taken 
off the slide by immersing slides in xylene, 100% alcohol and then diminishing 
concentrations of alcohol until the final buffer was aqueous. See appendix 3G “Preparation of 
paraffin sections for staining” for more details. 
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2.9.2 Antigen retrieval 
NBF fixation preserves tissue morphology through the formation of cross-linking bonds 
between tissue proteins. However, this stabilisation can also modify the antigen’s epitopes 
and its electrostatic charges, inhibiting the epitope to react with the paratope of the antibody. 
Subsequently, this can give weak or false negative staining for IHC detection of certain 
proteins. This can be corrected by restoring the epitope using various methods of antigen 
retrieval, see appendix 3H “Antigen Retrieval”. A series of preliminary experiments were 
conducted to validate the antibodies used in this study (refer to chapter 3) and to explore 
which antigen retrieval method would best suit each individual antibody. 
Heat induced epitope retrieval (HIER) and proteolytic induced epitope retrieval (PIER) are 
two main methods aimed to restore the affinity and avidity of the immune reaction.  
The use of heat in HIER methods causes cross-linked protein epitopes to ‘unfold’ while 
buffer solutions aid in maintaining the conformation of the unfolded protein. Citrate based 
buffer (pH6) was required for the use of PODXL antibody. On the other hand, Tris-EDTA 
buffer (pH9) is very useful for low affinity antibodies or when tissue antigens are not intense, 
and was used for COLIV, CK5/6 and SSEA1. For HIER methods, slides were immersed in an 
aluminium pressure cooker and were heated at 120˚C at full pressure for approximately one 
minute.   
Proteinase K (Qiagen, Qiagen house, Fleming Way, Crawly, West Sussex, RH10 9NQ) was 
used for PIER to prepare sections for laminin staining. This enzyme, isolated from 
saprophytic fungus Tritirachium album, possesses a high specific activity that particularly 
unmasks antigens of proteins found in the basal lamina. All tissue sections used for laminin 
staining were incubated in proteinase K at a concentration of 1:25 at room temperature, for 
approximately 5 minutes. Following all antigen retrieval methods, all slides were incubated in 
TBS for 5 minutes at room temperature.   
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2.9.3 Blocking endogenous peroxidise activity 
Sometimes tissues contain endogenous enzymes that are similar in specificity to the enzymes 
used in IHC detection system producing false positive signals. In particular, horseradish 
peroxidase (HPR) and alkaline phosphatase are the most common enzymes, found in a 
variety of tissues, known to generate such signals. Alkaline phosphatase is used as part of the 
avidin-biotin staining methods to localise antigens in tissue sections. However as the Vector  
ImmPRESS reagent kit is based on an HRP labelled polymer, any non specific staining 
resulting from endogenous avidin-biotin activity was eliminated. Like with any enzyme, 
enzymic activity is inhibited when there is excess substrate. Thus, slides were incubated in 
hydrogen peroxide solution for 10 minutes, as this excess substrate quenched the activity of 
endogenous peroxidase found in tissues.  
2.9.4 Two step staining technique 
Vector ImmPRESS IHC protocol particularly follows a two step staining technique. The first 
involves the application of the primary antibody to the tissue sections to bind with its 
corresponding antigen (figure 2.5).   
 
 
 
 
Figure 2.5. Step one of staining procedure: application of primary antibody.  
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The primary antibodies used and their incubation requirements are shown in the table below. 
Refer to appendix 5 for manufacturer antibody data sheets.  
 
Table 2.1 - Details of antibodies used in this study with incubation requirements.   
 
When using long overnight incubation periods, antibodies were incubated at low temperature 
of 4˚C to prevent over-staining, since antigen antibody reactions reach equilibrium more 
quickly at higher temperatures. Prior to application of laminin antibody, sections were 
incubated in hoarse serum to prevent non specific staining.  
After incubations with the primary antibody, the second step of staining technique is the 
application of the appropriate HRP-labelled polymer onto each section (figure 2.6). 
 
 
 
 
 
Figure 2.6. Step two of staining technique: Application of HRP-labelled polymer.  
Antibody Clone Supplier Concentration Duration Temperature 
Polyclonal rabbit anti-
human laminin 
n/a Dako 1:4000 Overnight 4˚C 
Monoclonal mouse 
anti-human collagen IV 
CIV 22 Dako 1:100 Overnight 4˚C 
Monoclonal mouse 
anti-human cytokeratin 
5/6 
D5/16B4 Millipore 1:350 Overnight 4˚C 
Monoclonal mouse 
anti-human PCLP1 
222328 R&D 1:100 1 hour Room temp. 
Monoclonal mouse 
anti-human SSEA1 
MC-480 Biolegend 1:800 Overnight 4˚C 
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HRP contains hematin which forms a complex with hydrogen peroxide (H2O2) causing it to 
decompose. The formation of this enzyme-substrate complex is dependent on the presence of 
an ‘electron donor’ to provide the driving force in the continuing catalysis of H2O2. 3,3’ 
diaminobenzidinetrahydrochloride (DAB) is a strong electron donor, and was applied to 
tissue sections to develop the enzyme-substrate reaction. The addition of DAB produced a 
brown precipitation which is highly insoluble in alcohol and other solvents. As DAB is 
classified as a potential carcinogen, it was handled and disposed of with appropriate care. 
Reaction was immediately arrested by immersing slides in water. Between incubations of 
primary antibody and HRP-labelled polymer and between HRP-labelled polymer and DAB 
development, all slides were incubated in two washes of TBS for 5 minutes at room 
temperature. Slides were counterstained with Gills 2 haematoxylin, and were then dehydrated 
in increasing concentrations of alcohol and then xylene.  
2.10 - Controls 
In order to test the IHC protocol used in the study, and the specificity of the primary 
antibodies, special controls were used. In this study, a negative control was used for each IHC 
staining procedure to assess the specificity of the primary antibodies used. The best form of 
negative control, for monoclonal antibodies, is to use the same isotope of the primary 
antibody in the same immunoglobulin concentration which exhibits no specific reactivity 
with the given tissue tested. For polyclonal antibodies, negative controls should be a dilution 
of IgG fractions or whole serum from the same animal source. Although ideal, these types of 
negative controls were not available for each antibody used in the study. Therefore a less 
optimal negative control was used that contained a mixture of antibodies representing most 
relevant IgG subtypes depending on what animal the antibody was raised in.  This was 
applied onto sequential sections of a few samples tested in each IHC staining batch.  
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Whilst validating each antibody, in order to assess whether the most appropriate antigen 
retrieval method and incubation requirements were used correctly, positive tissue controls 
were used. Positive control tissues are specific samples that the antibody is known to stain 
positively.  After antibody validation tests, an endometrial sample that was positively stained 
in the initial staining run was used in each successive IHC runs. This internal positive control 
was used to assess for any variations in staining between batches of stained sections, which 
could be due to factors that introduce variations in IHC method.    
2.11 - Image Analysis 
2.11.1 Collagen IV and Laminin 
Laminin and COLIV both stained BM supporting glandular and luminal epithelium and also 
around vascular endothelium, see figure 2.7.  
a.  b.  
c.  d.  
Figure 2.7. Endometrial micrographs showing COLIV (a,c) and laminin (b,d) immune-
localisation  in BM supporting glandular epithelium (GE) and vascular endothelium (VE) 
(a,b) and luminal epithelium (LE)(c,d).  
 
GE 
GE 
VE 
VE 
LE 
LE 
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To assess BM staining for both proteins, the luminal epithelium and 10 functional layer 
glands were photographed at X40 magnification. Functional layer glands were identified as 
the glands being closest to the luminal epithelium (see figure 2.11).  
Using a computer assisted image analysis, BM thickness in each photograph was first 
measured in two places around each gland, and in two places supporting the luminal 
epithelium, see appendix 6 “Image Analysis” for more details. Each thickness was measured 
in line with the direction of the cellular polarity as shown in figure 2.8.  
 
Figure 2.8. Measuring BM thickness using a computer assisted image analysis (Image J).  
 
The clarity of stained BM is mostly not uniform around the whole gland as in some areas the 
basal lamina appeared ‘hazy’. There are many factors that affect the solidarity and clarity of 
the BM seen including the angle at which sections are cut, the tortuous spiralling of glands, 
especially in the late secretory phase and the integrity of the tissue. Therefore, as only two 
points of the BM around each gland and luminal epithelium were needed, points were chosen 
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where BM appeared more clearly defined. Only glands in the functionalis were assessed as 
BM supporting glands in the basalis was more difficult due to the surrounding densely 
immune-positive stroma for both COLIV and laminin. Staining intensity of BM supporting 
glands, luminal epithelium and vessels were scored in each photograph using a semi-
quantitatively scoring system, scoring between 0-3, see appendix 7A & 7B. Due to areas of 
dense stromal staining in the basalis layer, BM around glands are obscure therefore only 
glands in the functionalis layer of the endometrium were assessed for BM thickness and 
staining intensity for both COLIV and laminin.    
2.11.2 PODXL 
PODXL mainly stained glandular secretions and the luminal surface of vessels as shown in 
figure 2.9. 
Figure 2.9. Endometrial micrograph showing positive staining for PODXL.  
In each tissue section, 10 randomly located glands, from both basalis and functionalis layers, 
were photographed using x40 magnification. A semi-quantitative modified ‘quick score’ 
Glandular 
Secretions 
Vascular 
endothelium 
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method, originally used by Scheissl et al, was utilised to analyse the expression of PODXL in 
glandular secretions(138). This method takes into account the staining intensity for each 
immune-positive gland, scoring between 0-3 (0: negative, 1: weak, 2: moderate, and 3: 
strong, see appendix 7C) and the percentage of the luminal surface of the gland lined with 
PODXL staining (0≤ 25%: 1, 25≤ 50: 2, 50≤75%: 3, 75≤ 100%: 4). The intensity and 
percentage scores were then multiplied to give a range of possible scores of 0-12. 
Additionally, staining intensity of immune-positive PODXL in vessels was also analysed 
using a semi-quantitative scoring system again scoring between 0-3 (0: negative, 0.5: very 
weak, 1: weak, 1.5: weak-moderate, 2: moderate, 2.5: strong, and 3: very strong).  
2.11.3 CK 5/6 
Overall Ck5/6 is a cytoplasmic marker staining the luminal epithelium consistently and 
occasional glands in the tissue sections as illustrated in figure 2.10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Endometrial micrograph showing staining pattern of cytokeratin 5/6 in glands 
and an insert micrograph showing staining in the luminal epithelium.  
Intermittent staining of 
glandular cells 
Staining in luminal 
epithelial cells 
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To score the frequency of glandular staining, a low power photograph was randomly taken at 
x10 magnification. The number of glands seen in the micrograph was counted along with the 
number of positive glands seen. The proportion of positive glands within the section was then 
calculated. A high power photograph, X40 magnification, of the luminal epithelium was also 
taken to semi-quantitatively score the staining intensity, scoring between 0-3 (see appendix 
7D).  
2.11.4 SSEA1 
SSEA1 stained the surface of glandular and luminal epithelial cells. After reviewing all 
control tissue sections stained with SSEA1 it was revealed that there was a big variation in 
the frequency, proportion of cellular staining and staining intensity between glands in the 
functionalis and basalis layers of the endometrium. To explore this further 10 glands were 
assessed in both functionalis and basalis layers of the endometrium. Functionalis glands were 
located as glands being closest to the luminal epithelium. Basalis layer glands were located as 
glands closest to the endo-myometrial junction as shown in figure 2.11.  
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Micrograph demonstrating the SSEA1 localisation in glandular and luminal 
epithelium and also how functional and basalis glands were located.  
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These glands were assessed for (a) positivity of immune-localisation of SSEA1 in glandular 
cells, (b) staining intensity using a semi-quantitative scoring system, scoring between 0-3 (see 
appendix 7E) and (c) proportion of glandular cellular staining, scoring between 0-3 (0: no 
cellular staining, 1: <50% of glandular staining, 2: >50% of glandular staining, 3: 100% of 
glandular staining). A combined score was then given by multiplying factors a, b and c 
together. Additionally staining intensity of immuno-positive cells in the luminal epithelium 
was also assessed using the same semi-quantitative scoring. 
2.11.5 – Analysis of PM endometrial samples 
As discussed before in chapter 1.1.3, PM endometrium is thin with flat luminal and glandular 
epithelium with stroma resembling the basalis stroma of cycling women. Whilst analysing the 
PM samples stained with COLIV and laminin it was interesting to see that there was very 
little stromal staining across the width of the endometrium. This was in stark contrast with 
cycling endometrium since the basalis layer contained strong stromal staining, see figure 
2.12, rendering analysis of BM supporting glandular epithelium in the basalis. Therefore, 
taking this into consideration, glands across the width of the PM endometrium could be 
analysed. However, for the purpose of being consistent, whilst analysing COLIV and laminin 
staining, only glands closest to the luminal epithelium were assessed.    
a.
 
b.
 
Figure 2.12. Laminin stromal staining in cycling and PM endometrium. Figure shows a 
comparison of stromal staining for anti-laminin between (a) PM endometrium and (b) Basalis 
layer of cycling endometrium.  
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As previously discussed SSEA1 staining analysis was divided into the basalis and 
functionalis layers of the endometrium. However as PM endometrium is very thin it is very 
difficult to define whether there are two layers of the endometrium, let alone discuss where 
the dividing line would be. Due to functional inactivity, PM endometrium is expected to 
resemble the basalis layer of endometrium of fertile controls, where the cells with 
regenerative capacity are thought to reside. We therefore considered that all glands assessed 
in PM endometrium were ‘basal’ glands. 
For PODXL and CK5/6 analysis, random glands will be analysed in PM endometrium, in the 
same manner as cycling endometrium.  
2.12 - Statistical Analysis 
The results obtained for this study was analysed using SPSS for window version 16. As the 
results were unlikely to be normally distributed non-parametric tests were used to analyze the 
results, such as Kruskal-Wallis (KW) and Mann-Whitney (MW) tests. After a positive 
(p<0.05) KW test, a MW post hoc test was performed to see where the differences lie. Two 
way analysis of variance (ANOVA), including interactions were used to explore for 
differences seen between the subject groups. Values of P<0.05 were considered significant. 
Additionally, Pearson’s correlation test was also used to assess for any significant 
relationships between the expression of BM components and stem cell markers.  
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Chapter Three:  
 
OPTIMISATION OF EXPERIMENT 
CONDITIONS 
In IHC, methods of antigen retrieval and antibody dilutions as well as incubation time and 
temperature are tightly interwoven in their effect on staining quality. To ensure all antibodies 
were used at optimal conditions, a number of preliminary experiments were conducted to test 
each of these factors.  
3.1 Optimisation of Laminin Antibody  
The type of anti-laminin used, supplied by Dako, is a pan-laminin antibody reacting with all 
subtypes of laminin. Initially anti-laminin was trialled at a concentration of 1:50, on tissues 
pre-treated with HIER using citric acid buffer solution, for overnight incubation at 4˚C. 
Tonsil tissue was used as a known positive control. The staining appeared very strong in all 
samples tested and the basal lamina could not be accurately recognised illustrated in figure 
3.1. 
  
 
 
Figure 3.1: Micrograph showing expression of laminin, with antibody used at 1:50, O/N  
Consequently, further dilutions of laminin antibody were tested, using concentrations of 
1:100, 1:200 and 1:400 (see figure 3.2). Dilutions of the primary antibody, with incubations 
over long durations allowed for greater economy. Nonetheless, even at the most dilute 
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concentration, laminin staining still appeared strong and non specific with ill defined BM in 
all specimens tested.  It was noted that the negative control also stained positively indicating 
either a lack of specificity of the antibody or non-specific background staining.  
   
   1:100 
  
    1:200 
    
   IgG Rabbit 
    
    1:400 
Figure 3.2: Micrographs showing expression of laminin in samples stained with antibody 
diluted at 1:100, 1:200 and 1:400 and IgG rabbit negative control.  
After reviewing the available literature on the use of laminin antibody, we chose the most 
popular method for antigen retrieval, proteolytic digestion. Therefore, tissue sections were 
incubated with proteinase K at a concentration of 1:10 for 5 minutes at room temperature. 
Additionally, horse serum was applied to all sections before the antibody was applied. Horse 
serum contains antibodies that have been raised against rabbit proteins, thus acts as a protein 
blocker to minimise non-specific staining. This protein blocker achieves this by competing 
for the non-specific protein binding sites on the specimen.  
Laminin antibody was then tested at 1:500, 1:1000, 1:2000 and 1:4000 for overnight 
incubation at 4˚C (figure 3.3).  All sections were analysed and these preliminary experiments 
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revealed laminin at a concentration of 1:4000, together with pre-proteolytic digestion and 
horse serum blocking provided very specific and distinct staining.  
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Figure 3.3: Micrographs showing laminin expression in two specimens with antibody 
concentration used at 1:500, 1:1000, 1:2000 and 1:4000 with their negative controls.  
Taking into consideration the fragility brought upon the tissues due to the vigorous nature of 
the enzyme pre-treatment, proteinase K trialled at more dilute concentrations. As staining 
around BM was less strong at 1:50, it was decided that 1:25 was an acceptable concentration 
(see figure 3.4).   
1:10 1:50 1:100 
   
Figure 3.4: Micrographs demonstrating the effects of proteinase K at different concentrations 
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3. 2 Optimisation of Collagen IV Antibody  
COLIV antibody was initially trailed at a concentration of 1:100 on tissues pre-treated with 
HIER using citric acid buffer solution, for overnight incubation at 4˚C. Placental tissues were 
used as known positive controls for these preliminary experiments. In all specimens tested, 
BM supporting glandular epithelium appeared very faint, whereas strong immune-reactivity 
was occasionally seen in BM supporting vascular endothelium. Thereafter, antibody 
concentrations at 1:50, 1:100 and 1:200 were considered for overnight incubation at 4˚C, and 
also for 1 hour at room temperature. As staining appeared very faint in samples stained 
during both incubation periods, new antigen retrieval methods were explored. A thorough 
literature review was conducted to investigate how this antibody was used in previous IHC 
studies. Nonetheless, there was no general consensus on how the antibody was prepared and 
what treatment conditions were required. Therefore, two additional methods of antigen 
retrieval were investigated in the same experiment; HIER Tris EDTA and PIER proteinase K. 
COLIV was tested at the three concentrations previously tested, for overnight incubation at 
4˚C. After a comprehensive analysis of all stained sections it was agreed that COLIV at 1:100 
using TRIS EDTA for antigen retrieval produced the best staining results (see figure 3.5).  
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Figure 3.5: Endometrial micrographs demonstrating differential COLIV expression when 
using different antigen retrieval methods and different concentrations of COLIV 
 
3.3 Optimisation of PODXL Antibody  
The supplier of PODXL antibody used in this study recommended a dilution between 1:8 and 
1:25.   Initially, 1:25 concentration of PODXL was tested, with an incubation period of 1 
hour at room temperature, on endometrial sections pre-treated with HIET using standard 
citric acid. In stained sections very strong staining was seen in glandular secretions, vessels 
and stroma with some evidence of background staining. Therefore further dilutions were 
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trialled, including 1:25, 1:50, 1:100 and 1:200 concentrations with an incubation period of 1 
hour at room temperature, see figure 3.6. Endometrial tissue sections used in this titration 
were pre-treated with citric acid using a HIER method.   
Figure 3.6: Endometrial micrographs to demonstrate variation in staining intensity of 
PODXL at 1:25, 1:50, 1:100 and 1:200 concentrations. 
 
PODXL antibody dilutions used at 1:25, 1:50 and 1:100 produced very similar staining 
intensities on tissue sections. However, a marked reduction in the staining intensity was seen 
at 1:200. Resultantly, it was concluded that 1:100 was the best economical concentration as it 
produced the same results with the recommended concentration from the manufacturer and is 
more dilute.  
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3.4 Optimisation of SSEA1 Antibody 
SSEA1 antibody obtained from R&D systems was also tested using a number of antigen 
retrieval methods and antibody dilutions. Initially a 1:25 dilution was used on a number of 
tissue sections that were pre- treated with either HIER methods (TRIS EDTA and citric acid) 
or proteolytic digestion using proteinase K. SSEA1 antibody was incubated on all tissue 
sections overnight at 4°C. As SSEA1 antibody has previously been reported to be expressed 
in the liver, sections of liver tissue samples were used a positive controls. 
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Figure 3.7: Endometrial micrographs to demonstrate differential SSEA1 staining when 
different antigen retrieval methods are used.  
From analysing the staining results shown in figure 3.7 it is clear that TRIS EDTA produced 
the most clear and strongest SSEA1 staining in all three tissue specimens tested. Titration of 
the antibody concentration was later performed using SSEA1 antibody purchased from 
Biolegend. Equivalent concentration of Biolegend SSEA1 antibody to R&D systems SSEA1 
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antibody was 1:200. Thus further dilutions of Biolegend SSEA1 antibody was tested 
including 1:200, 1:400 and 1:800, figure 3.8. 
 
Figure 3.8: Endometrial micrographs to show staining in luminal epithelium and strong and 
weak staining in glandular epithelium at 1:200, 1:400 and 1:800 SSEA1 concentrations 
 
After testing the new SSEA1 antibody at more dilute concentrations, results showed that 
1:800 produced very similar results when compared to the most concentrated dilution tested. 
In conclusion it was decided that 1:800 was used for the rest of the study.  
 
 
1:200 1:400 1:800 
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3.5 Optimisation of Cytokeratin 5/6 
CK5/6 was tested at a recommended concentration of 1:350, under two different types of 
HIER methods (citric acid and TRIS EDTA) and two different incubation conditions 
(overnight at 4ºC and for three hours at room temperature). After comprehensive analysis of 
all stained sections, it was confirmed that CK5/6 antibody optimally worked when tissue 
sections are pre-treated with HIER TRIS EDTA and when the antibody is applied for 
overnight incubation at 4ºC.  
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Chapter Four:  
 
RESULTS - Fertile Control & PM 
Endometrial Groups 
4.1 – Patient Demographics 
Table 4.1: Demographic data of fertile and post-menopausal control subjects 
  Age(years) BMI Weight (kg) Height (m) Parity 
Proliferative Phase            
Median 40 27.2 73 1.64 2 
Range 37-40 23.1-38.1 63.7-100 1.59-1.69 1-7 
Mid-Secretory Phase            
Median 34 25.55 69.5 1.61 2-3 
Range 27-44 21.7-30.4 57-83 1.52-1.72 1-4 
Late-Secretory Phase    
 
  
 
  
Median 39 24.3 62 1.65 3 
Range 27-45 21.1-41.5 53-113 1.49-1.7 1-4 
Post-Menopausal Controls           
Median 71 26.6 61 1.57 3-4 
Range 55-77 24.1-31.2 56-76 1.45-1.59 2-5 
 
Table 4.2: Demographic data of subjects in the endometriosis group 
  Age(years) BMI Weight (kg) Height (m) Parity 
Disease 
Stage 
Proliferative Phase              
Median 33 29.2 75 1.61 1 1-2 
Range 21-49 20.3-37.5 52-110 1.53-1.72 0-3 1-3 
Mid-Secretory Phase              
Median 38 24.25 70.5 1.7 1 2-3 
Range 21-47 20.5-32.9 58-95 1.63-1.83 0-2 1-4 
Late-Secretory Phase              
Median 33 25 72 1.69 0.5 1-2 
Range 18-43 20-28.7 56-84 1.59-1.76 0-3 1-2 
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Table 4.3: Demographic data of subjects in the endometrial cancer group 
  Age(years) BMI Weight (kg) Height (m) Parity 
Grade I           
Median 69.5 35.1 89.5 1.62 6 
Range 63-83 23.7-45.2 60-115 1.59-1.64 n/a 
Grade II           
Median 63 29.4 81 1.62 2-3 
Range 50-67 27.9-37.9 69-90 1.54-1.67 2-4 
Grade III     
 
    
Median 69 29.05 123.5 1.68 4 
Range 67-71 26.7-31.4 91-156 1.65-1.7 2-6 
 
Comparing the demographic data between the subject groups revealed a few statistically 
significant differences. Firstly, the PM group contained women who were significantly 
shorter (MW test; p=0.05) and older (MW test; p<0.0001) than the fertile control group. 
Additionally, women in the endometriosis group were significantly taller (MW test; p=0.19) 
and had a significantly lower number of live births than women in the control group (MW 
test; p<0.0001). Lastly women in the endometrial cancer subject group were significantly 
heavier (MW test; p<0.013) and taller (MW test; p<0.038) than women in the PM group, 
although no statistical significant difference was found between the two groups when 
comparing BMI. No significant differences were found within the fertile and endometriosis 
groups across the cycle. Demographic data values are missing for 10 recruited patients which 
are currently being tracked.  
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4.2 – Expression of Basal Lamina Components in the Normal 
Cycling and PM Endometrium 
For all results collected from the fertile control and PM groups, please refer to appendix 8A 
to 8J.  
Endometrial BM was visualised as narrow continuous bands supporting the luminal and 
glandular epithelium and vascular endothelium. Immuno-localisation of COLIV and laminin 
in BM supporting endometrial samples were analysed for thickness and staining intensities 
and were evaluated according to the phase of the menstrual cycle. 
Collagen IV  
Table 4.4. COLIV staining results in the fertile control and post-menopausal group. 
 
 
 
  
GE BM 
Thickness 
(μm) 
GE BM 
Staining Int. 
LE BM 
Thickness 
(μm) 
LE BM 
Staining Int. 
VE BM 
staining int.  
ProlP           
Median 0.851 1.050 0.833 1.500 2.050 
Range 0.637 - 0.996 0.700 - 2.000 0.705 - 1.125 0.500 - 1.500 1.450 - 2.550 
MSP           
Median 0.711 1 0.89 1 2.2 
Range 0.437 - 0.861 0.350 - 1.700 0.000 - 1.345 0.000 - 1.500 0.250 - 2.750 
LSP     
 
    
Median 0.789 1.625 0.808 1.25 2.2 
Range 0.684 - 0.901 0.950 - 2.050 0.000 - 0.985 0.000 - 2.000 1.550 - 2.350 
PM           
Median 0.69 1.25 0.67 1 0.9 
Range 0.132-3.553 0.150-1.650 0.000-1.175 0.000-1.500 0.100-1.150 
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ProlP a.  b.  
MSP c.  d.  
LSP e.  f.  
PM g.  h.  
Figure 4.1. Representative images showing COLIV staining in BM supporting the GE 
(a,c,e,g) and LE (b,d,f,h) in fertile control (ProlP,MSP,LSP) and PM endometrium.  
COLIV in BM supporting endometrial glands showed an apparent difference in thicknesses 
across the cycle, with a trend towards average BM thickness being lower in the MSP. 
However, this difference did not reach statistical significance (KW test; p=0.09). In contrast, 
the staining intensities of COLIV in endometrial BM showed significant differences across 
the cycle (refer figure 4.1). Firstly, COLIV staining intensities in BM underlying glandular 
epithelium was increased in the LSP than in other phases of the menstrual cycle (KW test; 
81 
 
p=0.003, MW test; ProlP p=0.004, MSP p=0.089). Secondly, COLIV staining intensity in 
BM supporting luminal epithelium in the MSP was significantly lower when compared to the 
ProlP (KW test; p=0.032, MW test; p=0.009).  
COLIV staining in PM endometrium showed differences when compared to the fertile control 
group. Firstly, PM endometrium showed significantly lower COLIV staining intensity in BM 
supporting the luminal epithelium when compared to the ProlP (MW test; p=0.04). Secondly, 
staining intensity in BM supporting the vascular endothelium was significantly lower in the 
PM group when compared with all phases of menstrual cycle studied (MW test; ProlP 
p=0.001, MSP p=0.005 and LSP p=0.006), refer fig 4.2.  
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Figure 4.2 Box and whisker plots demonstrating changes seen in COLIV staining intensity in 
endometrial BM supporting epithelial layers. All asterisks show a statistically significant 
result. a. COLIV staining intensity shown to be increased in BM supporting GE during the 
LSP. No significant difference found between cycling endometrium and PM endometrium.  
b. COLIV staining intensity supporting the LE is significantly decreased in the MSP and PM 
endometrium when both are compared with the ProlP. C. COLIV staining intensity in BM 
supporting VE in PM endometrial samples is significantly decreased when compared to 
cycling endometrium.   
 
 
Laminin 
Table 4.5. Laminin staining results in the fertile control and post-menopausal group. 
  
GE BM 
Thickness (μm) 
GE BM 
Staining Int. 
LE BM 
Thickness (μm) 
LE BM Staining 
Int. 
VE BM 
staining int.  
ProlP           
Median 0.962 1.400 0.833 1.000 1.625 
Range 0.570-1.332 0.400-2.550 0.000-1.140 0.000-2.000 0.650-2.200 
MSP           
Median 0.690 0.825 0.000 0.000 1.225 
Range 0.000-1.016 0.000-1.800 0.000-1.005 0.000-1.500 0.200-2.400 
LSP     
 
    
Median 0.912 1.475 0.810 0.500 1.600 
Range 0.491-1.244 0.250-3.500 0.000-1.170 0.000-2.000 0.500-2.250 
PM           
Median 0.891 1.400 0.655 1.000 1.500 
Range 0.196-1.045 0.200-2.350 0.000-1.060 0.000-2.000 0.050-2.200 
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Figure 4.3. Representative images showing laminin staining in BM supporting the GE 
(a,c,e,g) and LE (b,d,f,h) in fertile control (ProlP,MSP,LSP) and PM endometrium. 
 
As seen for COLIV, immuno-located laminin in BM supporting the glandular epithelium 
showed a trend towards average BM thickness being lower in the MSP (KW test; p=0.046)., 
and this was statistically significant when compared with the ProlP (MW test; p=0.019) and 
ProlP a.  b.  
MSP c.  d.  
LSP e.  f.  
PM g.  h.  
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suggestive when compared with the LSP (MW test; p=0.075). This trend was also 
demonstrated for laminin staining intensity in BM supporting the glandular epithelium, 
however this did not reach statistical significance (KW test; p=0.08, MW test; Prolp p=0.052, 
LSP p=0.052), refer to figure 4.4. When studying the staining intensity of immuno-localised 
laminin in BM supporting the LE, a significant reduction was also found during the MSP 
when compared with the ProlP (MW test p=0.043). No differences were found for laminin 
expression in BM vascular endothelium across the cycle.  Additionally, no significant 
differences in the immuno-expression of laminin were found between fertile control and PM 
groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Box and Whisker plot showing changes in thickness of immuno-located laminin 
in endometrial BM. A. BM supporting GE is significantly thinner in MSP than in ProlP. B. 
BM  supporting GE is also significantly thinner in MSP when compared with the ProlP.  
 
 
85 
 
4.3 - Expression of Stem Cell Markers in the Normal Cycling and 
PM Endometrium 
PODXL  
Table 4.6. PODXL results in the fertile control and post-menopausal group. 
  Average combined quick score  Vessel intensity 
ProlP     
Median 8.70 1.54 
Range 3.05-10.30 1.00-2.70 
MSP     
Median 4.95 1.70 
Range 0.05-8.00 1.25-2.90 
LSP     
Median 0.25 1.92 
Range 0.00-4.45 1.50-2.24 
PM     
Median 7.00 1.55 
Range 3.95-7.50 1.05-1.93 
ProlP a.  
 
 
 
 
 
 
 
MSP b.  
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Figure 4.5. Representative images showing PODXL staining in glandular secretions and 
vascular endothelium in fertile control (ProlP,MSP,LSP) and PM endometrium. 
 
As previously described, PODXL is expressed in glandular secretions and was analysed by 
combining the staining intensity of immuno-located PODXL with the proportion of the 
luminal surface of the glandular epithelium covered with PODXL. This gave a ‘quick score’ 
for each gland. When evaluating the overall quick-scores across the menstrual cycle, 
interesting differences were seen. The ProlP showed the highest overall quick scores 
demonstrating ProlP glands had the highest staining intensities and percentage coverage in 
glands for immuno-located PODXL. As the menstrual cycle progressed, PODXL quick 
scores significantly reduced (KW test; p<0.00001), as staining intensities in glandular 
secretions were significantly decreased from ProlP to MSP (MW test; p=0.03) and from MSP 
to LSP (MW test; p=0.009). Staining intensity of PODXL expression was also assessed in the 
vascular endothelium but no significant changes were seen along with the phase of the 
menstrual cycle. In post-menopausal endometrium, the combined quick-scores resembled to 
that seen in the ProlP, and were significantly higher than LSP quick-scores (MW test; 0.005). 
LSP c.  
PM d.  
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In contrast, LSP staining intensity for PODXL in the vascular endothelium was significant 
higher than in PM endometrium(MW test; 0.0028), refer fig 4.6.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Box and Whisker plot to show significant changes in PODXL staining across the 
menstrual cycle and in PM endometrium. A. PODXL quick-scores significantly reduced 
along the menstrual cycle. PODXL quickscores in PM endometrium was significantly higher 
than LSP. B. Staining intensity of PODXL in VE was significantly lower in PM endometrium 
when compared with the LSP.   
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Cytokeratin 5/6  
Table 4.7. CK5/6 staining results in the fertile control and post-menopausal group. 
  % +ve glands  LE staining intensity 
ProlP     
Median 40.00 1.25 
Range 0.00-100.00 0.00-2.50 
MSP     
Median 6.50 2.00 
Range 0.00-96.60 0.50-3.00 
LSP     
Median 4.15 1.25 
Range 0.00-48.00 0.00-2.50 
PM     
Median 3.23 0.00 
Range 0.00-20.00 0.00-0.25 
 
ProlP a.  b.  
MSP c.  
 
 
d.  
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Figure 4.7 Representative images illustrating CK5/6 staining in glandular epithelium (a,c,e,g) 
and luminal epithelium (b,d,f,h) in fertile control (ProlP,MSP,LSP) and PM endometrium. 
 
There were no significant changes in the percentage of CK5/6+ glands across the phases of 
the menstrual cycle and between cycling and PM samples. Nonetheless, there was a higher % 
staining in the ProlP than in the LSP, however this did not reach statistical significance (MW 
test; p=0.063). Additionally, staining intensity of CK5/6 immuno-localisation in the luminal 
epithelium was similar in all samples taken from fertile controls. Whereas, in PM samples 
there was significantly lower staining intensity in the luminal epithelium when compared to 
ProlP (MW test; 0.0036), MSP (MW test; 0.006) and LSP (MW test; 0.006), see figure 4.8. 
However, out of the 5 PM samples included for the study, due to differences in the integrity 
of endometrial biopsies and their orientation in paraffin embedding, only three contained a 
clearly identifiable luminal epithelium. Therefore, we can not speculate a great deal on 
luminal CK5/6 staining intensity pattern in PM women with a small sample size.  
 
 
LSP e.  f.  
 
 
PM g.  h.  
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Figure 4.8: Box and whisker plots showing CK5/6 expression throughout the menstrual 
cycle. A. Proportion of CK5/6 immuno-positivity in GE did not significantly change across 
the menstrual cycle. B. Graph illustrates the significant reduced of CK5/6 staining intensity in 
the luminal epithelium in PM endometrium when compared to each tested phase of the 
menstrual cycle.  
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SSEA1 
Table 4.8. SSEA1 staining results in the fertile control group 
 
Table 4.9. SSEA1 staining results in the PM group 
  
no. +ve 
glands 
GE staining 
int. 
proportion of GE 
stained Quickscore  LE staining int. 
PM     
 
    
Median 1.00 2.50 2.70 6.25 1.5 
Range 0.90-1.00 1.95-3.00 1.90-3.00 1.90-3.00 0.50-3.00 
 
 
  
Basalis  Functionalis 
no. +ve 
glands 
GE staining 
int. 
proportion of GE 
stained Quickscore  
no. +ve 
glands 
GE staining 
int. proportion of GE stained Quickscore  
LE Staining 
Int. 
ProlP                   
Median 1.00 1.65 2.80 4.62 1.00 1.13 1.55 1.74 2.00 
Range 1.00-1.00 1.35-2.05 2.70-3.00 3.65-6.15 0.70-1.00 0.65-1.85 0.80-3.0 0.52-5.55 1.00-2.50 
MSP             
 
    
Median 0.45 0.38 0.45 0.17 0.60 0.50 0.60 0.30 0.50 
Range 0.20-0.90 0.10-0.65 0.20-1.50 0.02-0.98 0.00-1.00 0.00-1.15 0.00-2.00 0.00-2.30 0.00-0.50 
LSP                   
Median 0.50 0.50 0.50 0.25 0.60 0.73 0.66 0.47 1.50 
Range 0.40-0.90 0.45-1.15 0.40-0.90 0.18-1.04 0.30-1.00 0.20-1.75 0.40-1.80 0.08-3.15 0.00-2.00 
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Figure 4.9: Representative micrographs showing SSEA1 staining in fertile control 
endometrium. Micrographs illustrate staining in ProlP (a-c), MSP (d-f) and LSP (g-i) 
showing the full thickness of the endometrium (a,d,g), basalis layer of the endometrium 
(b,e,h) and in the upper functionalis layer and the luminal epithelium (c,f,i).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: SSEA1 localisation in glandular and luminal epithelium in PM endometrium.  
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As previously discussed, the basal and functional layers were considered as separate entities 
for analysis of SSEA1. It is generally accepted that when the endometrium is sampled with an 
endometrial pipelle sampler, only the functional layer of eutopic endometrium is obtained. 
Therefore, for SSEA1 staining both the full thicknesses and pipelle samples were included for 
the analysis of the functional layer but only full thickness sections were analysed in the basal 
layer. Glandular epithelium in both layers of the endometrium were assessed for number of 
SSEA1 immuno-positive glands, percentage of positive cells and staining intensity of 
glandular epithelium. A GE staining quick-score was attained by multiplying the three 
descriptive factors together carried out in both layers in cycling endometrium and also PM 
endometrium. 
i. Basalis Layer  
All fertile control full thickness samples taken during the ProlP (n=5), MSP (n=4) and LSP 
(n=3) had positive glandular epithelial staining in the basalis layer of the endometrium. When 
studying the number of SSEA1 positive glands, all 10 basal glands analysed in each ProlP 
sample were SSEA1 immuno-positive. Additionally, virtually all of the 10 glands analysed in 
each of the PM sample were strongly positive for SSEA1. Compared with the basal glands of 
the ProlP, the basal glands of the secretory phase endometrium had significantly lower 
number of SSEA1 immuno-positive glands (KW test; p=0.012, MW test; MSP p=0.007, LSP 
p=0.01). This significant decrease is observed when comparing SSEA1 positive basal glands 
of the PM endometrium with MSP (MW test; p=0.0016) and LSP (MW test; p=0.0036) 
endometrium.  
A similar picture was observed when the percentage of SSEA1 positive cells were analysed 
in each positive gland, with basal glands of the ProlP and PM having similar percentages. 
Additionally, secretory phase endometrium has significantly lower SSEA1 positive basal 
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glandular cells when compared to the ProlP (KW test; p=0.016, MW test; MSP p=0.014, LSP 
p=0.024) and PM endometrium (MW test; MSP p=0.016, LSP p=0.036).  
SSEA1 staining intensity in basal glandular epithelium showed marked differences according 
to the phase of the cycle (KW test; p=0.012). Within the fertile control group, basal glandular 
staining intensity was highest in ProlP samples and decreased significantly across the 
secretory phase to have the weakest intensity in LSP (MW test; MSP p=0.016, LSP p=0.025). 
Overall, staining intensity for SSEA1 was seen to be the highest in PM glands being 
apparently higher when compared with ProlP glands (MW test; 0.0056) and a significantly 
higher when compared with MSP (MW test; 0.016) and LSP (MW test; 0.0036) glands.  
When multiplying the three descriptibe factors to obtained an overall ‘Combined SSEA1 
quickscore’ in both basalis and functionalis layers the same significant differences were 
mirrored, illustrated in figure 4.11. In the basalis layer, firstly, the overall glandular staining 
was significantly lower in the secretory phase when compared with the ProlP (MW test; MSP 
p=0.016, LSP p=0.036) and PM endometrium (MW test; MSP p=0.016, LSP p=0.036). No 
differences were seen between the MSP and LSP and also between ProlP and PM 
endometrium.  
 
 
 
 
 
 
 
 
Figure 4.11: Box and whisker plot demonstrating significant decrease in basal SSEA1 
glandular staining in the secretory phase when compared with the ProlP and PM 
endometrium.  
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ii. SSEA1 in the Functionalis Layer 
For all three descriptive factors, functional glands in the ProlP showed significantly higher 
number of positive glands (KW test; p=0.002); percentage of SSEA1+ cells (KW test; 
p=0.013); and staining intensity (KW test; p=0.002) in the glandular epithelium when 
compared to the MSP (MW test; p=0.001, p=0.001, p=0.003 respectively) and LSP (MW 
test; p=0.023, p=0.005, p=0.089 respectively). However, there was only an apparent 
difference in the staining intensity of SSEA1 in GE between ProlP and LSP. No significant 
differences were found between the MSP and LSP.  These significant differences were 
resultantly mirrored when analysing the overall combined scores (KW test; p=0.002). In the 
functionalis layer, the overall glandular staining was significantly lower in the secretory 
phase when compared with the ProlP (MW test; MSP p<0.0001, LSP p=0.023). No 
differences were seen between the MSP and LSP. Figure 4.12 illustrates these overall results 
in the functionalis.  
 
Figure 4.12: Box and whisker plot showing higher SSEA1 glandular staining in proliferative 
than in secretory phase samples.  
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Lastly, SSEA1 staining intensity in the luminal epithelium was compared between all phases 
of the menstrual cycle and in PM endometrium, see fig 4.13. Within the fertile control group 
SSEA1 staining intensity in the luminal epithelial was lower in the MSP (KW test p=0.001) 
when compared to the ProlP (MW test; p<0.0001) and LSP (MW test; p=0.065 – apparent 
difference) and was significantly lower than the staining intensity observed in PM luminal 
epithelium (MW test; p=0.02). 
 
 
 
 
 
 
 
 
 
Figure 4.13: Box and whisker plot demonstrating changes in SSEA1 staining intensity in 
luminal epithelium (LE) across the menstrual cycle.  LE staining intensity has shown to be 
significantly lower in the MSP when compared with the ProlP and PM endometrium.   
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4.4 Correlation between BM and Stem Cell Markers in Normal 
Cycling and in PM Endometrium  
 
Expression of stem cell marker PODXL in fertile controls appear to be negatively correlated 
with the expression of endometrial COLIV. In particular, PODXL combined quick-scores 
show a negative correlation with the combined scores for COLIV expression BM supporting 
glands (r=-0.362, P=0.049). Combined score for COLIV was taken by multiplying together 
the staining intensity and thickness of BM supporting the GE and LE.  
 
Figure 4.14. Scatter graph to illustrate the negative correlation between combined COLIV 
expression in BM supporting GE with the PODXL quick-scores, in the fertile control group. 
 
In contrast, the number of positive CK5/6 glands in fertile control endometrium positively 
correlates with the thickness (r=-0.520, P=0.006) of BM supporting luminal epithelium 
immuno-located with COLIV.  
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Figure 4.15. Scatter graph to illustrate positive correlation between the thickness of immuno-
located COLIV in BM supporting LE with the percentage of CK5/6 glands found in the 
fertile control group.  
 
Numerous associations were found between BM components and SSEA1 expression in the 
endometrium. Firstly, a positive correlation was seen between the number of positive 
functionalis SSEA1 glands of fertile controls, with firstly the combined laminin expression in 
BM supporting glands (r=0.369, P=0.045) and LE (r=0.418, P=0.027), and secondly the 
combined COLIV (r=0.392, P=0.047) and in the LE. Additionally, LE immuno-staining 
intensities of SSEA1 also showed a positive correlation with the combined COLIV staining 
(r=4.02, P=0.046) and laminin thickness (r=0.47, P=0.013) for BM supporting the luminal 
epithelium in fertile controls. Additionally, in PM women the overall SSEA1 glandular 
staining positively correlates with combined laminin scoring in BM around glands (r=0.932, 
P=0.021) and vascular endothelium (r=0.979, P=0.004). Figure 4.16 graphically illustrates 
some these findings.  
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Figure 4.16. Scatter graph to show the positive correlation between the combine laminin 
quickscore with the number of positive SSEA1 glands in the functionalis layer in the fertile 
control group. Second scatter graph also shows positive correlation between laminin 
thickness in the immuno-located BM supporting the LE with the SSEA1 staining intensity in 
the LE.  
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Also, associations were found between the different stem cell markers. Interestingly, 
combined PODXL quick-scores shows a positive correlation with SSEA1 combined gland 
score for both basalis (r=0.723, P=008) and functionalis (r=0.385, P=0.036) layers of fertile 
control endometrium, see figure.  
 
 
Figure 4.17. Scatter graphs to show positive correlation between PODXL quickscore with 
the quickscore for SSEA1 GE staining in both basalis and functionalis layers of the 
endometrium in the fertile control group.  
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Chapter Five:  
 
RESULTS –Endometriosis group 
 
For all results collected from the endometriosis  group, please refer to appendix 8K to 8O.   
 
5.1 - Expression of Endometrial Basal Lamina Components in 
Patients with Endometriosis 
 
Collagen-type four 
Table 5.1. COLIV staining results in the endometriosis group 
  
GE BM 
Thickness 
(μm) 
GE BM 
Staining Int. 
LE BM 
Thickness 
(μm) 
LE BM 
Staining Int. 
VE BM 
staining int.  
ProlP           
Median 0.753 1.000 0.880 1.000 1.850 
Range 0.00-0.928 0.000-1.85 0.990-1.110 0 – 2.000 0.650-2.650 
MSP           
Median 0.663 0.600 0.650 1.000 1.950 
Range 0-1.269 0-1.900 0-2.090 0-2.000 0-2.650 
LSP     
 
    
Median 0.942 1.128 0.720 0.750 2.010 
Range 0.128-1.340 0.200-1.500 0-1.455 0-2.000 1.100-2.650 
 
 
ProlP a.  b.  
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Figure 5.1. Representative images showing COLIV staining in BM supporting the GE (a,c,e) 
and LE (b,d,f) in cycling (ProlP,MSP,LSP) endometrium samples from women with 
endometriosis.  
 
 
Laminin 
 
Table 5.2. Laminin staining in the endometriosis group.  
  
GE BM 
Thickness 
GE BM 
Staining Int. 
LE BM 
Thickness 
LE BM 
Staining Int. 
VE BM 
staining int.  
ProlP           
Median 0.914 1.000 0.400 0.250 1.500 
Range 0.372-9.770 0.250-2.100 
0.000-
0.950 0.000-2.000 0.600-2.350 
MSP           
Median 0.770 1.300 0.513 1.500 1.850 
Range 0.630-0.938 0.800-1.700 
0.000-
1.285 0.000-2.000 1.350-2.400 
LSP     
 
    
Median 0.856 1.075 1.340 0.500 1.600 
Range 0.547-1.043 0.150-2.071 
0.000-
1.340 0.000-2.000 0.500-2.071 
 
 
 
MSP c.  
 
d.  
LSP e.  f.  
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Figure 5.2. Representative images showing laminin staining in BM supporting the GE (a,c,e) 
and LE (b,d,f) in cycling (ProlP,MSP,LSP) endometrium samples from women with 
endometriosis.  
Although immuno-located COLIV and laminin in endometrial BM were seen to be altered 
across the menstrual cycle in the fertile control group, no significant changes in BM 
thicknesses and staining intensities were seen in the endometriosis group.  
 
 
 
 
 
 
 
ProlP a.  b.  
MSP c.  
 
d.  
LSP e.  f.  
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5.2 - Expression of Endometrial Stem Cell Markers in Patients 
with Endometriosis 
 
PODXL 
Table 5.3. PODXL staining results in the endometriosis group 
  Average combined quick score  
Vessel 
intensity 
ProlP     
Median 5.00 2.20 
Range 0.00-8.65 0.95-2.75 
MSP     
Median 2.80 2.30 
Range 0.00-8.60 1.30-2.75 
LSP     
Median 0.40 1.68 
Range 0.00-3.60 1.00-2.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Representative images showing PODXL staining in glandular secretions and 
vascular endothelium in endometrium collected from women with endometriosis.  
ProlP a.  
 
 
 
 
 
 
 
MSP b.  
LSP c.  
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Similar to the fertile control group, the endometriosis group also showed strong significant 
changes in PODXL quick-scores within phases of the menstrual cycle (KW test; p=0.014). 
PODXL quick-scores were highest in the ProlP and significantly decreased as the menstrual 
cycle progressed, with a significant reduction in scores in the LSP (MW test; p=0.004), see 
figure 5.4. Additionally, there is a difference in the staining intensity of PODXL expression 
within the vascular endothelium, with staining intensity in the LSP being lower than in the 
MSP (MW test; p=0.026). 
 
Figure 5.4: Box and whisker plot demonstrating changes in PODXL quick-scores across the 
menstrual cycle in the endometriosis group.   
Cytokeratin 5/6 
 
Table 5.4. Table to show CK5/6 result in eutopic endometrium in the endometriosis group 
  % +ve glands  LE staining intensity 
ProlP     
Median 19.20 1.00 
Range 0.00-100.00 0.00-2.50 
MSP     
Median 12.00 1.50 
Range 0.00-100.00 1.00-3.00 
LSP     
Median 11.15 1.50 
Range 0.00-42.90 0.50-2.50 
 
106 
 
 
Figure 5.5. Representative images illustrating CK5/6 staining in glandular epithelium 
(a,c,e,g) and luminal epithelium (b,d,f,h) in eutopic endometrium collected from women with 
endometriosis.  
 
When analysing the proportion of CK5/6+ glands in a low power field and staining intensity 
of immuno-located CK5/6 in the luminal epithelium, no changes were seen across the 
menstrual cycle, and this is consistent with results seen in the fertile control group.  
ProlP a.  b.  
MSP c.  
 
 
d.  
LSP e.  f.  
 
 
107 
 
SSEA1 
Table 5.5. Table showing results of SSEA1 expression in eutopic endometrium collected from women with endometriosis.  
 
 
  
Basalis  Functionalis 
no. +ve 
glands 
GE staining 
int. 
proportion of GE 
stained Quickscore  
no. +ve 
glands 
GE staining 
int. 
proportion of GE 
stained Quickscore  
LE Staining 
Int. 
ProlP                   
Median 1.00 1.65 2.80 4.62 1.00 0.85 1.60 1.40 1.50 
Range 0.70-1.00 0.95-2.05 1.10-3.00 0-5.37 0.80-1.00 0.50-2.70 1.00-2.80 0.55-6.75 0.50-3.00 
MSP             
 
    
Median 0.95 1.25 1.50 0.00 0.20 0.15 0.20 0.03 1.25 
Range 0.90-1.00 1.20-1.30 1.30-1.70 0.00-2.21 0.00-0.70 0.00-0.70 0.00-0.700 0.00-0.49 0.00-2.50 
LSP                   
Median 0.60 0.80 0.80 0.79 0.30 0.43 0.30 0.06 1.50 
Range 0.20-1.00 0.30-1.30 0.40-1.20 0.024-1.56 0.00-0.80 0.00-0.70 0.00-0.80 0.00-0.28 0.50--2.50 
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i. Basal Layer 
In the endometriosis group, there were no distinct differences in basal gland SSEA1 immuno-
staining across phases of the menstrual cycle studied, when analysed for all three descriptive 
factors previously described, refer figure 5.6. This is in contrast with the fertile control group, 
where significant difference in basal gland staining was seen across the cycle.  
 
 
 
 
 
Figure 5.6. Box and whisker plot to demonstrate overall SSEA1 staining in basalis layer 
glands in the endometriosis group. No significant changes across the menstrual cycle seen. 
  
ii. Functional Layer 
In contrast, analysis of SSEA1 immuno-positive glands in the functional layer demonstrated 
significant changes across the menstrual cycle. For all three descriptive factors, functional 
glands in the ProlP showed significantly higher number of positive glands (KW test; 
p<0.0001); higher percentages of SSEA1+ glandular cells (KW test; p<0.0001); and higher 
staining intensities (KW test; p<0.0001) in the glandular epithelium when compared to the 
MSP (MW test; p<0.0001 all three descriptive factors) and LSP (MW test; p<0.0001, 
p<0.0001, p=0.001 respectively). These significant differences were resultantly mirrored 
when analysing the overall combined scores with ProlP functionalis glands with higher 
SSEA1 glands than secretory phase (KW test; p<0.0001, MW test; MSP p<0.0001, LSP 
p<0.0001), see figure 5.7. In contrast, staining intensities of immuno-located SSEA1 in the 
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luminal epithelium remained similar across all three phases of the menstrual cycle tested in 
the endometriosis group. 
 
 
 
 
 
 
 
 
Figure 5.7: Box and whisker plot demonstrating changes in combined SSEA1 functional 
gland combined scores across the menstrual cycle. Significant reduction in staining in 
secretory phase with compared with the proliferative phase.  
 
5.3 Correlation between BM and Stem Cell Markers in the 
Endometriosis Group 
When evaluating the relationship between BM components and stem cell marker expression 
in eutopic endometrium from women with endometriosis, significant trends are observed, 
some of which have been previously observed in the fertile control group. Firstly, PODXL 
combined quick-score in the endometriosis group are negatively correlated with COLIV 
staining intensity in BM supporting glands (r=-276, P=0.026). In contrast, PODXL 
expression in vessels seem positively correlates with the laminin combined scores in BM 
supporting luminal epithelium (r=0.313, P=0.02) and vascular endothelium (r=0.386, 
P=0.002). Additionally, COLIV immuno-staining intensity in BM supporting vessels 
positively correlates with CK5/6 staining intensity in the luminal epithelium (r=0.328, 
P=0.013). 
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Positive correlation is also found between laminin combined scores for staining in BM 
supporting the glands, with the combined SSEA1 staining score for glands residing in the 
basalis (r=0.496, P=0.008) and functionalis (r=0.358, P=0.005), and also with SSEA1 
staining in the luminal epithelium (r=367, P=0.007).  
When looking at the relationship between stem cell markers in the endometriosis group, 
PODXL combined quick-score positively correlates for all overall SSEA1 staining 
assessment in the basalis (r=0.596, P=0.001), functionalis (r=0.384, P=0.002) and also in the 
luminal epithelium (r=0.271, P=0.045).  
 
 
Figure 5.8. Scatter graphs to demonstrate the positive correlation relationships between 
PODXL expression with basalis and functionalis layer SSEA1 positive glands in the 
endometriosis group. 
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5.4 Difference between expression of BM components and 
stem/progenitor cell markers in eutopic endometrial samples 
taken from fertile control and women with endometriosis  
To analyse the difference in BM components and stem/progenitor cells markers, between the 
fertile control and endometriosis groups, a two way analysis of variance (ANOVA) statistical 
test was used. Values of P<0.05 were considered significant.  When performing ANOVA on 
all markers, no significant difference was found. However, apparent differences that did not 
reach statistical significance were seen between the groups. Firstly, there was an apparent 
difference in the combined laminin score in BM supporting the GE (as it was slightly higher 
in the MSP in the endometriosis group than in the fertile control group (F=2.417, p=0.099). 
Refer to figure 5.9  
 
 
 
 
 
 
 
Figure 5.9. Line graph to show estimated marginal means of the combined score of laminin 
staining immuno-located in the BM supporting the GE. Graph shows in the endometriosis 
group there is no decrease in overall staining in the MSP when compared with the ProlP and 
LSP in the endometriosis group, unlike the fertile control group.  
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Secondly, there was also an apparent difference in the staining intensity in laminin immuno-
located in BM supporting vascular endothelium, with staining being higher in the 
endometriosis group than fertile control group, see figure 5.10 (F=2.491, p=0.092).  
 
Figure 5.10. Line graph to show estimated marginal means of the laminin staining intensity 
immuno-located in the BM supporting the vascular endothelium. Graph shows in the 
endometriosis group there is increase in staining intensity of laminin during the MSP when 
compared to the fertile control group. However this did not reach statistical significance.   
 
Finally, an apparent difference was also seen between the staining intensity of SSEA1 
immuno-localised in the LE between the subject groups, being higher in the endometriosis 
group than fertile control group, refer to figure 5.11. However, this did not reach statistical 
significance (F= 2.637, p=0.083).   
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Figure 5.11. Line graph to show estimated marginal means of SSEA1 staining intensities 
immuno-located in the luminal epithelium. Graph shows in the endometriosis group there is 
increase in staining intensity of SSEA1 when compared to the fertile control group. However 
this did not reach statistical significance.   
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Chapter Six:  
 
RESULTS - Endometrial Cancer Group 
BM components and the panel of stem cell markers were also studied on grade I (n=5), grade 
II (n=5) and grade III (n=3) endometrioid adenocarcinoma tissue specimens. Due to the 
disorganisation of uterine tissue seen in this pathological condition, similar quantitative and 
semi quantitative analysis previously performed on cycling and PM endometrial specimens 
could not be performed. Therefore only descriptive analysis was made to assess endometrial 
expression of these markers in this subject group. Varying levels of disorganisation were seen 
between grade types of endometrial cancer samples, with grade 1 having the least amount of 
disorganisation and grade 3 having the most, as described in the FIGO classification. 
6.1 - Expression of Endometrial Basement Membrane Components in Patients with 
Endometrial Cancer 
COLIV 
In virtually all grade I and II endometrial cancer samples, all glandular structures failed to 
express COLIV immuno-staining in the supporting BM. As glandular architecture was lost in 
Grade III endometrial cancer sample, the supporting glandular BM could not be analysed. 
Vessels in all endometrial cancer samples were identified, even though their normal 
architecture was altered, and were immuno-positive for COLIV in most samples. Particularly, 
staining intensity for COLIV in vessels was observed to be increased in ascending levels of 
endometrial cancer grade type, being strongest in grade III samples. This correlates with 
cellular staining in cancerous cells, as more cancer cells in grade III endometrial cancer 
samples were COLIV immuno-positive. Refer to fig 4.12. 
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(a) Grade I 
 
 
 
 
 
 
 
 
(b) Grade II 
 
 
 
 
 
 
 
 
(c) Grade III 
 
 
 
 
 
 
 
 
Figure 6.1. Endometrial micrographs showing COLIV immuno-localisation in (a) grade I, (b) 
grade II and (c) grade III endometrial cancerous tissues 
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Laminin 
Laminin was immuno-positive in all endometrial tissue samples collected from this group 
with most samples having staining intensities between moderate and strong. In virtually all 
grade I and II endometrial cancer samples tested, laminin appeared to be positive in elongated 
linear structures that either resembled BM supporting glandular epithelium or BM supporting 
endothelium of vessels with lost architecture. Cancer cells seen in all grade types were 
positive for laminin. In grade II and III samples laminin appeared to be present in BM 
supporting endothelium of more regular looking vessels and also in the intercellular spaces 
separating cancerous cells. Refer to fig 4.13 
(a) Grade I 
 
 
 
 
 
 
 
 
 
(b) Grade II 
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(c) Grade III   
 
 
 
 
 
 
 
 
 
Figure 6.2: Endometrial micrographs showing laminin immuno-localisation in (a) grade I, 
(b) grade II and (c) grade III endometrial cancerous tissues 
 
6.2 - Expression of Endometrial Stem Cell Markers in Patients with Endometrial 
Cancer 
PODXL 
All endometrial cancer samples were also tested for PODXL. Cancerous cells in each sample 
were identified, however, most were observed to be immuno-negative for PODXL. One 
grade 2 sample appeared to be cellular staining in cancerous cells, see figure 4.14(c). In PM 
samples, PODXL was densely localised in glandular secretions and in the vascular 
endothelium, as also seen in the fertile control and endometriosis groups. However, as 
endometrial tissue samples from endometrial cancer subjects is very disrupted, glands even 
still present in grade 1 and grade 2 samples were difficult to analyse. Nonetheless, in some 
samples PODXL staining was still present in glandular secretions. PODXL staining was 
mainly seen in the vessels in all samples tested. Staining intensities for PODXL staining in 
vascular endothelium ranged from moderate to strong in this subject group.  
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(a) Grade I 
 
 
 
 
 
 
 
 
 
(b) Grade II 
 
 
 
 
 
 
 
 
 
(c) Grade III 
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Grade III 
 
 
 
 
 
 
Figure 6.3: Endometrial micrographs showing PODXL immuno-localisation in (a) grade I, 
(b,c) grade II and (d) grade III endometrial cancerous tissues 
 
Cytokeratin 5/6 
No differences were seen when comparing the CK5/6 immuno-positive staining between 
grade types of endometrial cancer. Most samples contained weak staining, but at least one 
sample from each grade type (refer to right hand column of figure 4.15) contained small 
frequent clusters of moderate-strong CK5/6+ cellular staining in cancerous cells.   
 
(a) Grade I 
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(b) Grade II 
 
 
 
 
 
 
 
(c) Grade III 
 
 
 
 
 
 
 
Figure 6.4: Endometrial micrographs showing CK5/6 immuno-localisation in (a) grade I, (b) 
grade II and (c) grade III endometrial cancerous tissues 
 
 
SSEA1 
In grade I endometrial cancer samples, architecture of glandular epithelium was altered. 
However, like in some PM biopsy sections, cells were still intermittently stained within the 
glandular epithelium. Cellular staining of cancerous cells was mainly seen in grade II and III 
samples. A couple of endometrial cancer samples from each grade type contained small dense 
aggregates of cells that were strongly SSEA1+ immuno-stained (refer to right column of 
figure 4.16). 
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Grade I 
  
 
 
 
 
 
 
Grade II 
 
 
 
 
 
 
 
Grade III 
 
 
 
 
 
 
 
Figure 6.5: Endometrial micrographs showing SSEA1 immuno-localisation in (a) grade I, (b) 
grade II and (c) grade III endometrial cancerous tissues 
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Chapter Seven:  
 
DISCUSSION 
This was an IHC study exploring the expression of a panel of stem cell markers in 
conjunction with examining the BM integrity in the endometrium of normal fertile women 
along the menstrual cycle; of women with the benign metastatic disease endometriosis and of 
women with the malignant metastatic disease of endometrioid adenocarcinoma.  
7.1. Fertile Control Group 
 
Immuno-located COLIV and laminin in endometrial BM was visualised as narrow 
continuous bands supporting the luminal and glandular epithelium, and vascular endothelium 
throughout all phases of the menstrual cycle. Within the fertile control group, COLIV 
expression in BM was distinctly altered during the menstrual cycle, with expression peaking 
in different endometrial structures at different time points of the menstrual cycle. During the 
ProlP, COLIV expression appeared to be high, although Tanaka et al reported a contradictory 
decrease of COLIV in the late ProlP in comparison to other cycle phases(35). This 
contradictory finding could be due to the fact that most of our proliferative endometrial 
samples were from women in the early- or mid-ProlP. Therefore we could not comment on 
how the COLIV in BM was altered within the ProlP. Our results show that COLIV 
expression in the BM supporting the luminal epithelium was significantly lower in the MSP 
than in other phases of the menstrual cycle. This agrees with previous studies that suggests 
breakage of BM at the luminal epithelium is necessary for successful implantation of the 
invasive blastocyst(s)(139). Highest COLIV levels seen in the BM, supporting the glandular 
and the luminal epithelium during the LSP, also agree with the previous study reported by 
Tanaka et al(35). As COLIV has shown to inhibit endometrial epithelial cell growth whilst 
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enhancing epithelial apoptosis, it’s dominance during the LSP may suggest a role in 
preparing the endometrium for the inevitable process of menstruation where endometrium is 
disrupted and shed at the absence of embryo implantation(35). Expression and activity of 
endometrial MMPs, proteolytic enzymes that are responsible for breaking down ECM 
components, are shown to be minimal during the secretory phase(140). Therefore, high 
expression of COLIV observed in the LSP further validates that MMP activity is suppressed 
during this period and they will be subsequently up regulated during the actual menstrual 
shedding.  
Tanaka et al, previously showed that laminin is significantly decreased in the BM supporting 
the luminal epithelium during the secretory phase(35). We also found a similar decrease in 
laminin expression during the MSP in fertile controls; in our study however, this reduction 
was found in the BM supporting the glandular epithelium. During the proliferative phase, 
stromal cells, unlike endometrial epithelial cells, are thought to produce the BM component 
laminin.   Laminin is then transported to the intercellular spaces first and subsequently to the 
sub-epithelial BM structures(38). However, during the secretory phase laminin mRNA signal 
appears stronger in stromal cells, particularly in cells adjacent to glandular structures, and has 
been shown to play a key role in endometrial pre-decidualisation to prepare for embryo 
implantation(38). Therefore, since the role of laminin in the stroma becomes more important 
in order to prepare for decidualisation during the MSP, transportation of laminin to the BM 
supporting structures such as the glandular epithelium, may not occur to the similar extent 
seen in the ProlP and this is reflected in our results.  
In contrast, laminin expression in the BM supporting the luminal epithelium and vascular 
endothelium remained to be similar throughout proliferative and secretory phases of the 
menstrual cycle. Laminin is an important protein in regulating intracellular signalling 
involved in angiogenesis and vasculogenesis(141). Therefore the observed persistent 
expression of laminin around vessels throughout all the phases of the menstrual cycle 
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indicates its crucial role in endometrial angiogenesis in the ProlP and in differentiation and 
remodelling which happens during the secretory phase. BM components supporting the 
luminal epithelium is needed to modulate cell recruitment, and migration in preparation for 
embryo-maternal recognition leading to implantation(37). One particular study showed that 
COLIV and laminin were virtually immuno-absent in endometrium sampled from women 
with unexplained infertility(37). This strongly suggests that the absence of these crucial ECM 
components may have a negative effect on the events leading to endometrial receptivity 
leading to implantation failure. Even though BM is needed to prepare the luminal epithelium 
for implantation, according to previous authors, a reduction/disruption of the BM components 
during the MSP allows embryo invasion and implant on the luminal epithelium. However, 
this study did not see laminin to be reduced during the window of implantation, suggesting 
either mainly COLIV is down-regulated in the luminal epithelium to coordinate endometrial 
receptivity to implantation or the reduction of laminin may only occur upon the endometrial-
embryo interaction. A thorough examination of the initial events surrounding endometrial-
embryo interaction, employing one of the in-vitro culture systems and embryos, will help to 
answer this question conclusively(142). 
CK5/6 has shown to be a marker of undifferentiated cells in the human breast (myoepithelial 
cells), that is very similar to the endometrium in which they both undergo remarkable 
morphological changes in response to ovarian steroid hormones(80). CK5/6 was present in 
glandular and luminal epithelium in the endometrium; however expression did not change 
across the cycle. As CK5/6 was negatively correlated with COLIV expression in BM 
supporting the luminal epithelium, this suggests CK5/6 may have a role in the events that 
prepare for endometrial receptivity to an implanting embryo.  
SSEA1 is a cell surface carbohydrate antigen and is the first cellular component encountered 
by approaching cells and molecules(99). This antigen is known to be present on pluripotent 
EC, ES and multi-potenital cells illustrating its role as a marker for undifferentiated cells, 
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however in humans embryos it is present on the more differentiated cells(103). Therefore, 
SSEA1 has been utilised to isolate multi-potential embryonic stem cells for further 
characterisation especially in neural stem cells(100). Unlike SSEA1, PODXL has been shown 
to be a marker of pluripotent stem cells in humans. Complementing its role as a stem cell 
marker, PODXL is emerging as a marker of human malignancy, including testicular, breast, 
liver, kidney and blood cell cancers(143).  
Expression of both PODXL and SSEA1 in the endometrium varied significantly according to 
the phase of the menstrual cycle. PODXL immuno-localisation in the functionalis layer was 
significantly higher in glandular secretions during the ProlP in cycling women. However, 
PODXL significantly decreased along the menstrual cycle, being weakest in the LSP. This 
trend was also seen for SSEA1 expression in glandular epithelium in both basalis and 
functionalis layers of the endometrium. Since dynamic endometrial remodelling occurs along 
the cycle, the phase dependent changes in the expression of these stem cell markers may 
indicate a functional relevance. During the ProlP, the functionalis layer undergoes 
considerable regeneration(18). The high expression of these stem/progenitor cell markers 
during this time suggests that potential stem/progenitor cells with known high proliferative 
potential are activated, contributing to the proliferation of the endometrium(51). Later, in the 
secretory phase, the proliferation in endometrial epithelium is terminated as progesterone 
exerts its effects on the oestrogen primed endometrium, and induces cellular 
differentiation(20). Therefore we expect that endometrial stem/progenitor cellular activity 
ceases from the secretory phase onwards, and this is represented by the significant reduction 
of endometrial expression of stem call markers PODXL and SSEA1. Even at a comparatively 
low level, stem cell markers are still expressed during the secretory phase, suggesting that 
possible endometrial stem/progenitor cells are still present due to their known clonogenic 
potential in the endometrium(51). In mouse EC cells, FUT4 has been shown to be involved in 
the regulation of SSEA1(101). Ponnampalam and Rogers have used IHC to test the immuno-
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expression of FUT4 in the endometrium. Interestingly they showed that FUT4 localises in the 
glandular and luminal epithelium which is significantly up-regulated during the ESP and 
MSP compared with other phases of the menstrual cycle(106). Since we have shown that 
SSEA1 is significant down-regulated during the secretory phase (MSP and LSP) FUT4 may 
have a significant functional relevance controlling the expression of endometrial SSEA1. In 
addition to endometrial regeneration, SSEA1 may also have a role in implantation due to its 
significant reduction in the BM supporting the luminal epithelium during the MSP. It is likely 
that may FUT4 regulate the expression of this carbohydrate antigen that facilitate the initial 
attachment of blastocysts to endometrial epithelium(106)  
Overall, these phase dependent changes indicates that circulating levels of ovarian hormones 
may have regulatory control of the activation of endometrial stem cells, as seen in mammary 
stem cells, in order to control the endometrial events that lead to implantation(144).  
Since there is a positive correlation between PODXL and SSEA1 expression in the 
endometrial samples tested, this may indicate that these two proteins co-exist in the same 
endometrial stem/progenitor cell and therefore maybe functionally related. However, 
functional experiments need to be carried to investigate this further. The expression of these 
known stem cell markers in both basalis and functionalis layers of the endometrium also 
encourages the idea that endometrial stem/progenitor cells not only reside in the basalis but 
are also present within the functionalis layer of the endometrium(55, 60).  
When compared to BM components, PODXL expression showed significant negative 
correlation with the overall COLIV expression in BM supporting glandular epithelium. In the 
kidney, PODXL is detected in the lining of podocyte foot processes and is connected to 
glomerular BM at focal contacts, overall contributing to glomerular filtration(90, 93). At 
these focal contacts PODXL has shown to inhibit spreading of BM components and cell 
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binding, and is therefore thought to have anti-adhesive effects(93). Therefore this may 
explain the inverse relationship between endometrial PODXL and COLIV expression.   
In contrast, SSEA1 positive functionalis glands positively correlates with both COLIV and 
laminin expression in BM supporting glandular epithelium. Within stem cell niches, 
specialised BM is needed to maintain stem cell properties, particularly during stem cell 
development(71). Thus, the positive relationship seen here suggests a favourable BM 
integrity is mandatory to modify the cellular behaviour of potential endometrial 
stem/progenitor cells, in order to function in the highly dynamic functionalis layer of the 
endometrium. 
7.2. Endometriosis Group 
In contrast with the fertile control group, no cyclic variation of BM components (COLIV and 
laminin) was seen in the endometriosis group. Consequently, apparent differences in laminin 
expression were observed between the endometriosis and fertile control groups. These 
differences included reduced laminin expression in the BM supporting the glandular 
epithelium, and higher expression in the BM supporting the vascular endothelium in the 
endometriosis group when compared to the fertile controls.  
During the menstrual phase, increased disruption of both functionalis and basalis layers of 
eutopic endometrium, have been reported in women with endometriosis(130). Laminin is a 
key protein needed for the initial BM assembly and is a crucial ECM component providing 
structural support to tissues(32). The decreased laminin expression observed in the BM 
supporting the glandular epithelium indicates there is altered BM integrity in endometriosis 
patients, therefore making endometrium more prone to extensive disruption during 
menstruation. The reduced expression seen may either be due to lack of production of 
laminin or up-regulation of MMPs and other proteolytic agents in eutopic endometrium from 
women with endometriosis, events which have also been postulated to occur in endometrial 
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cancer(48). As experiments have shown that the exposure of sub-epithelial structures is 
important for cell adhesion events, extensive exfoliation of endometrium is more likely to 
result in attachment of endometrial debris onto the peritoneal environment when transported 
in a retrograde fashion(114).  
In contrast to the reduced expression in BM supporting glands, an apparent increase in 
laminin expression has also been observed in BM supporting vessels when compared to 
fertile controls. Given that laminin is an important protein needed for the intracellular 
signalling to modulate angiogenesis, the increase in BM supporting vessels may indicate 
increased angiogenic activity in the endometrium of women with endometriosis(141).  
Enhanced endometrial angiogenic activity in endometriosis has previously been reported and 
is thought to contribute to development of ectopic lesions(145, 146).  
COLIV expression in the eutopic endometrium in women with endometriosis remained 
consistent throughout the phases of the menstrual cycle studied, with no particular increase in 
the LSP, as seen in the fertile controls. This may reflect the attenuated MMP activity seen in 
eutopic endometrium of women with endometriosis, especially MMP9 that preferentially 
degrades BM components(147). Increased MMP activity in the endometrium is thought to 
lead to endometriosis as it increases the invasive properties of the endometrium leading to 
ectopic implantation after retrograde menstruation(148). Additionally, a previously described 
study reported absent immuno-localisation of both COLIV and laminin in the endometrium 
sampled from women with unexplained infertility(37). Due to the absence of demographic 
information gathered from some of the study participants and study sample sizes we were 
unable to study the differences of endometrial COLIV and laminin expression between 
endometriosis patients with and without infertility.  
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Endometrial expression of PODXL and CK5/6 in the endometriosis group was similar to the 
fertile control group, with PODXL expression being highest in the ProlP and decreasing 
along the cycle and no changes in CK5/6 seen across the cycle.  
In contrast, SSEA1 expression in the basalis layer of the endometrium was similar across all 
phases of the menstrual cycle studied. As the endometrial stem/progenitor cells are thought to 
mainly reside in the basalis layer of the endometrium, the unchanged stem cell marker 
SSEA1 in the basal layer across the menstrual cycle suggests that stem cell activity also 
remains unchanged. This is in comparison to the reduced SSEA1 expression in the secretory 
phase in fertile controls, when it is expected that stem cell activity is thought to be decreased 
after the ProlP. The persistence of SSEA1 expression into the secretory phase may contribute 
to the pathophysiology of endometriosis. Leyendecker et al showed that there is increased 
exfoliation of both basal and functional layers of eutopic endometrium in women with 
endometriosis during the menstrual phase(130). Our study also supports this finding with 
evidence of altered endometrial basal lamina seen in the endometriosis group. In addition 
Hyodo et al conducted a study that showed endometrial injury can also potentially increase 
SP cells in the endometrium(149). Altogether these previously reported findings, in 
conjunction with our results, may suggest that there is increased retrograde transportation of 
basal endometrium that has altered stem cell activity. Consequently, this may contribute to 
the endometrial growth of ectopic implants contributing to the pathophysiology of 
endometriosis. To date there is no direct evidence that stem cell activity has a role in the 
pathogenesis of endometriosis. However, we have shown that SSEA1 is a possible marker of 
increased endometrial stem/progenitor stem cell activity and this may utilised in the future to 
implement the characterisation of stem/progenitor cells in ectopic implants. The positive 
relationship between laminin and PODXL with SSEA1 expression in the endometrium seen 
in fertile control group, also persists in the endometriosis group indicating the possible 
regulation between these components still functions in endometriosis.  
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7.3 Post Menopausal Group 
As reported in previous studies, laminin was localised in the BM supporting structures in the 
oestrogen and progesterone deprived PM endometrium(48). Additionally, there were no 
significant differences in laminin expression when compared to the fertile control group. This 
reinforces the assumption that laminin synthesis is constant and regulation is independent of 
circulating ovarian hormones. However, in contrast with previous reports, COLIV appeared 
to be present in the PM samples tested, with expression in BM supporting glandular and 
luminal epithelium similar to mostly all phases of the menstrual cycle tested in fertile 
controls. Whereas, COLIV expression in BM supporting vascular endothelium was seen to be 
significantly lower in the PM group when compared to the fertile control group and this was 
also seen for laminin in a previous report(35). This may be due to the lack of circulating 
ovarian hormones altogether stimulating less angiogenic activity therefore resulting in less 
COLIV and/or laminin production in BM supporting endothelial cells.   
The transition of PM non-functional endometrium to atrophic endometrium can take up to 
several years, with proliferative activity persisting for many years(7). The similar change in 
staining intensities of stem cell markers SSEA1 and PODXL expression in PM endometrium 
with the basal endometrium taken during the ProlP from cycling women provides 
confirmatory evidence of this persisting proliferative activity. As previously described, the 
functional inactivity of PM endometrium is expected to resemble the basalis layer of 
endometrium of cycling women, where endometrial stem/progenitor cells are thought to 
reside regenerating the functionalis after menstruation. Since SSEA1 expression in PM 
endometrium was significantly similar to the ProlP of cycling women, this suggests that stem 
cells still remain in the endometrium after menopause. This is supported with evidence that 
the clonogenic activity does not differ between endometrial samples from reproductive and 
post-menopausal women(61, 64). These stem cells may be regulated by ovarian hormones 
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since endometrial growth has show to occur when PM women take exogenous oestrogen 
therapy. 
7.4 Endometrial Cancer Group 
This study confirms the disruption of both COLIV and laminin BM components in the 
malignant metastatic disease of endometrial cancer. As we have shown that eutopic 
endometrium from women with endometriosis have disrupted BM, this further suggests the 
similar characteristics endometriosis has with malignant disorders.  
A small number of cells within the tumours have shown to have stem cell properties that 
contribute to its growth and metasteses and they are referred to as CSCs, and this has been 
reported to occur in endometrial cancer. The strong immuno-positivity of CK5/6 and SSEA1 
seen in areas of cancerous cells suggests that they may be possible markers of these CSCs 
that may have evolved from endometrial stem/progenitor cells that were also expressing these 
markers(51). However, this can only be confirmed by performing functional studies.  
7.5 Validity of Stem/progenitor cell markers in the endometrium 
Chan et al provided the first evidence for the existence of endometrial stem/progenitor cells 
using cell cloning studies(56). They demonstrated endometrial cell clonogenicity, as they 
found 0.22% of epithelial cells and 1.25% of stromal cells were able to form individual 
colonies when seeded at clonal density and they also demonstrated the differentiation 
potential of these cells(62).  Based on these findings we would expect that less than 1% of 
endometrial epithelial cells would be stained by a putative endometrial stem cell marker. 
However, all these possible stem/progenitor cell markers we studied, stained more than 1% of 
epithelial cells in the paraffin sections. Therefore, these markers are most likely to be markers 
of progenitor cells that are precursors to differentiated cells. We can say that these markers to 
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not stain fully differentiated cells due to the inconsistent staining of endometrial epithelial 
cells, especially for CK5/6 and SSEA1.   
7.6 Limitations of the study  
No significant differences were observed in the thicknesses of BM supporting glandular 
epithelium between different phases of the menstrual cycle in cycling endometrium and 
between cycling and PM endometrium. Additionally, no significant differences in BM 
thicknesses were found between the fertile control and endometriosis subject groups. 
Although these findings could represent a true consistency of BM thickness in all fertile 
control, endometriosis and PM subject groups, it could also be due to factors affecting the 
measurement of the true BM thicknesses, masking potential differences in BM thicknesses. 
One major factor affecting the measurement of the true BM thickness was the angle at which 
the wax embedded tissue biopsies were cut using a microtome. If glands within the paraffin 
section were cut along the longitudinal axis or perpendicular to the longitudinal axis, staining 
of BM around gland would appear clean and non-hazy and therefore measurement of the 
thickness would be accurate. However, if glands were cut at any other angle within the 
section then this would lead to areas of the BM around the gland to appear hazy making the 
measurement of thicknesses and scoring staining intensities of the BM difficult and subject to 
reader bias. This was especially significant in the LSP where glands were very tortuous and 
the BM of majority of secretory glands was difficult to measure.   
It is generally accepted that when the endometrium is sampled with an endometrial pipelle 
sampler, only the functional layer of eutopic endometrium is obtained. However, this is only 
an assumption and to date no evidence confirms that this is true, and therefore pipelle 
endometrial biopsies could also contain a sample of the basalis layer too. This could 
introduce a potential flaw in our analysis, since glands analysed for SSEA1, PODXL and BM 
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components in paraffin sections from pipelle samples were all considered as functionalis 
glands, which potentially can skew the results.   
7.7 Future Work  
Both laminin and COLIV were also expressed in the stroma of the endometrium. However, 
due to time deficiencies during the course of the project a comprehensive analysis of stromal 
staining could not be carried out. This analysis could form as part of future work and would 
include both scoring the staining intensity of stromal cells with these BM components, and 
additionally counting the number of immuno-positive stromal cells using assisted computer 
image analysis software. This analysis can be divided into both basalis and functionalis layers 
of the endometrium as obvious differences were seen between the two layers. By analysing 
the stromal staining patterns we can look for any correlation seen with the BM supporting 
endometrial structures that explain for changes in BM staining across the menstrual cycle.  
Although this study assessed the changes in BM and stem cell activity across the menstrual 
cycle, more patients would need to be recruited to increase the power of the study. More 
endometrial samples especially taken from women in the ProlP of their menstrual cycle 
would be needed to observe how the BM changes along the early, mid and late stages of the 
ProlP. Additionally, since we conclude that it is the alteration of menstrual endometrial debris 
that is transported in a retrograde fashion leading to endometriosis, we also need to examine 
the BM integrity and expression of endometrial stem/progenitor cell markers during the 
menstrual phase. By increasing the sample size in the endometriosis group this will firstly 
allow us to explore changes of BM integrity and identification of potential endometrial 
stem/progenitor cells, along with the severity of endometriosis (under the AFS classification). 
Secondly, it will allow to us compare the expression of these components between 
endometriosis subjects with and without infertility. Additionally, we could also perform 
further IHC studies on ectopic endometriosis lesions and compare it with results from eutopic 
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endometrium from women with endometriosis, especially to see whether potential stem cell 
markers are also present in ectopic lesions. This is especially important as evidence 
supporting the presence of stem cells in ectopic implants is lacking. Since there is a well 
known link between endometriosis and ovarian cancer, we should also look at the ovarian 
cancer tissue and assess BM integrity along with the expression of the panel of stem cell 
markers. Additionally, as baboons are commonly used as a model for endometriosis 
development, we can perform IHC methodologies on both matched eutopic and ectopic 
endometrial samples collected from these animals, to observe how BM components and stem 
cell markers are expressed throughout the course of the disease. 
Since laminin and COLIV has been previous shown to increase adhesion and proliferation in 
ectopic endometrial implants, we also need to assess their complement integrins since these 
receptors modulate the interaction between BM components and endometrial cells(1, 33). 
Also, we can assess the expression of CD34, a known glycoprotein to mediate the attachment 
of stem cells to ECM. This will further improve our understanding of how changes within the 
ECM structure can affect the activity of endometrial stem cells.   
Our IHC methodologies have shown the presence of the BM and stem cell markers within the 
endometrium. In order to test whether these results are not artefact, alternative laboratory 
methods are needed to confirm these immunohistochemistry results. Other methods include 
western blotting to give both qualitative and semi-quantitative confirmatory results, and 
quantitative real-transcriptase polymerase chain reactions (QRT-PCR) to quantify the mRNA 
levels of the proteins to be tested. Since carbohydrates are formed as a result of post-
translational modification of proteins, assessment of mRNA levels cannot be carried out for 
carbohydrate antigen SSEA1. To analyse the functional properties of the BM components 
and stem cell markers in endometrial tissue, in-vitro cell culture experiments are needed to 
assess the effects of these components on cell growth and survival. Conversely, suppressing 
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the genes for these components in in-vitro experiments, by using silence RNA (siRNA), 
allows us to analyse what effect this has on endometrial cells.  
7.8 Summary 
There is growing evidence that the eutopic endometrium of women with endometriosis is 
different from that of women without endometriosis. BM integrity is known to be altered in 
the malignant metastatic disease of endometrial cancer and we have shown that it is also 
altered in the benign metastatic disease of endometriosis, further suggesting similar 
characteristics between the two pathological conditions. Stem cells are increasingly becoming 
the focus of many areas of biomedical research. We have tested a panel of known stem cells 
markers including CK5/6, PODXL and SSEA1 in endometrial samples, all of which show 
some relationship with the expression of BM components. Interestingly, PODXL and SSEA1 
are significantly up-regulated during the ProlP in the endometrium, when we expect stem 
cells to be most active contributing to endometrial regeneration after menstrual shedding. The 
aberrant expression of SSEA1 in eutopic endometrium collected from endometriosis patients 
may indicate an altered activity of possible endometrial stem cells, of which may contribute 
to its pathophysiology. Extensive research into the role of stem cells in endometriosis is still 
needed. It is an area difficult to investigate; nonetheless, we provide a stepping stone into 
providing potential endometrial stem cell markers.   
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APPENDIX 4 
STANDARD OPERATING PROCEDURES 
(SOP) 
4A. TISSUE PROCESSING 
Background 
Formalin fixed tissue is dehydrated, cleared then impregnated with paraffin wax using the 
automated Shandon Citadel 1000 processing machine. The processing setting for most 
sample types is programme A which operates using the schedule provided below. The total 
processing time is 18 ¾ hours, therefore the processor is generally run overnight. Starting the 
processor at 2pm will result in completion of the cycle at 8:45 the following morning. 
 
Programme A Processing Schedule: 
4% formalin in neutral buffer 45 minutes 
60% Ethanol 1 hour 
70% Ethanol    1 hour 
90% Ethanol     1 hour 
100% Ethanol    1 hour 
100% Ethanol    1 ½ hours  
100% Ethanol    2 hours 
Xylene 1    1 hour  
Xylene 2    1 ½ hours  
Xylene 3    2 hours 
Wax 1    2 ½ hours  
Wax 2    3 ½ hours 
 
Equipment information: 
Citadel processor (serial number CA 1390 EO 608) manufacturer: Thermo electron 
Corporation. Manufacturer’s address: 93 – 96 Chadwick Road, Astmoor, Runcorn, Cheshire, 
WA7 1PR England. 
 
Maintenance and contract: 
Maintained/serviced by Thermo Fisher Scientific 93 – 96 Chadwick Road, Astmoor, 
Runcorn, Cheshire, WA7 1PR England. Tel: 01928 562 541, Fax: 01928 562 512. 
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Solvent Information: 
Ethanol and xylene are purchased from Chemistry solvent stores (University of Liverpool). 
The wax (Histoplast PE REF8330) is purchased from Thermo Scientific 93 – 96 Chadwick 
Road, Astmoor, Runcorn, Cheshire, WA7 1PR England.  The 10% neutral buffered formalin 
is purchased from Sigma Life science, Fancy Road, Poole, Dorset, BH12 4QH. 
 
Health and Safety Precautions  
Wear a laboratory coat, safety spectacles and nitrile gloves. Xylene and formalin are harmful 
by contact to skin and eyes or if ingested or inhaled. Refer to the risk assessments and 
COSHH forms before starting procedure. 
 
Overnight processing procedures requires the completion of permits provided in safety 
circular SCR14/3 (link to document provided below). A ‘Yellow permit’ (for long term 
operation) should be prepared by the DSC or laboratory manager and the copy secured in a 
clear plastic folder on the door outside laboratory 4. The ‘Pink’ permit (valid for the duration  
of the experiment only) should be prepared by the processor user and the document should be 
placed on or adjacent to the apparatus. Information that needs to be recorded on the pink copy 
includes: 
a) experimental details 
b) times and dates of experiment 
c) emergency procedures 
d) name, address and telephone number of the processor user 
e) signature of researcher concerned and a countersignature from the laboratory 
manager/DSC. 
 
PROTOCOL 
A Preparation of Solvent Containers on Processing Machine: 
Between processing runs, ethanol solutions are stored in labelled bottles to prevent 
evaporation. These are found in the metal solvent cabinet under the bench in Laboratory 4. 
Therefore the solvent containers must be re-filled before tissue processing commences. To 
access the processor solvent container, press the raise button on the hand held controller. 
Remove the evaporation covers from the top of the processor then press rotate or check/fill 
button. The rotate function will cause the operating head assembly to advance one position 
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and the check/fill option rotates the head three positions. Remove the container using the 
metal handles and add 1.5L of the required ethanol solution (the top of the bevelled edge on 
the solvent container is approximately 1.5L). Repeat process until all ethanol containers are 
filled. It is also advisable to check the level of the xylene, formalin and the wax containers on 
a regular basis. If fresh 100% ethanol is used to top up or prepare solutions for the processor 
ensure the ethanol log is updated with the volume used. The ethanol log is situated in DSC 
office (room 1128).  
 
B Sample Processing Procedure 
1. Label plastic cassettes with the sample ID number using pencil. 
2. Carefully remove the tissue from the formalin pot using forceps and place into the small 
wire inserts. Secure the inserts into the plastic cassettes and re-check the sample ID. 
Dispose of the used formalin in the red labelled waste container which is stored below 
the fume hood. 
2. Arrange the cassettes so they are loosely spaced in the processing baskets 
3. Press Go To 1 on the hand held controller, slot the processing baskets onto the holder 
over the formalin and place weight on top of the basket. 
4. Press Lower button on the hand held controller (to lower the basket into the formalin). 
5. Check the time is correct by pressing clock (alter time by pressing the + button or whilst 
holding in the clock button if necessary). 
6. Select the appropriate processing time function: 
 
Date of 
Processing 
Processing 
Time 
Hand Held Controller Action 
Monday-Thursday Before 2pm Press delay on button 
Monday-Thursday After 2pm Press autostart button 
Friday Before 2pm Press days delay, hold this in, scroll to 2 days using the + 
button then press delay on. 
Friday After 2pm press days delay, hold this in, scroll to 1 day using the + 
button, then press delay on 
 
7. Complete the citadel 1000 user log (the folder is situated by the embedding staition in 
laboratory 4) with sample, solvent and programme information.. 
8. When the processing cycles are completed, switch on the Shandon Histocentre 3 
embedding machine. 
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9. Press raise button on the hand held controller and remove baskets from holder. 
10. Place blocks into heated reservoir in the embedding machine. 
11. Wipe processing baskets with absorbent towels to remove surplus wax then place 
equipment into the oven (heated to ~100°C) for several minutes to remove any 
residue.  
12. Soak biopsy inserts in xylene for several hours/overnight to remove wax residues. 
Leave the inserts in the fume hood to air dry  
13. Remove the alcohols from the processing machine using the method described in 
section A and pour solutions in the labelled storage bottles using a funnel. The storage 
bottles are then placed in the flammable solvent metal storage cabinets.  
14. Update the citadel 1000 processing user log.  
 
C Disposal of Waste Solvents 
The solvents must be changed on a regular basis (depending on time of year and processor 
usage) to ensure efficient processing of the tissue samples. Waste solvents must be placed in 
the red solvent waste containers and identified clearly with the appropriate labels provided by 
Lisa Heathcote or Jo Drury. Contaminated waste wax can be discarded by pouring the molten 
solution into a container and cooling until the wax is set. The wax container can then be 
disposed of in the LWH clinical waste. Refer to the waste disposal protocol (SOP 25) for 
further information. 
 
4B: EMBEDDING TISSUE BIOPSIES 
BackgroundACKGROUND 
The Shandon Histocentre provides easy convenient embedding of histological specimens. 
Prior to operating the unit, be sure to read and observe the safety instructions in the operator 
manual. 
EQUIPMENT INFORMATION: 
Plastic cassette 
Shandon HistoCentre 3 Embedding Station 
Hot forceps 
Metal Moulds  
HEALTH AND SAFETY REQUIREMENTS 
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Normal laboratory precautions, including the wearing of gloves, laboratory coat, safety 
goggles and the use of a fume cupboard, should be taken when handling the samples. Refer to 
the risk assessments and COSHH forms before starting procedure. Place all waste in clinical 
waste bin. 
METHOD: 
1. When the processing cycles are completed, switch on the Shandon Histocentre 3 
embedding machine. 
2. Press raise button on the hand held controller and remove baskets from holder 
(use paper towels to ensure that wax doesn’t drip on the floor). 
3. Place blocks into heated reservoir in the embedding machine. 
4. Wipe processing baskets with absorbent towels to remove surplus wax then place 
equipment into the oven (heated to ~100°C) for several minutes to remove any 
residue. 
5. Take a metal mould from the heated unit, place it underneath the wax tap and half-
fill it with wax. 
6. Take a cassette and place on the heated area by the wax tap to prevent 
solidification of the wax. 
7. Open the cassette, and transfer the sample to the wax-filled mould using hot 
forceps. 
8. Move the mould to the “cold spot” at the front of the dispensing unit 
9. Position tissue to bottom surface of metal mould using hot forceps to stabilise 
tissue in place.  
10. Cover with a plastic cassette (number upwards) and hold in place by applying 
pressure with hot forceps on top of cassette.  
11. Top up wax by hovering above the heated area and place on pre-cooled cooling 
block. 
12. Using forceps tap against top of plastic cassette to release any air bubbles within 
the liquid wax. 
13. Leave on cooling area* for at least 30 minutes 
14. Cassette should come cleanly away from the metal mould.  If necessary use 
forceps or a scalpel to loosen the edges. 
164 
 
15. Store the block in the metal storage cabinet (trays 5 and 6) in numerical order 
(room 1125). 
16. Place the metal biopsy inserts into a container of xylene to clean off the wax. 
4C: CUTTING PARAFFIN SECTIONS 
Background 
Preparation of 3-5 micron thick sections from wax – embedded tissue is a commonly used 
histological technique. This SOP will describe how to prepare these using the Microm HM335 rotary 
microtome and attaching sections onto aminopropyl triethoxy silane (APES) coated slides. 
HEALTH AND SAFETY REQUIREMENTS 
Wear a laboratory coat and nitrile gloves. Care needs to be taken when performing this 
procedure because there is a risk of sharps injury from the microtome blades. Refer to the 
physical hazards safety circular, risk assessments and COSHH forms before starting 
procedure. Also ensure waste wax sections are cleaned from the floor and the general 
working area at the end of the procedure to prevent risk of slip/trip injuries. Place all waste 
tissue sections in the clinical waste bags and the used microtome blades and slides into the 
yellow clinical waste sharps bins. DO NOT COMMENCE WORK WITH THE 
MICROTOME UNTIL SUFFICIENT TRAINING HAS BEEN PROVIDED AND 
AUTHORISATION HAS BEEN RECEIVED FROM LISA HEATHCOTE OR JO DRURY. 
EQUIPMENT INFORMATION: 
 Microm HM335 rotary microtome is supplied by MICROM Company. Manufacturer’s 
address: Microm UK Ltd., 8 Thame Park Business Centre, Leinman Road, Thame, 
OX9 3XA. Further information can also be obtained on http://www.microm-
online.com. 
 Microscope slides (twin frost size 26 x 76mm-Printed “IVD CE” 90º ground edges, 
catalogue number MAE-1000-03P Pack of 1000) are purchased from Liverpool 
Women’s Hospital (NHS) purchasing department.  
 Coverslips 22 x 22mm, 22 x 40mm and 22 x 50 are purchased from Liverpool 
Women’s Hospital (NHS) purchasing department. 
 Microtome blades (MB Dynasharp Catalogue Reference 3050836) are purchased from 
Thermo Scientific 93 – 96 Chadwick Road, Astmoor, Runcorn, Cheshire, WA7 1PR 
England. 
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 Forceps, paint brush, section dryer and water bath are supplied by Raymond A Lamb 
Ltd. Manufacturer’s address: Units 4 & 5, Parkview industrial estate, Eastbourne, East 
Sussex, BN23 6QE England. 
METHOD: 
1. Carefully fill the water bath with distilled water ensuring the electrical connection 
points remain dry.  
2. Turn on water bath from the plug and set the power switch from O to I 
3. The water will need to be heated to 40°C. The best way do to this is to first turn the 
temperature dial to 10 (maximum setting) for 7-8 minutes and then turn the dial down 
to 2.5. If the temperature of the bath is above 40°C, pour in distilled water to lower the 
temperature.  
4. Scrape away any surplus wax from the edges of the cassette to ensure a good fit in the 
holder then place the tissue block in the refrigerator. Cool the block for at least 30 min 
prior to cutting. 
5. Ensure that the handwheel is locked in the upper range of the vertical movement by 
turning the lever downwards.  
6. Press the reverse course feed button          to move the knife carrier away from the 
specimen. 
7. Turn the clamping lever on the blade holder to the front and swing the protective 
bracket forwards. Insert the feather S35 blade into the slot behind the clamping plate 
ensuring the blade is level on the rail (use forceps to manipulate the blade if necessary). 
Use half of the blade for cutting at a time. Preferably use left side first and then the 
right side.  
8. Return the clamping lever to the original position (in line with the black frame of the 
blade) to lock the blade in place. The protective bracket should also be returned to the 
original position when the microtome is not in use to minimise the risk of sharps injury.  
9. The blade angle is pre-set to 10-12 and should not require adjustment. These settings 
should remain the same to ensure minimal amounts of tissue are wasted when different 
laboratory workers prepare sections from the same block.  
10. Insert the specimen against the ‘fixed jaw’ of the universal cassette clamp and secure 
by pulling the lever to the front. Ensure that each specimen cassette is always inserted 
in the same orientation (horizontal placement in the universal cassette clamp with the 
specimen number on the left) and inserted to the far left of the clamp.  
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11. Unlock the handwheel by turning the lever upwards. Rotate handwheel in a clockwise 
direction until the centre of the tissue block is level with the blade holder. Then lock the 
handwheel by turning the lever downwards.  
12. Press the forward course feed button          to move the blade carrier near to the 
specimen. To establish whether the blade is close to the specimen view the distance 
between the two at a side angle. Also, gently move the handwheel up and down to see if 
the specimen is not touching the blade. When you are satisfied that both blade and 
specimen are close to each other move the handwheel so the specimen is away from the 
blade, this prevents scoring the specimen block in the middle. 
13. The required section and trimming thickness are set by means of a circular knob on the 
left of the instrument. Press the circular control knob to switch between section (FEED) 
and trimming (TRIM) thickness. The corresponding LED will be displayed on the 
operating control panel:  
 Green LED lights up when the FEED function is used 
 Yellow LED lights up when the TRIM function is selected. 
14. When a new tissue block is used, select TRIM and turn the control knob until the 
corresponding LED is set at 20µm. 
15. Unlock the handwheel and start trimming by rotating the handwheel in a clockwise 
direction. Once you begin to see specks on tissue in the sections change the TRIM 
settings from 20µm to 10µm.  
16. Continue to trim on the new setting until a representative amount of tissue is exposed in 
the tissue block. 
17. Select FEED and turn the control knob until the corresponding LED is set at the 
required section thickness (usually 3-5µm). Rotate the handwheel until the first section 
generated. Gently hold the end of the section with forceps and continue to cut until a 
ribbon (consisting of approximately 6 sections) is produced. Discard the first few 
sections when first cutting on the feed section as usually the first few are too thick.  
18. Carefully float the sections onto the pre-warmed water bath. Leave or a minute or so 
until the wrinkles in the section disappear. Separate the sections by applying gentle 
pressure using forceps. Select the best sections and float onto APES-coated slides. It is 
considered to be good laboratory practice to attach each section in the same orientation 
on the surface of the slide where you can read the IVD sign.  
19. Label the frosted part of the slide with the specimen ID and thickness (using a pencil). 
Place slides in a rack to dry at room temperature for several hours (preferably over 
night).  
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20. When not cutting for a few minutes the specimen block moves slightly out of place 
which potentially can create thicker sectioning when you go back to cutting. To avoid 
creating thicker sections press the reverse course feed button         very slightly to move 
the knife carrier away from the specimen by a small amount.  
21. During the cutting procedure a build up of wax on either side of the blade carrier. This 
can potentially cause scoring of the section. Using a soft brush, brush in an upward 
direction against the blade carrier to remove the wax, this is to prevent blunting of the 
blade and cutting down of the brush if a downward direction was used.  
22. If the sections start to wrinkle during the cutting procedure, then the tissue block has 
become too warm and needs to be refrigerated for at least 10 minutes. To remove the 
tissue block, press the reverse course feed button until the specimen is safely away from 
the blade holder. Return the safety bracket to the upright position. Remove the tissue 
block by pressing the lever on the universal cassette clamp. 
23. Remove any unused tissue sections from the water bath surface using kitchen roll.  
24. When the microtome blade needs to be replaced, return the tissue block to the furthest 
position using the course feed button and lock the handwheel. Unlock the lever on the 
blade carrier and place the microtome blade into the yellow clinical waste sharp bin. 
NEVER try to remove the microtome blade when the tissue block is close to the blade 
edge because there is a risk of sharps injury and also the risk of damaging the tissue 
block. 
25. When the sections have dried, place the slides into a staining rack and bake for 60 
minutes in a slide drier (pre-warmed to 60°C), or 37º C overnight. Place slides in a 
suitable ‘dust free’ container until required for the immunohistochemical staining 
procedure. 
 
4D: APES COATING PROCEDURE 
Background  
The Aminopropyl triethoxy silane (APES) coating procedure is used to improve tissue adhesion by 
producing a positive charge on the surface of the slide. The protocol described below was modified 
from the original method described by Maddox and Jenkins in 1991 (full reference provided in the 
appendices). 
HEALTH AND SAFETY REQUIREMENTS 
The APES concentrate is a toxic chemical that is moisture sensitive and requires storage at 0 -
5°C; it is an irritant and can cause burns. Normal laboratory precautions, including the 
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wearing of gloves and the use of a fume cupboard, should be taken when handling the 
concentrate solution. Refer to the risk assessments and COSHH forms before starting 
procedure. Place all waste solutions into a labelled red solvent waste can and attach a solvent 
label (available from Lisa Heathcote or Jo Drury by request). 
EQUIPMENT INFORMATION: 
 Microscope slides (twin frost size 26 x 76mm-Printed “IVD CE” 90º ground edges, 
catalogue number MAE-1000-03P Pack of 1000) are purchased from Liverpool 
Women’s Hospital (NHS) purchasing department.  
 APES solution (catalogue number A3648) is purchased from Sigma-Aldrich Company 
Ltd. UK distributor address: The Old Brickyard, New Road, Gillingham, Dorset, SP8 
4XT. 
 Staining racks and glass jars are supplied by Raymond A Lamb Ltd. Manufacturer’s 
address: Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 6QE 
England. 
METHOD: 
26. Place slides into plastic racks. Each rack holds 24 slides 
27. Prepare a 2% APES working solution by mixing 5ml APES with 245ml 100% ethanol, 
or for the bulk method 40ml APES with 1960ml 100% ethanol. The APES solution is 
stable for several hours; therefore coat as many racks as possible to save reagents and 
time. 
28. Prepare a glass staining trough containing 100% ethanol 
Position 1: APES working solution 
Positions 2 – 4: distilled water 
29. Place slides racks in 100% ethanol. Dip several times to dislodge dust etc., and then 
drain the staining racks on absorbent paper towels. 
30. Incubate the slides for 5 minutes in APES working solution.  
31. Rinse slides in three changes of distilled water (2 minutes incubation for each rinse). 
32. Drain slides on absorbent towels and air dry overnight, or dry in a section dryer for 1 
hour at 37°C. 
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33. Discard the first change of distilled water. Place the staining jar containing fresh 
distilled water at the last rinse location (position 5). Therefore the 2
nd
 change of water 
has becomes the first etc. 
34. Repeat steps 5 through to 9 for each rack of slides. 
35. Transfer the coated slides to a dust free container labelled ‘APES’ and the date of 
coating (APES slides are stable for approximately 3 months).  
 
4E: HAEMATOXYLIN AND EOSIN STAINING OF BIOPSY TISSUE SAMPLES 
Background 
The Haematoxylin and Eosin stain is probably the most widely used stain in Histopathology/ 
Cytopathology. It has the ability to demonstrate an enormous amount of tissue structures. The 
haematoxylin component stains cell nuclei blue / black with good intranuclear detail whilst 
the eosin stains cell cytoplasm and most connective tissue fibres in varying shades of pink. 
Health and Safety Precautions 
The main health and safety risks to this procedure arise from chemicals/reagents that are 
potentially hazardous, gloves must be worn at all times. Eosin Y aqueous contains 
(formaldehyde: 50 – 00 – 0), causes burns, and may cause sensitisation by skin contact. In 
addition, it is toxic by inhalation, in contact with skin and if swallowed. Haematoxylin (Gill 
2) contains (ethylene glycol: 107 – 21 – 1; aluminium sulphate 10043 – 01 – 3; acetic acid: 
64 – 19 – 7). This is harmful if swallowed; very toxic by inhalation; causes severe burns, and 
is irritating to eyes. 
METHOD 
Work in a fume hood 
For paraffin sections:   
 1.  Dewax prior to staining: 10 min Xylene 1 
   10 min Xylene 2 
   5 min 100% Ethanol 1 
   5 min 100% Ethanol 2 
   1 min 90% Ethanol  
   1 min 70% Ethanol  
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2. 2 min water 
3. Gills 2 Haematoxylin 
4. Rinse in tap water 
5. Acid alcohol dip 
6. Blue in tap water (approximately 5 min) 
7. 70% alcohol – 45seconds 
8. 95% alcohol - 45seconds 
9.  Eosin Y, aqueous 4 min 
10. Water rinse x 2 
11. Incubate water 2 min 
12. 95% alcohol 20 - 30s 
13. 100% alcohol 1: - 45seconds 
14. 100% alcohol 2: - 45seconds 
15. Xylene 1: 5mins 
16. Xylene 2: 10mins 
17. DPX and mount 
4F: IMMUNOHISTOCHEMISTRY – GET FROM JO  
Background 
Immunohistochemical staining is a valuable tool for detecting specific antigens in tissues. In 
order to perform the standard staining procedure, first the tissue section has to be prepared 
(SOP 04, 05 and 06), deparaffinized and then rehydrated (SOP 08). Antigen retrieval (SOP 
09) is then performed to break any protein cross-links, therefore unmasking the antigens and 
epitopes in the tissue sections. The Vector immPRESS 
TM
 reagent kit, HRP is a two-step 
Immunohistochemical staining technique. This system is based on an HRP labelled polymer 
which is conjugated with secondary antibodies. The labelled polymer does not contain avidin 
or biotin. Consequentially non-specific staining resulting from endogenous avidin-biotin 
activity in liver, kidney, lymphoid tissues and cryostat sections is eliminated or significantly 
reduced. The interpretation of any positive staining or its absence should be complemented 
by morphological and histological studies with proper counts. Any endogenous peroxidase 
activity is quenched by incubating the specimen with Peroxidase block. The specimen is 
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incubated with an appropriately characterised and diluted mouse primary antibody, followed 
by incubation with the labelled polymer. Staining is completed by incubation with 3’3-
Diaminobenzindine (DAB)+ substrate - chromogen  which results in a brown–coloured 
precipitate. 
Definition 
This SOP will explain how to stain tissue using an unlabelled antibody. Please read entire 
procedure before staining sections. Perform all antibody and staining incubations in a humid 
chamber and do not allow sections to dry out. Isotype and system controls should also be run. 
Carefully time all tests. Do not touch test specimens on slides during the staining procedure. 
Health and Safety Precautions 
The main health and safety risks to this procedure arise from chemicals/reagents that are 
potentially hazardous, such as hydrogen peroxide (H2O2), xylene, ethanol, and DAB (3’3-
diaminobenzindine).  Gloves must always be worn when working with any of these 
chemicals.  
EQUIPMENT INFORMATION 
Staining dishes 
Humidified chamber 
Cover slips 
General points: 
Ensure that solutions cover the whole specimen – if necessary use a piece of Parafilm to 
spread. 
Antibody information: 
All current antibody datasheets are held in a labelled lever arch file in room 1128.  Additional 
information on appropriate antibody concentration, antigen retrieval conditions and 
incubation time/temperature is held in an Excel spreadsheet (C:\Documents and 
Settings\jadrury.livad\My Documents\Dharani\Dharani abs.xlsx). 
Reagent information: 
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TBS: 6 g/l Trizma base (T1503, Sigma-Aldrich) + 8.7 g/l NaCl (S7653, Sigma-Aldrich).  
Adjust pH to 7.6 with HCl. 
BSA: A3803 (Sigma Aldrich) 
H2O2: H1009 (Sigma-Aldrich) 
ImmPRESS anti-mouse IgG kit (50 ml) (MP-7402, Vector Laboratories) 
ImmPRESS anti-rabbit IgG kit (50 ml) (MP-7401, Vector Laboratories) 
ImmPRESS anti-goat IgG kit (50 ml) (MP-7405, Vector Laboratories) 
ImmPACT DAB (120 ml) (SK-4105, Vector Laboratories) 
Shandon Gill 2 Haematoxylin (Thermo Scientific) 
1% acid alcohol: 1 ml HCl/100 ml 70% ethanol 
Shandon Consul-Mount (Thermo Scientific) 
Supplier information: 
Sigma-Aldrich Company Ltd, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT.  
Tel: 0800 717181.  Fax: 0800 378785.  Web: www.sigma-aldrich.com. 
Thermo Scientific, Bishop Meadow Road, Loughborough, LE11 5RG.  Tel: 01509 231166 
Fax: 01509 231893. 
Vector Laboratories Ltd. 3, Accent Park, Bakewell Road, Orton Southgate, Peterborough, 
PE2 6XS.  Tel: 01733 237999.  Fax: 01733 237119.  Web: www.vectorlabs.com. 
METHOD (Paraffin sections): 
1. Place slides in a staining dish containing TBS and incubate 5 minutes at room 
temperature. 
2. Prepare 0.3% H2O2/TBS (2.5 ml 30% H2O2 + 247.5 ml TBS) 
3. Incubate slides in 0.3% H2O2/TBS bath 10 minutes at room temperature. 
4. Prepare humidified chamber by placing folded paper towels in the centre gulley’s and 
soaking with distilled water. 
5. Decant H2O2/TBS and tap off any remaining solution.  Carefully wipe around the 
specimen and the back of the slides with a tissue to remove excess liquid. 
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6. Place slides in a staining dish filled with TBS and incubate 5 minutes at room 
temperature. 
7. Tap off any remaining solution, carefully wipe around the specimen and the back of 
the slides with a tissue to remove excess liquid. 
8. Mark area to be stained with DAKO hydrophobic marker pen ensuring that the tissue 
is surrounded with sufficient space to allow spreading of antibodies. 
9. Place slides in a staining dish filled with TBS and incubate 5 minutes at room 
temperature. 
10. Prepare antibody diluent (TBS/0.5 % BSA eg. 250 µl 10% BSA + 4750 µl TBS) 
11. Prepare appropriate dilutions of each antibody, allowing 50 µl per section. 
12. Tap off any remaining solution, carefully wipe around the specimen and the back of 
the slides with a tissue to remove excess liquid. 
13. Place slides in humidified chamber. 
14. If necessary, add one drop horse serum block to each section, spread with parafilm to 
ensure that the whole section is covered, and incubate 20 min at room temperature. 
15. Tap off the serum block and proceed to step 17.   
16. Steps 14 and 15 can be omitted if staining is clean without blocking. 
17. Apply 50µl of the appropriate antibody to each section, spread with parafilm to ensure 
that the entire section is covered and incubate 30-120 min at room temperature or 
overnight at 4C.  See C:\Documents and Settings\jadrury.livad\My 
Documents\Dharani\Dharani abs.xlsx for specific conditions for each antibody. 
18. Tap off the antibody solution onto paper towels prior to placing the slides in a staining 
dish filled with TBS. 
19. Incubate 5 minutes at room temperature. 
20. Decant TBS and refill. 
21. Incubate 5 minutes at room temperature. 
22. Tap off any remaining TBS, carefully wipe around the specimen and the back of the 
slides with a tissue to remove excess liquid. 
23. Return slides to the humidified chamber and apply 1 drop labelled polymer-HRP.  
Ensure that the polymer matches the primary antibody. 
24. Spread with parafilm to ensure that the entire section is covered and incubate 30 min 
room temperature.  
25. Tap off the polymer solution onto paper towels prior to placing the slides in a staining 
dish filled with TBS. 
26. Incubate 5 minutes at room temperature. 
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27. Decant TBS and refill. 
28. Incubate 5 minutes at room temperature. 
29. Prepare substrate/chromogen solution: 30µl/1ml substrate (require 50 µl per section). 
30. Tap off any remaining TBS, carefully wipe around the specimen and the back of the 
slides with a tissue to remove excess liquid. 
31. Return slides to the humidified chamber and apply 50 µl substrate/chromagen 
solution.   
32. Spread with parafilm to ensure that the entire section is covered and incubate 10 min 
room temperature. 
33. Place slides in staining rack and immerse immediately in tap water to stop the 
reaction. 
34. Turn on fume hood in lab 4. 
35. Counterstain using filtered Gill 2 haematoxylin in lab 4.  Immerse for 1 min 30s. 
36. Immerse in tap water and rinse until water is clear. 
37. Dip briefly in acid alcohol, and immediately back into tap water (5 min). 
38. Incubate 1 min in 70% ethanol.   
39. Blot off excess and incubate 1 min in 90% ethanol. 
40. Blot off excess and incubate 3 min in 100% ethanol. 
41. Repeat step 40. 
42. Blot off excess and incubate 5 min in xylene. 
43. Blot off excess and incubate 10 min in xylene. 
44. Remove a few slides at a time and apply sufficient mountant to cover the section. 
45. Choose an appropriately sized coverslip and apply to the slide. 
46. Remove air bubbles by using a cocktail stick or yellow pipette tip to gently press on 
the coverslip and “chase” bubbles to the edge. 
47. Leave to dry in fume hood. 
 
3G: PREPARATION OF PARAFFIN SECTIONS FOR STAINING 
Background 
Factors that prevent adhesion of sections to blank slides are usually attributed to moisture 
under the section, and almost always become apparent after heat antigen retrieval.  The 
method of heating slides prior to immunohistochemical staining ensures tissue sections 
adhere to the glass slide.  It is important the sections are not over-baked, however, as this 
could increase background and decrease target staining. 
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In order to prepare slides for staining, tissue must be deparaffinised using xylene and 
gradually rehydrated with descending grades of alcohol.  
Health and Safety Precautions: 
Wear a laboratory coat, safety spectacles and nitrile gloves. Xylene is harmful by contact to 
skin and eyes or if ingested or inhaled.  Work in the fume hood for dewaxing procedure.  
Refer to the risk assessments and COSHH forms before starting procedure. 
Materials 
- Staining racks and glass jars are supplied by Raymond A Lamb Ltd. Manufacturer’s 
address: Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 6QE 
England. 
- Ethanol and xylene are purchased from Chemistry solvent stores (University of Liverpool). 
- Section Dryer. Model E28.5. Supplier information: Raymond A. Lamb, Eastbourne, BN23 
6QE, England.  
Method 
1. Switch on Section Dryer Model E28.5. Adjust temperature using the temperature dial (see 
below for temperature required). 
2. Label slides with the stain/antibody and concentration to be used, and date in pencil.  
3. Place slides for staining in metal slide racks.  
4. Heat to 60oC for 60 minutes or overnight at 37 oC. 
5. Dewaxing solutions are in staining dishes in the fume hood in room 1125.  Place the slide 
rack in xylene-1 for 10 minutes.  Long forceps can be used to facilitate the transfer of the 
slide rack between dishes. 
6. Drain off excess xylene, and transfer to the dish labelled “xylene-2” for 10 minutes. 
7. Drain off excess xylene, and briefly blot on paper towel. 
8. Place the slide rack in the dish labelled “100% ethanol-1” for 5 minutes. 
9. Drain off excess ethanol, and transfer to the dish labelled “100% ethanol-2”. 
10. Drain off excess ethanol, briefly blot on paper towel and transfer to 90% ethanol for 1 
minute. 
11. Drain off excess ethanol, briefly blot and transfer to 70% ethanol for 1 minute. 
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12. Drain off excess ethanol, briefly blot and transfer to a clean staining dish containing tap 
water. 
3H: ANTIGEN RETRIEVAL  
BACKGROUND  
The mechanisms of formalin-fixation have been thought to be due to the formation of cross-
linking bonds between tissue proteins, stabilising them to withstand subsequent processing 
(Mason and O’Leary 1991). Whilst preserving tissue morphology, the formation of cross 
linking bonds may, however modify the antigen’s epitopes and/or it’s electrostatic charges, 
thus producing weak or false negative staining during immunohistochemical detection of 
certain proteins. Restoring the epitopes enables the antigen to react with the paratope of the 
antibody. Methods of proteolytic pre-treatment and heat retrieval of tissue antigenicity aim to 
restore the avidity of the immune reaction.  
Proteinase K is a type of proteolytic agent which is isolated from the saprophytic fungus 
Tritirachium album. It possesses a high specific activity which remains stable over a wide 
range of temperatures and pH values with substantially increased activity at higher 
temperature. It particularly unmasks antigens of proteins found in the basement membranes 
including laminin and collagen IV.   
There are 2 commonly used heat retrieval buffers, which vary in their pH. Heat causes cross-
linked protein epitopes to ‘unfold’ (in manner similar to DNA denaturation), while buffer 
solutions aid in maintaining the conformation of the unfolded protein. The citrate based 
solution is designed to break the protein cross-links, therefore unmask the antigens and 
epitopes in formalin-fixed and paraffin embedded tissue sections, thus enhancing staining 
intensity of antibodies.    Tris-EDTA is very useful for low affinity antibodies or when tissue 
antigens are not intense. This buffer works well for many antibodies, but it often gives high 
background staining (maybe due to endogenous biotin revealed after this pretreatment), so 
primary antibody can often be highly diluted. 
HEALTH AND SAFETY REQUIREMENTS 
Care needs to be taken when performing heat based retrieval procedures because there is a 
risk of burns from the hotplate and pressure cooker. There is also a risk of chemical burns 
from sodium hydroxide and there is a mild irritant effect from citric acid. Suitable personal 
protection equipment (Nitrile gloves, safety glasses and a lab coat etc) should be worn. Refer 
to the physical hazards safety circular, risk assessments and COSHH forms before starting 
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procedure. DO NOT COMMENCE WORK WITH THE PRESSURE COOKER UNTIL 
SUFFICIENT TRAINING HAS BEEN PROVIDED AND RECEIVED AUTHORISATION 
FROM LISA HEATHCOTE OR JO DRURY. THE SEAL ON THE PRESSURE COOKER 
SHOULD BE INSPECTED PRIOR TO EVERY USE AND REPLACED ANNUALLY. 
EQUIPMENT INFORMATION:  
 Proteinase K supplied by QIAGEN. QIAGEN HOUSE, Fleming Way, Crawley  
West Sussex, RH10 9NQ 
 Diluent 
 Humidity Chamber  
 Sodium Hydroxide pellets and citric acid are supplied by VWR International Ltd, 
Poole, BH15 1TD England (Future orders will be obtained from Sigma or Thermo 
Fisher).  
 Trizma base (T1503, Sigma- Aldrich Chemical Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT.  Tel: 0800 717181.  Fax: 0800 378785.  
Web: www.sigma-aldrich.com) 
 EDTA (disodium, dehydrate) is supplied by VWR International Ltd, Pole, BH15 
1TD.  Future orders will be obtained from Sigma (E4884). 
 Tefal Clipso Easy 6L pressure cooker and Russell Hobbs hotplate are obtained 
commercially from John Lewis department store. Annual Insurance check TBC. The 
seal/gasket needs to be replaced annually. Gasket (part number SA793145) is 
obtained directly from: http://www.homeandcook.co.uk  refer to section 
accessories/pressure cookers. 2010 price £8.50 +£1.50 delivery 
 Slide racks are supplied by Raymond A Lamb Ltd. Manufacturer’s address: Units 4 & 
5, Parkview industrial estate, Eastbourne, East Sussex, BN23 6QE England.  
 
 Tris-EDTA Buffer (10mM Tris Base, 1mM EDTA Solution, pH 9.0): 
Tris Base  12.1 g 
EDTA   3.7 g 
Distilled water 2 l to make 5x stock solution 
Mix to dissolve, pH is usually at 9.0. Store this solution at room temperature for 3 
months or at 4C for longer storage. 
METHOD A (Proteinase K): 
 Prepare a volume of proteinase K with a 1:25 concentration of the working stock 
that is sufficient for 50μl per section. Allow larger volume for larger sections.  
 Once all slides have been de-waxed place into distilled water  
 Prepare humidified chamber 
 Remove slides from the staining dish and wipe the backs of the slides and place 
onto the humidified chamber.  
 Distribute 50μl of proteinase K onto each section and spread over whole of tissue 
using a piece of parafilm. Take care whilst spreading to ensure sections do not get 
dried or damaged in any way. 
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 All sections should be incubated with proteinase K for 5 minutes at room 
temperature. 
 After 5 minutes tap the solution off the slide and place slides in a glass staining dish 
filled with TBS. 
 See SOP 12 for immunohistochemistry protocol. 
 
METHOD B (Heat based antigen retrieval): 
1. Either:  
(a) Prepare a 10mM solution of citrate buffer, pH=6.0 by adding 3.15g citric acid 
to 1.5 litre of distilled water and adjust pH to 6.0 with 2M NaOH. 
Or: 
(b) Dilute stock 5x Tris-EDTA buffer, pH=9.0 by adding 300 ml to 1.2 l of 
distilled water. 
2. Place buffer in the pressure cooker and place on the hotplate. 
3. Turn on the hotplate to the maximum heat setting. 
4. Loosely place the lid back on pressure cooker. Bring the buffer to a rolling boil. 
5. Immerse the slide rack in the buffer using long forceps. 
6. Engage the lid, turn the valve to pressure symbol and press the lid down until it 
clicks. 
7. Set timer for 1 minute, when steam starts to vent, start timer. After 1 minute, turn 
off the hotplate and release the pressure by turning the vent to the “steam” symbol, 
and cool as quickly as possible by transferring the pressure cooker to the sink and 
running under cold water. 
8. Transfer the slides back to the glass staining jar containing distilled water. 
9. Transfer to TBS ensuring that the tissue does not dry out. 
10. See SOP 12 for immunohistochemistry protocol. 
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APPENDIX 5 
ANTIBODY DATA SHEETS 
 
 
Denmark A/S · Produktionsvej 42 · DK-2600 Glostrup · Denmark · Tel. +45 44 85 95 00 · Fax 
+45 44 85 95 95 · CVR No. 33 21 13 17 
 
Polyclonal Rabbit 
Anti-Laminin 
Code No./ Code/ Code-Nr. Z 0097 
 
Intended use  
For in vitro diagnostic use. Polyclonal Rabbit Anti-Laminin is intended for use in 
immunocytochemistry. The antibody labels laminin, which is present in the basement 
membrane. The antibody may be useful in the characterization of basement membrane 
preservation, e.g. in breast cancer (1, 2) and adenocarcinomas of the lung (3). Differential 
identification is aided by the results from a panel of antibodies. Interpretation must be made 
within the context of the patient’s clinical history and other diagnostic tests by a qualified 
pathologist. 
 
Introduction  
Laminins are large heterotrimeric basement membrane glycoproteins composed of an α−, a 
β− and a γ−chain. At present 5 α−chains, 3 β−chains, and 3 γ−chains are known to form at 
least 15 different isoforms (4). The laminin isoforms have different tissue- and 
developmental-specific localizations, and more than 20 cell surface receptors have been 
identified for laminin, including integrins, proteoglycans, lectins, gangliosides, sulphatides, 
amyloid precursor protein and galactosyltransferases (5, 6). Laminins have been found to 
promote cell adhesion, migration, protease activity, proliferation, tumour growth, 
angiogenesis and metastasis. 
 
Reagent provided Purified immunoglobulin fraction of rabbit antiserum provided in liquid 
form in 0.1 mol/L NaCl, 15 mmol/L NaN3. 
Protein concentration g/L: See label on vial. 
 
Immunogen Laminin isolated from the rat yolk sac tumour cell line L2. 
 
Specificity The antibody labels laminin in basement membranes. Traces of contaminating 
antibodies have been removed by solidphase absorption with human and rat plasma 
proteins as well as rat immunoglobulins. In crossed immunoelectrophoresis, using 12.5 μL 
antibody per cm2 gel area against 2 μL human plasma, 2 μL rat plasma or 20 μg of rat 
immunoglobulins, only one precipitate corresponding to laminin appears. Staining: 
Coomassie Brilliant Blue. As demonstrated by immunocytochemistry, the antibody cross-
reacts with the laminin-equivalent protein in man, mouse (7) and rat (8). 
 
Precautions  
1. For professional users. 
2. This product contains sodium azide (NaN3), a chemical highly toxic in pure form. At 
product concentrations, though not classified as hazardous, sodium azide may react with 
lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, 
flush with large volumes of water to prevent metal azide build-up in plumbing. 
3. As with any product derived from biological sources, proper handling procedures should 
be used. 
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Storage  
Store at 2-8 °C. Do not use after expiration date stamped on vial. If reagents are stored 
under any conditions other than those specified, the user must verify the conditions. There 
are no obvious signs to indicate instability of this product. Therefore, positive and negative 
controls should be run simultaneously with patient specimens. If unexpected staining 
is observed, which cannot be explained by variations in laboratory procedures, and a 
problem with the antibody is suspected, contact our Technical Services. 
 
Specimen preparation Paraffin sections: The antibody can be used for labelling paraffin-
embedded tissue sections fixed in formalin. Pretreatment of tissues with DakoCytomation 
Proteinase K, code No. S 3020 is recommended. Heat-induced epitope retrieval with 
DakoCytomation Target Retrieval Solution, pH 6, code No. S 2369, DakoCytomation Target 
Retrieval Solution, code No. S 1700, DakoCytomation Target Retrieval Solution, pH 9, code 
No. S 2368, or DakoCytomation Target Retrieval Solution, High pH, code No. S 3308, was 
found inefficient. The tissue sections should not dry out during the treatment or during the 
following immunocytochemical staining procedure. 
 
Staining procedure  
Dilution: Polyclonal Rabbit Anti-Laminin, code No. Z 0097, should be diluted in 
DakoCytomation Antibody Diluent, code No. S 0809, and may be used at a dilution range of 
1:25-1:50 when applied on formalin-fixed, paraffin-embedded sections of tonsil and using 5 
minutes pre-treatment at room temperature with DakoCytomation Proteinase K, code No. 
S 3020, and 30 minutes incubation at room temperature with the primary antibody. Optimal 
conditions may vary depending on specimen and preparation method, and should be 
determined by each individual laboratory. 
The recommended negative control is DakoCytomation Rabbit Immunoglobulin Fraction 
(Solid-Phase Absorbed), code No. X 0936, diluted to the same protein concentration as the 
primary antibody. Unless the stability of the diluted antibody and negative control has been 
established in the actual staining procedure, it is recommended to dilute these reagents 
immediately before use, or dilute in DakoCytomation Antibody Diluent, code No. S 0809. 
Positive and negative controls should be run simultaneously with patient specimen. 
code Nos. K 4008 and K 4010 are recommended. Follow the procedure enclosed with the 
kit. 
 
Performance characteristics  
Extracellular matrix labelled by the antibody display staining of the basement membrane. 
Normal tissues: The antibody was found to label basement membranes in human tonsil and 
kidney. Abnormal tissues: In a study of 220 cases of ER-positive non-invasive breast 
lesions, labelling of 20 cases with the antibody revealed no distinct immunoreactivity in the 
surrounding disrupted myoepithelial cell layers, suggesting disruption of the basement 
membrane also. In a study of 53 cases of lung carcinomas of the adenocarcinoma mixed 
bronchioloalveolar subtype, labelling with the antibody was lost in collapsed alveolar regions 
in 40/53 cases and in scarred regions in 53/53 cases indicating complete destruction of the 
basement membrane in these areas.  
 
 
DakoCytomation Denmark A/S · Produktionsvej 42 · DK-2600 Glostrup · Denmark · Tel. +45 
44 85 95 00 · Fax +45 44 85 95 95 · CVR No. 33 21 13 17 
Monoclonal Mouse 
Anti-Human 
Collagen IV 
Clone CIV 22 
Code No./ Code/ Code-Nr. M 0785 
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Intended use  
For in vitro diagnostic use. 
Monoclonal Mouse Anti-Human Collagen IV, Clone CIV 22, is intended for use in 
immunocytochemistry. The antibody labels type IV collagen and is a useful tool for the 
identification of basement membranes. Differential identification is aided by the results from 
a panel of antibodies. Interpretation must be made within the context of the patient’s clinical 
history and other diagnostic tests by a qualified pathologist. 
 
Introduction  
Collagen IV is a major constituent in particular of the lamina densa of basement membranes 
and ultrastructurally it looks amorphous. Basement membranes are thin extracellular 
matrices separating parenchymal, endothelial, and epithelial cells from underlying 
connective tissue. In glomerular and tubular basement membranes 40% of the protein is 
type IV collagen. Detection of intracellular type IV collagen is generally difficult owing to a 
low concentration. In newly formed capillaries found in the inflammatory sites of rheumatoid 
arthritis synovium, intracellular type IV collagen may, however, be detected (1). Structurally 
the protein consists of four domains. One of these, the triple helical collagen IV domain, is 
formed by the association of two polypeptide chains of type α1 and one of type α2. This 
domain is 340 nm long and is highly crosslinked by disulphide bridges (1, 2). Diagnostic 
applications of collagen type IV immunostaining have mostly centered around the 
demonstration of basal lamina in invasive tumours. In particular, the demonstration of an 
intact basal lamina has been used to distinguish benign glandular proliferations, such as 
microglandular adenosis and sclerosing adenosis, from well-differentiated carcinoma, like 
tubular carcinoma of the breast (3). 
 
Reagent provided  
Monoclonal mouse antibody provided in liquid form as cell culture supernatant dialysed 
against 50 mmol/L Tris/HCl, pH 7.2, and containing 15 mmol/L NaN3. Clone: CIV 22 (2). 
Isotype: IgG1, kappa. IgG concentration: see label on vial.  
 
Immunogen  
Purified pepsin fragments of type IV collagen isolated from human kidney (2). 
 
Specificity The specificity of the antibody has been assessed in radioimmunoassay (RIA) 
where it recognizes an epitope present in the human type IV collagen in native conformation, 
whereas it does not recognize the reduced and alkylated protein in the denatured state. 
Staining of immunoblots with the antibody was negative, further indicating that the antibody 
recognizes a conformational epitope on type IV collagen (2). In immunoblotting or RIA, no 
cross-reactivity of the antibody with isolated human collagen types I, II, III and V could be 
detected (2). As demonstrated by RIA, the antibody cross-reacts with the collagen IV-
equivalent protein in cow (2). 
 
Precautions  
1. For professional users. 
2. This product contains sodium azide (NaN3), a chemical highly toxic in pure form. At 
product concentrations, though not classified as hazardous, sodium azide may react with 
lead and copper plumbing to form highly explosive build-ups of metal azides. Upon disposal, 
flush with large volumes of water to prevent metal azide build-up in plumbing. 
3. As with any product derived from biological sources, proper handling procedures should 
be used. 
 
 
 
Storage  
Store at 2-8 °C. Do not use after expiration date stamped on vial. If reagents are stored 
under any conditions other than those specified, the user must verify the conditions. There 
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are no obvious signs to indicate instability of this product. Therefore, positive and negative 
controls should be run simultaneously with patient specimens. If unexpected staining is 
observed which cannot be explained by variations in laboratory procedures and a problem 
with the antibody is suspected, contact our Technical Services. 
 
Specimen preparation Paraffin sections: The antibody can be used for labelling paraffin-
embedded tissue sections fixed in formalin. Pre-treatment of tissues with heat-induced 
epitope retrieval is required. Optimal results are obtained with DakoCytomation Target 
Retrieval Solution, code No. S 1700. Less optimal results are obtained with 10 mmol/L 
citrate buffer, pH 6.0, or 10 mmol/L Tris buffer, 1 mmol/L EDTA, pH 9.0. However, 
DakoCytomation Target Retrieval Solution, High pH, code No. S 3308 and pre-treatment of 
tissues with proteinase K were found inefficient. The tissue sections should not dry out 
during the treatment or during the following immunocytochemical staining procedure. 
Frozen sections and cell preparations: The antibody can be used for labelling acetone fixed, 
frozen sections (5, 6). 
 
Staining procedure  
Dilution: Monoclonal Mouse Anti-Human Collagen IV, code No. M 0785, may be used at a 
dilution range of 1:25-1:50 when applied on formalin-fixed, paraffin-embedded sections of 
human kidney and using 20 minutes heat-induced epitope retrieval in DakoCytomation 
Target Retrieval Solution, code No. S 1700, and 30 minutes incubation at room temperature 
with the primary antibody. Optimal conditions may vary depending on specimen and 
preparation method, and should be determined by each individual laboratory. The 
recommended negative control is DakoCytomation Mouse IgG1, code No. X 0931, diluted to 
the same mouse IgG concentration as the primary antibody. Unless the stability of the 
diluted antibody and negative control has been established in the actual staining procedure, 
it is recommended to dilute these reagents immediately before use, or dilute in 
DakoCytomation Antibody Diluent, code No. S 0809. Positive and negative controls should 
be run simultaneously with patient specimen. Visualization: DAKO LSAB™+/HRP kit, code 
No. K 0679, and DAKO EnVision™+/HRP kits, code Nos. K 4004 and K 4006, are 
recommended. For frozen sections and cell preparations, the DakoCytomation APAAP kit, 
code No. K 0670, is a good alternative if endogenous peroxidase staining is a concern. 
Follow the procedure enclosed with the selected visualization kit. Automation: The antibody 
is well-suited for immunocytochemical staining using automated platforms, such as the 
DakoCytomation Autostainer. 
 
Performance characteristics Normal tissues: The antibody shows the characteristic 
labelling of basement membranes in a variety of tissues and organs tested, including kidney, 
skin, striated and smooth muscle, spleen, lymph node, lung, placenta and tendon. In spleen 
and lymph nodes, the expected fragmented labelling of the discontinuous basement 
membranes of the sinusoids is observed, whereas other blood vessels exhibit a linear, 
continuous labelling. In kidneys, basement membranes of capillaries, parts of the mesangial 
matrix and the Bowman's capsule, and the tubular basement membranes are labelled by the 
antibody. The only basement membrane showing negative labelling with the antibody is that 
of the corneal epithelium. All structures others than basement membranes are consistently 
negative with this antibody (2). Abnormal tissues: In congenital epidermolysis bullosa (EB), 
the antibody allowed a rapid distinction between the two major variants, EB simplex, and EB 
dystrophica (4). Around dilated vessels of port-wine stains, the antibody labelled much 
broader belts than around vessels in normal skin (5), and in angioimmunoblastic 
lymphadenopathy, vascular proliferation and small amounts of intercellular collagenous 
fibrils were reliably revealed by the antibody (6). 
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APPENDIX 6 
IMAGE ANALYSIS SOP 
Immunohistochemically stained endometrium was previously analysed manually down the 
microscope but this was subject to wide inter-observer variability. There was potential for 
error from observer fatigue, and inter-observer quality control was not possible as different 
areas of endometrium were likely to be examined. There was also no guarantee that the same 
area had not been analysed more than once. Digital image analysis offers greater 
reproducibility, quality control and may be faster than manual counting. This SOP will  
explain how to capture images of stained endometrial biopsies using NIS Elements-F and 
Eclipse Net and how to measure BL thickness using Image J. 
Health and Safety Precautions 
The main health and safety risks to this procedure arise from the use of Display Screen 
Equipment (DSE).  DSE risks are the possibility of upper limb disorders (e.g. repetitive strain 
injury (RSI)), eye strain and eye fatigue and the effects of mental stress.  In order to minimise 
these risks, users should endeavour to create a comfortable work position and layout of work, 
ensure that the screen is regularly cleaned and avoids glare and reflections, take short breaks 
or changes of activity, report and problems straight away and arrange to have eyesight 
checks.  Users should have a copy of the HSE leaflet “Working with VDUs” if they work on 
DSEs for at least one continuous hour on 10 occasions.   
EQUIPMENT INFORMATION 
Setup 1 
 Nikon Biophot Microscope, Nikon Corporation, Tokyo 100-8331, Japan 
 Nikon DS-5M camera head 5M pixel, Nikon Corporation, Tokyo 100-8331, Japan 
 Nikon Digital Sight DS-U1 digital control unit, Nikon Corporation, Tokyo 100-8331, 
Japan 
 Nikon C-Mount TV adaptor 0.6x, Nikon Corporation, Tokyo 100-8331, Japan 
 Eclipsenet software, developed by Laboratory Imaging s.r.o. for Nikon Instruments 
Europe B.V., 1170AE Badhoevedorp, The Netherlands       
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Setup 2 (supplied by Jencons-PLS) 
 Nikon Eclipse 50i Microscope, Nikon Corporation, Tokyo 100-8331, Japan  
 Nikon DS-Fi1 digital camera Head 5M pixel, Nikon Corporation, Tokyo 100-8331, Japan 
 Nikon Digital control unit DS-U2 USB, Nikon Corporation, Tokyo 100-8331, Japan 
 Nikon C-Mount TV adaptor, 0.63x, Nikon Corporation, Tokyo 100-8331, Japan 
 NIS-Elements-F software, developed for Nikon Instruments  
Both systems 
 Personal computer (minimum specification 1GB RAM, 2.8GHz processor) 
 Adobe Photoshop CS2 software, Education Version.  Adobe Systems Incorporated. 345 
Park Avenue, San Jose, CA 95110-2704 USA www.adobe.com 
 MacBiophotonics Image J    http://www.macbiophotonics.ca/downloads.htm 
Methods 
1. Turn on the PC and for “Setup 2”, log on to the University Managed Network. 
2. Switch on the Nikon Digital Sight Box and wait until a continuous green light is 
displayed. 
3. Load the Image Capture Software (Eclipse Net for Setup 1, and NIS-Elements F for 
Setup 2) by double clicking the icon on the desktop with the mouse. 
4. Turn on the microscope. 
5. Check the condenser  
- Place a slide on the microscope stage, and move to an area containing no tissue. 
- Use the 4x objective and close the diaphragm (dial on the bottom right hand side 
of the microscope). 
- Adjust the condenser until the diaphragm is sharply in focus (just changing from 
blue to red “halo”). 
6. Check settings: 
Setup 1 Setup 2 
Nikon DS-U1 Camera Driver tool box: 
AE P (autoexposure program) 
AE lock on (tick box) 
Live fast: 640x480 full 
Live quality: 1280x960 Interlaced 
Mode – Normal 
Resolution –  640 x 480 (fast focus) 
 1280 x 960 (quality capture) 
AE lock on (tick box) 
Exposure – Mode – Auto exposure 
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Exposure and gain are automatically 
adjusted by the software. 
Compensation: +1.0-+1.6 EV 
Contrast: High 
Sharpness: High 
AE comp +1.0 EV - +1.6 EV (+1.0 will be 
darker) 
Colour – Contrast – High 
Sharpness -  high (Scene mode| 
commands|advanced) 
Nb. Higher resolution images can be taken (2560x1920), but these are very large and 
should not be used for analysis with ImageJ. 
7. Ensure that the objective selected in the software matches the objective being used on 
the microscope. 
8. Check exposure – for Setup 1, use “probe” (⬚) to select area of interest; For Setup 2, 
click “AE area” and a box will appear. 
- If necessary adjust the size and position of the box to an area that is clear and 
white. 
- Click “Autowhite” (under white balance for Setup 1, and colour section of camera 
settings for Setup 2). 
- It is only necessary to “autowhite” once for each slide and objective combination.  
9. Check calibration - click “├┤” for Setup 1 or “scale” for Setup 2 - scale bar with µM 
appears.  For Setup 1, calibration settings are unlikely to require adjustment.  For 
Setup 2, calibration must be performed for each new user. 
10. Calibrate each objective using the scale slide. 
- Starting with the 4x objective, focus on the scale bar ensuring that the highest 
possible focus number is obtained in the focus bar at the bottom of the software 
screen by adjusting first the coarse, then the fine focus knobs on the microscope. 
- Ensure that the image displayed is on “1:1”. 
- For Setup 1, Click on Calibrations|Recalibrate, ensure correct objective name is 
displayed and click “OK”.  For Setup 2, Click on Camera|calibrate. 
- Click at both ends of the largest length that can fit on the screen, and enter the 
length in the text box (ensure units are µm).  Nb. 1 mm = 1000 µm.  Click “OK”.  
- Repeat for each objective. 
- Nb.  This procedure should only need to be performed once for each new user. 
- Check calibration by applying scale bar and moving over the calibration slide 
image. 
- The colour, style, line thickness and font for the scale bar can all be changed by 
Right hand mouse clicking on the scale bar and changing the settings as required. 
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11. Scan the whole tissue section on slide, firstly on 4X, then 10X then 40X, this will give 
a good indication of which areas to photograph. Always check the negatives on each 
slide as no staining should be observed. 
12. For each new sample, create a new working folder.  For Setup 1, click 
Camera|Capture & Save Options.  In “Save to file” section, select directory and prefix 
if desired for autocapture, ensuring that file format is “tif”.  For Setup 2, click 
File|options|working folder|New folder.                                                                          
Procedure: Measuring BM Thickness 
1. Before measuring BM thicknesses, size dimensions should be calibrated. To do this, 
first open an image with an already inserted scale bar (50μm). Zoom into the picture 
making the size of the scale bar as big as possible in the window. Click on the line 
button and carefully draw a line along the whole length of the scale bar. Click on 
analyse button on image J and then click on set scale. Change size to 50 and units to 
um. Click on global calibration setting and then ok.  
2. Open the desired endometrial micrographs through image J. Zoom into the 
micrograph as much as possible without greatly sacrificing the resolution of the 
image. Using the line button again, measure the BM along the direction of the cell 
polarity. Points of measurement should be the most well defined stained BM for both 
COLIV and laminin.  
3. Once satisfied with the line measurement click ‘m’ key to measure the BM thickness 
in μm. Measurements should automatically appear in an excel spreadsheet.    
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APPENDIX 7 
STAINING INTENSITY ASSESSMENT 
7A: Collagen IV 
NIL: 0       WEAK: 1  
 
 
 
 
 
 
 
 
MODERATE: 2     STRONG: 3 
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7B: Laminin 
NIL: 0      WEAK: 1 
 
 
 
 
 
 
 
MODERATE:  2 
 
 
 
 
 
 
 
STRONG: 3 
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7C: PODXL 
NIL: 0        WEAK: 1 
 
 
 
 
 
 
 
MODERATE: 2     STRONG: 3 
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7D: CK 5/6 
NIL: 0       WEAK: 1 
 
 
 
 
 
 
MODERATE: 2     STRONG: 3 
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7E: SSEA1 
NIL:  0          WEAK: 1 
 
 
 
 
 
 
 
 
 
MODERATE: 2         STRONG: 3  
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APPENDIX 8 
STUDY RESULTS 
8A. Results of COLIV expression in fertile control group 
COLLAGEN IV CONTROLS 
PP 
AV gland 
thickness 
AV gland 
intensity Gland QS 
AV LEE 
thickness 
AV LEE 
intensity LE QS 
AV vessel 
intensity 
1 0.712 0.750 0.534 0.705 1.500 1.058 1.450 
2 0.852 1.100 0.937 0.905 1.500 1.358 1.900 
3 0.743 0.750 0.557 0.965 0.500 0.483 1.650 
4 0.729 0.700 0.510 0.705 2.000 1.410 1.850 
5 0.888 1.200 1.065 0.710 1.500 1.065 2.300 
6 0.996 2.000 1.992 0.845 2.500 2.113 2.550 
7 0.851 1.150 0.979 0.775 1.500 1.163 2.350 
8 0.899 1.200 1.078 0.820 1.000 0.820 2.550 
9 0.637 0.600 0.382 1.125 1.500 1.688 2.100 
10 0.894 1.000 0.894 1.100 2.000 2.200 2.000 
Median 0.851 1.050 0.915 0.833 1.500 1.260 2.050 
WOI               
1 0.778 1.050 0.817 0.820 0.500 0.410 2.550 
2 0.878 1.150 1.010 0.670 1.000 0.670 2.250 
3 0.437 0.350 0.153 N/A N/A   0.250 
4 0.861 1.700 1.463 0.990 1.500 1.485 2.750 
5 0.661 0.800 0.528 0.960 1.000 0.960 1.850 
6 0.725 1.050 0.761 N/A N/A   2.200 
7 0.698 1.000 0.698 1.075 1.000 1.075 2.400 
8 0.505 0.750 0.379 0.000 0.000 0.000 1.900 
9 0.765 1.000 0.765 1.345 1.000 1.345 2.200 
10 0.484 0.350 0.169 0.000 0.000 0.000 1.950 
Median 0.711 1.000 0.729 0.890 1.000 0.815 2.200 
LSP               
1 0.684 0.950 0.650 N/A N/A   1.750 
2 0.787 2.000 1.573 0.505 1.500 0.758 2.300 
3 0.721 1.650 1.189 0.805 1.000 0.805 1.650 
4 0.901 2.050 1.847 0.000 0.000 0.000 2.400 
5 0.803 2.050 1.646 N/A N/A   2.100 
6 0.718 1.500 1.077 0.950 2.000 1.900 2.400 
7 0.864 1.350 1.166 0.810 1.000 0.810 2.050 
8 0.791 1.750 1.384 0.985 2.000 1.970 2.350 
9 0.735 1.200 0.882 0.705 0.500 0.353 1.550 
10 0.978 1.600 1.565 0.820 1.500 1.230 2.550 
Median 0.789 1.625 1.287 0.808 1.250 0.808 2.200 
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8B. Results of Laminin expression in fertile control group 
LAMININ CONTROLS 
PP 
AV gland 
thickness 
AV gland 
intensity 
GLAND 
QS 
AV LEE 
thickness 
AV LEE 
intensity 
GLAND 
QS 
AV vessel 
intensity 
1 0.957 1.050 1.005 0.825 1.500 1.238 0.800 
2 0.966 1.350 1.304 0.840 1.000 0.840 1.550 
3 1.332 2.550 3.395 0.975 2.000 1.950 2.200 
4 1.151 1.400 1.611 0.980 1.000 0.980 1.750 
5 0.570 0.400 0.228 0.000 0.000 0.000 0.650 
6 0.849 1.700 1.442 0.560 0.500 0.280 1.250 
7 0.916 1.400 1.282 1.140 0.500 0.570 1.700 
8 0.712 1.300 0.925 0.000 0.000 0.000 0.800 
9 1.228 1.450 1.781 0.780 1.000 0.780 2.100 
10 1.056 1.500 1.584 0.845 1.000 0.845 1.950 
Median  0.962 1.400 1.373 0.833 1.000 0.810 1.625 
WOI     0.000     0.000   
1 0.914 0.950 0.868 0.000 0.000 0.000 1.100 
2 0.712 0.700 0.498 0.600 1.500 0.900 1.350 
3 0.669 1.050 0.702 0.000 0.000 0.000 1.500 
4 1.016 1.800 1.829 1.005 1.500 1.508 1.850 
5 0.000 0.000 0.000 0.000 0.000 0.000 0.200 
6 0.929 1.450 1.346 N/A N/A   2.400 
7 0.547 0.500 0.274 0.000 0.000 0.000 0.600 
8 0.618 0.500 0.309 0.000 0.000 0.000 0.950 
9 0.601 1.100 0.661 0.550 0.500 0.275 0.850 
10 0.712 0.650 0.463 0.000 0.000 0.000 1.400 
Median  0.690 0.825 0.580 0.000 0.000 0.000 1.225 
LSP     0.000     0.000   
1 0.914 2.000 1.828 N/A N/A   1.800 
2 0.874 0.850 0.742 0.000 0.000 0.000 1.400 
3 0.910 3.500 3.185 0.880 1.000 0.880 1.600 
4 0.994 1.300 1.292 0.000 0.000 0.000 1.600 
5 1.244 2.350 2.923 0.000 0.000 0.000 1.900 
6 1.001 1.650 1.652 0.810 0.500 0.405 2.200 
7 0.491 0.250 0.123 0.000 0.000 0.000 0.500 
8 1.158 1.950 2.257 1.170 2.000 2.340 2.250 
9 0.712 0.900 0.640 0.925 1.000 0.925 0.900 
10 0.819 1.200 0.982 0.830 0.500 0.415 1.600 
Median  0.912 1.475 1.472 0.810 0.500 0.405 1.600 
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8C. Results of PODXL expression in fertile control group 
PODXL CONTROLS 
Proliferative  Average combined quick score  
Vessel 
intensity 
1 10.2 1.95 
2 9.2 1.53 
3 8.8 1.3 
4 9.2 2.39 
5 8.6 1 
6 6.5 1.55 
7 8.4 1.125 
8 6.95 1.4 
9 10.3 2.7 
10 3.05 2.11 
Median 8.7 1.54 
Window of Implantation   
1 4.9 1.89 
2 2.4 2.07 
3 6.6 1.5 
4 5 1.4 
5 0.05 1.25 
6 6.4 2.78 
7 8 2.9 
8 3.14 1.389 
9 0.5 2 
10 8 1.35 
Median  4.95 1.695 
Late secretory Phase   
1 4.1 1.8 
2 4.45 1.8 
3 0 1.95 
4 4.45 1.8 
5 0.65 2.24 
6 0 2.12 
7 0 2.2 
8 0.4 2.12 
9 0.1 1.5 
10 0.05 1.89 
Median 0.25 1.92 
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8D. Results of CK5/6 expression in fertile control group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokeratin 5/6 Controls 
Proliferative  % +ve glands  LE SI 
1 3.60 0.00 
2 100.00 2.50 
3 100.00 2.00 
4 0.00 1.00 
5 50.00 2.50 
6 0.00 0.50 
7 5.00 0.50 
8 30.00 1.50 
9 55.60 2.00 
10 100.00 1.00 
Window of Implantation   
1 0.00 0.50 
2 96.60 3.00 
3 0.00 3.00 
4 46.20 1.50 
5 13.00 2.00 
6 0.00 N/A 
7 52.00 1.50 
8 0.00 2.00 
9 73.00 3.00 
10 0.00 1.00 
Late secretory Phase   
1 8.30   
2 0.00 1.00 
3 29.60 N/A 
4 0.00 1.00 
5 11.10 N/A 
6 27.80 2.50 
7 0.00 1.50 
8 48.00 2.50 
9 0.00 1.00 
10 0.00 1.50 
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8E. Results of SSEA1 expression in fertile control group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SSEA1 CONTROLS 
  Basal  Functional 
PP 
no. +ve 
glands  
Av 
Gland 
SI 
Av % 
of 
glands 
Combined 
Quickscore  
no. +ve 
glands 
Av 
Gland 
SI 
Av % 
of 
glands 
Combined 
Quickscore  LE SI 
1         0.9 0.75 1.2 0.81 2 
2 1 1.65 3 4.95 1 1.85 3 5.55 1 
3         1 1.1 1.5 1.65 1.5 
4         0.7 0.65 0.8 0.364 1 
5 1 2 2.7 5.4 1 1.7 2.5 4.25 2 
6 1 1.35 2.7 3.645 1 0.75 1.8 1.35 2.5 
7         1 1.55 1.5 2.325 2 
8 1 2.05 3 6.15 1 1.15 1.6 1.84 1.5 
9         1 1.35 2.4 3.24 2 
10 1 1.45 2.8 4.06 1 1.1 1 1.1 2 
WOI                   
1 0.2 0.1 0.2 0.004 0.7 0.65 0.7 0.3185 0.5 
2         0.6 0.8 0.6 0.288 0 
3         0 0 0 0 0.5 
4         0.6 0.65 0.6 0.234 0.5 
5 0.5 0.35 0.5 0.0875 0.7 0.35 0.8 0.196 0.5 
6         1 1.05 2 2.1 N/A 
7 0.9 0.65 1.5 0.8775 0.6 0.35 0.6 0.126 0.5 
8         0 0 0 0 0.5 
9 0.4 0.4 0.4 0.064 0.8 1.15 0.8 0.736 0 
10         0.2 0.1 0.2 0.004 0.5 
LSP                   
1         0.4 0.35 0.4 0.056 2 
2         0.3 0.2 0.4 0.024 0.5 
3         1 1.55 1.7 2.635 N/A 
4         1 1.75 1.8 3.15 2 
5         0.6 0.65 0.6 0.234 0 
6         0.6 0.55 0.6 0.198 1.5 
7 0.9 1.15 0.9 0.9315 0.6 0.8 0.6 0.288 0 
8         1 1.1 1 1.1 2 
9 0.4 0.45 0.4 0.072 0.8 0.85 0.8 0.544 1.5 
10 0.5 0.5 0.5 0.125 0.7 0.43 0.71 0.21371 2 
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8F. Results of COLIV expression in PM control group 
COLLAGEN IV POST MENOPAUSAL 
PM 
AV gland 
thickness 
AV gland 
intensity Gland qs 
AV LEE 
thickness 
AV LEE 
intensity 
LEE 
QS 
AV vessel 
intensity 
1 1.057 1.650 1.744 0.925 1.000 0.925 1.150 
2 3.553 1.250 4.441 1.175 1.500 1.763 0.900 
3 0.132 0.150 0.020 0.000 0.000 0.000 0.150 
4 0.561 1.100 0.617 0.670 1.000 0.670 0.100 
5 0.690 1.250 0.863 0.545 0.500 0.273 1.200 
Median  0.690 1.250 0.863 0.670 1.000 0.670 0.900 
 
8G. Results of Laminin expression in PM control group 
LAMININ POST MENOPAUSAL 
PM 
AV gland 
thickness 
AV gland 
intensity Gland QS 
AV LEE 
thickness 
AV LEE 
intensity LEE QS 
AV vessel 
intensity 
1 0.8855 1.05 0.929775 0 0 0 0.65 
2 1.045 2.35 2.45575 0.655 1 0.655 2.2 
3 0.1955 0.2 0.0391 0 0 0 0.05 
4 0.891 1.4 1.2474 0.865 2 1.73 1.5 
5 0.913 1.55 1.41515 1.06 2 2.12 1.65 
Median 0.891 1.4 1.2474 0.655 1 0.655 1.5 
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8H. Results of PODXL expression in PM control group 
 
 
 
 
 
 
8I. Results of CK5/6 expression in PM control group 
CK5/6 post menopausals controls 
Post 
menopausals 
% +ve 
glands  
LE 
SI 
1 20.00 n/a 
2 6.45 0.50 
3 3.23 0.00 
4 0.00 0.00 
5 0.00 0.50 
 
8J. Results of SSEA1 expression in PM control group 
SSEA 1 POST MENOPAUSALS   
PM 
no. +ve glands/10 
glands 
Av Gland 
SI 
No. of G with +ve 
GS 
Av % of 
glands 
LE 
SI QS 
1 0.9 2 10 2.4 N/A 4.32 
2 1 3 10 3 0.5 9 
3 1 1.95 10 1.9 1 3.705 
4 1 2.55 10 2.7 3 6.885 
5 1 2.5 10 2.7 2 6.75 
 
 
 
 
 
PODXL PM 
PM Average combined quick score  Vessel intensity 
1 3.95 1.4 
2 7 1.55 
3 7.5 1.05 
4 7.2 1.7 
5 6.286 1.929 
Median 7 1.55 
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8K. Results of COLIV expression in endometriosis group 
COLLAGEN IV ENDOMETRIOSIS 
PP 
AV gland 
thickness 
AV gland 
intensity 
AV gland 
QS 
AV LEE 
thickness 
AV LEE 
intensity AV LE QS 
AV vessel 
intensity 
1.000 0.621 0.600 0.373 N/A N/A   1.000 
2.000 0.826 1.400 1.156 1.110 2.000 2.220 2.650 
3.000 0.681 0.650 0.442 0.890 0.500 0.445 1.400 
4.000 0.753 1.000 0.753 N/A N/A   2.000 
5.000 0.863 1.850 1.597 0.665 0.500 0.333 2.400 
6.000 0.812 1.350 1.096 0.880 1.000 0.880 1.850 
7.000 0.000 0.000 0.000 0.000 0.000 0.000 0.650 
8.000 0.619 0.500 0.310 0.920 1.000 0.920 2.000 
9.000 0.132 0.100 0.013 N/A N/A   0.950 
10.000 0.865 1.000 0.865 0.855 1.000 0.855 1.800 
11.000 0.928 1.650 1.530 N/A N/A   2.300 
Median 0.753 1.000 0.753 0.880 1.000 0.855 1.850 
WOI               
1.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
2.000 0.054 0.050 0.003 0.000 0.000 0.000 0.900 
3.000 0.056 0.050 0.003 0.650 0.500 0.325 0.500 
4.000 0.526 0.400 0.210 N/A N/A   1.150 
5.000 0.663 0.650 0.431 0.000 0.000 0.000 1.950 
6.000 0.694 0.950 0.659 0.890 2.000 1.780 2.200 
7.000 0.411 0.600 0.246 0.565 1.000 0.565 2.050 
8.000 0.733 0.750 0.550 1.560 1.500 2.340 2.200 
9.000 1.094 1.900 2.079 0.785 1.500 1.178 2.250 
10.000 1.269 0.450 0.571 2.090 2.000 4.180 0.910 
11.000 1.814 1.750 3.175 N/A N/A   2.650 
Median 0.663 0.600 0.431 0.650 1.000 0.565 1.950 
LSP               
1.000 1.340 0.550 0.737 N/A N/A   1.100 
2.000 1.070 0.450 0.481 0.000 0.000 0.000 1.150 
3.000 0.840 1.500 1.260 0.000 0.000 0.000 2.600 
4.000 0.794 1.357 1.077 N/A N/A   2.071 
5.000 0.985 0.900 0.886 1.455 0.500 0.728 2.200 
6.000 0.128 0.200 0.026 0.620 1.000 0.620 1.550 
7.000 0.986 2.000 1.972 1.075 2.000 2.150 2.650 
8.000 0.899 1.400 1.259 0.820 1.000 0.820 1.950 
Median 0.942 1.129 0.982 0.720 0.750 0.674 2.011 
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8L. Results of laminin expression in endometriosis group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LAMININ ENDOMETRIOSIS 
PP 
AV gland 
thickness 
AV gland 
intensity 
GLAND 
QS 
AV LEE 
thickness 
AV LEE 
intensity LEE QS 
AV vessel 
intensity 
1 1.391 2.050 2.852 0.950 2.000 1.900 2.200 
2 0.977 1.550 1.514 0.800 0.500 0.400 1.600 
3 0.914 0.950 0.868 0.000 0.000 0.000 1.100 
4 0.680 0.600 0.408 N/A N/A N/A 0.700 
5 1.039 1.850 1.922 0.000 0.000 0.000 1.750 
6 1.042 2.100 2.188 0.970 1.500 1.455 2.350 
7 0.444 0.350 0.155 0.000 0.000 0.000 1.200 
8 1.108 1.650 1.828 0.900 1.000 0.900 2.250 
9 0.431 0.250 0.108 N/A N/A N/A 1.050 
10 0.745 1.000 0.745 0.000 0.000 0.000 1.500 
11 0.372 0.450 0.167 N/A N/A N/A 0.600 
Median 0.914 1.000 0.868 0.400 0.250 0.200 1.500 
WOI               
1 0.630 0.800 0.504 0.000 0.000 0.000 1.700 
2 0.684 1.300 0.889 0.490 2.000 0.980 2.150 
3 0.728 1.650 1.200 1.285 2.000 2.570 2.150 
4 0.770 1.550 1.194 N/A N/A   2.400 
5 0.882 1.150 1.014 0.535 2.000 1.070 2.100 
6 0.897 1.700 1.524 0.980 2.000 1.960 1.700 
7 0.752 1.100 0.827 0.000 0.000 0.000 1.850 
8 0.654 1.000 0.654 0.715 1.000 0.715 1.450 
9 0.938 1.200 1.125 0.000 0.000 0.000 1.500 
10 0.911 1.400 1.275 N/A N/A N/A 1.350 
11 0.924 1.700 1.571 N/A N/A N/A 1.850 
Median 0.770 1.300 1.125 0.513 1.500 0.848 1.850 
LSP               
1 0.864 1.250 1.079 N/A N/A N/A 1.700 
2 0.898 0.150 0.135 0.525 0.500 0.263 1.900 
3 0.849 1.200 1.018 0.000 0.000 0.000 1.350 
4 1.043 2.071 2.160 N/A N/A N/A 2.071 
5 0.666 0.650 0.433 0.000 0.000 0.000 0.500 
6 0.942 1.500 1.413 0.825 2.000 1.650 2.050 
7 0.547 0.550 0.301 0.700 0.500 0.350 0.650 
8 0.605 0.950 0.575 1.340 1.500 2.010 1.500 
Median 0.856 1.075 0.796 0.613 0.500 0.306 1.600 
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8M. Results of PODXL expression in endometriosis group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PODXL ENDOMETRIOSIS 
Proliferative  Average combined quick score  
Vessel 
intensity 
1 5.000 2.350 
2 7.300 2.550 
3 7.650 2.500 
4 7.250 2.280 
5 1.900 0.950 
6 4.850 2.200 
7 1.850 1.300 
8 8.650 2.750 
9 4.200 1.300 
10 6.100 2.150 
11 0.000 1.750 
Median 5.000 2.200 
Window of Implantation   
1 3.650 1.900 
2 2.950 2.750 
3 6.800 2.750 
4 0.250 2.300 
5 2.800 2.650 
6 2.800 2.500 
7 6.800 1.690 
8 8.600 2.700 
9 0.550 1.800 
10 0.000 1.300 
11 0.450 1.950 
Median 2.800 2.300 
Late secretory Phase   
1 0.300 1.375 
2 0.500 1.600 
3 0.560 2.250 
4 0.000 1.330 
5 0.050 1.000 
6 3.600 2.083 
7 0.050 1.800 
8 1.850 1.750 
Median 0.400 1.675 
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8N. Results of CK5/6 expression in endometriosis group 
 
Cytokeratin 5/6 Endometriosis 
Proliferative  
% +ve 
glands  
LE 
SI 
1 15.80 0.00 
2 7.10 1.00 
3 19.20 1.50 
4 84.60 N/A 
5 0.00 1.50 
6 30.80 0.50 
7 0.00 0.00 
8 100.00 2.50 
9 100.00 1.00 
10 0.00 1.00 
11 26.70 N/A 
Window of Implantation   
1 100.00 1.00 
2 0.00 2.00 
3 12.00 1.50 
4 0.00 1.00 
5 100.00 1.00 
6 22.20 2.00 
7 23.80 3.00 
8 0.00 2.50 
9 6.70 1.50 
10 0.00 1.50 
11 47.40 N/A 
Late secretory Phase   
1 0.00 0.50 
2 0.00 1.00 
3 42.90 2.50 
4 23.00 N/A 
5 0.00 1.50 
6 14.30 2.00 
7 42.90 1.00 
8 8.00 2.00 
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8O. Results of SSEA1 expression in endometriosis group 
 
SSEA1 ENDOMETRIOSIS 
  Basal    Functional 
PP 
no. 
+ve 
glands 
Av Gland 
SI 
Av % of 
glands 
Combined 
Quickscore  
no. 
+ve 
glands 
Av Gland 
SI 
Av % of 
glands 
Combined 
Quickscore  LE SI 
1         1 2.7 2.5 6.75 3 
2         1 0.75 1.5 1.125 2 
3         1 0.5 1.6 0.8 0.5 
4 1 1.6 2.9 4.64 0.8 0.55 1 0.44 N/A 
5 1 1.6 3 4.8 0.9 0.85 1.6 1.224 0.5 
6 1 2.05 2.5 5.125 1 1.9 2.5 4.75 1.5 
7 0.7 0.95 1.1 0.7315 0.8 0.55 1.3 0.572 1 
8         1 1.35 2.5 3.375 2.5 
9 1 1.85 2.9 5.365 1 1.4 2.8 3.92 2 
10         1 1.45 1.6 2.32 1.5 
11 1 1.7 2.7 4.59 0.9 0.85 1.7 1.3005 N/A 
WOI                   
1         0.2 0.1 0.2 0.004 2.5 
2         0.3 0.25 0.3 0.0225 1.5 
3         0.2 0.1 0.2 0.004 2 
4         0.2 0.15 0.2 0.006 N/A 
5         0.5 0.5 0.5 0.125 0.5 
6         0 0 0 0 0 
7         0.7 0.7 0.7 0.343 1 
8 1 1.3 1.7 2.21 0 0 0 0 2 
9         0.4 0.4 0.5 0.08 1 
10         0 0 0 0 N/A 
11 0.9 1.2 1.3 1.404 0.6 0.5 0.6 0.18 N/A 
LSP                   
1         0.2 0.2 0.2 0.008 N/A 
2         0.6 0.7 0.6 0.252 2.5 
3         0.4 0.6 0.4 0.096 0.5 
4         0 0 0 0 N/A 
5 0.2 0.3 0.4 0.024 0 0 0 0 0.5 
6         0.6 0.45 0.7 0.189 2 
7 1 1.3 1.2 1.56 0.2 0.4 0.2 0.016 1.5 
8         0.8 0.45 0.8 0.288 1.5 
 
